Publication O
date: O
2018/12/07 O
00:00 O
[accepted] O
[]

The O
mean O
pain B-outcome ['Physiological-Clinical']
scale O
values O
on O
first O
postoperative O
was O
4.24 O
in O
the O
drainage O
by O
the O
same O
intercostal O
group O
and O
3.95 O
in O
the O
traditional O
chest O
drainage O
(p=0.733). O
[['Physiological-Clinical']]

CONCLUSIONS: O
Our O
mixed O
results O
pose O
challenges O
that O
are O
too O
infrequently O
exposed O
in O
public O
heath O
intervention O
trials. O
[]

Publication O
date: O
['2019/10/16 O
06:00' O
[]

The O
primary O
end O
point O
was O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
. O
RESULTS: O
A O
total O
of O
647 O
patients O
underwent O
randomization O
from O
December O
2008 O
through O
January O
2012, O
were O
assigned O
to O
undergo O
lymphadenectomy O
(323 O
patients) O
or O
not O
undergo O
lymphadenectomy O
(324), O
and O
were O
included O
in O
the O
analysis. O
[['Mortality']]

Feasibility B-outcome ['Life-Impact']
outcomes O
included O
rates O
of O
recruitment B-outcome ['Life-Impact']
, O
retention B-outcome ['Life-Impact']
, O
outcome B-outcome ['Life-Impact']
completion I-outcome ['Life-Impact']
, O
and O
exercise B-outcome ['Life-Impact']
attendance I-outcome ['Life-Impact']
. O
Data O
were O
collected O
on O
cardiorespiratory B-outcome ['Physiological-Clinical']
fitness I-outcome ['Physiological-Clinical']
(e.g., O
peak B-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
uptake I-outcome ['Physiological-Clinical']
), O
disease B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
, O
fatigue B-outcome ['Physiological-Clinical']
, O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
, O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
, O
and O
intervention O
acceptability B-outcome ['Life-Impact']
(via O
interviews). O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact'], ['Adverse-effects'], ['Life-Impact']]

BACKGROUND: O
Large O
scale O
administration O
of O
the O
anthelminthic O
drug O
praziquantel O
(PZQ) O
to O
at-risk O
populations O
is O
the O
cornerstone O
of O
schistosomiasis O
control, O
although O
persisting O
high O
prevalence O
of O
infections O
in O
some O
areas O
and O
growing O
concerns O
of O
PZQ O
resistance O
have O
revealed O
the O
limitations O
of O
this O
strategy. O
[]

Additionally, O
both O
groups O
had O
similar O
safety O
profile. O
[]

Publication O
date: O
2019/01/08 O
06:00 O
[medline] O
[]

Journal O
ID: O
101521595 O
[]

METHODS: O
The O
design O
for O
the O
evaluation O
of O
the O
Nia O
Project O
is O
a O
longitudinal, O
cluster-randomized O
controlled O
trial O
consisting O
of O
a O
baseline O
survey O
with O
a O
cohort O
of O
Class O
7 O
girls, O
a O
school O
quality O
survey, O
qualitative O
data O
collection, O
school O
attendance O
tracking, O
and O
an O
endline O
survey O
at O
the O
completion O
of O
the O
18-month O
intervention O
period O
with O
the O
same O
cohort. O
[]

Such O
information O
provides O
important O
knowledge O
that O
may O
help O
to O
inform O
decisions O
of O
municipalities, O
employers O
and O
other O
public O
health O
decision O
makers, O
when O
and O
if O
implementing O
weight O
loss O
interventions. O
[]

The O
primary O
endpoint O
was O
the O
response B-outcome ['Physiological-Clinical']
rate O
compared O
to O
the O
historical O
response O
rate. O
[['Physiological-Clinical']]

This O
study O
was O
done O
with O
the O
goal O
of O
comparing O
the O
effect O
of O
Ginger O
and O
Novafen O
on O
the O
menstrual B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
. O
MATERIALS O
AND O
METHODS: O
This O
crossover O
clinical O
trial O
study O
was O
done O
in O
Iran O
on O
168 O
single O
girl O
students O
18-26 O
years O
old O
in O
Babol O
University O
of O
Medical O
Sciences O
with O
primary O
menstrual O
pain. O
[['Physiological-Clinical']]

At O
10 O
minutes O
after O
the O
beginning O
of O
atomization, O
the O
inspiratory B-outcome ['Physiological-Clinical']
tidal I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
monitored O
by O
ventilator O
in O
different O
preset O
VT O
groups O
was O
significantly O
lower O
than O
tidal B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
showed O
by O
simulated O
water O
lung O
(mL: O
649.67+/-5.03 O
vs. O
840.00+/-10.00 O
at O
650 O
mL O
of O
preset O
VT O
and O
9 O
L/min O
of O
atomized O
oxygen O
flow, O
P O
< O
0.05), O
and O
exhaled B-outcome ['Physiological-Clinical']
tidal I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
was O
significantly O
higher O
than O
tidal B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
showed O
by O
simulated O
water O
lung O
(mL: O
1 O
270.33+/-11.06 O
vs. O
840.00+/-10.00 O
at O
650 O
mL O
of O
preset O
VT O
and O
9 O
L/min O
of O
atomized O
oxygen O
flow, O
P O
< O
0.05). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

RESULTS: O
The O
mean O
age O
in O
the O
2 O
groups O
was O
similar O
and O
almost O
equal O
to O
52 O
years; O
there O
was O
no O
difference O
in O
the O
sex O
ratios O
in O
both O
groups O
(P O
> O
.05). O
[]

METHODS: O
The O
present O
double-blind O
randomized O
controlled O
trial O
included O
women O
who O
underwent O
home O
deliveries O
in O
Chitral O
district, O
Khyber O
Pakhtunkhwa O
province, O
Pakistan, O
after O
presenting O
at O
healthcare O
facilities O
during O
the O
third O
trimester O
of O
pregnancy O
between O
May O
28, O
2012, O
and O
November O
27, O
2014. O
[]

CONCLUSION: O
There O
was O
no O
significant O
difference O
in O
clinical O
outcomes O
between O
the O
two O
trial O
arms. O
[]

Publication O
date: O
2019/01/11 O
06:00 O
[entrez] O
[]

RESULTS: O
The O
incidence O
of O
shoulder B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
was O
significantly O
reduced O
in O
EMLA O
group O
(56%) O
compared O
to O
control O
(88%) O
or O
TPI O
(88%) O
groups O
(P O
= O
.025 O
in O
both); O
the O
severity O
of O
shoulder B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
was O
mitigated O
in O
EMLA O
and O
TPI O
groups O
compared O
to O
control O
group O
(P O
< O
.001, O
each). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

CONCLUSION: O
The O
results O
of O
this O
study O
showed O
that O
ET O
as O
an O
adjunctive O
therapy O
to O
montelukast O
may O
benefit O
for O
children O
with O
MA. O
[]

However, O
there O
are O
limited O
data O
on O
the O
time O
course O
of O
changes O
in O
forced O
expiratory O
volume O
in O
1 O
s O
(FEV1) O
preceding O
the O
first O
reported O
symptom O
and O
after O
the O
start O
of O
an O
exacerbation. O
[]

Title: O
Navy O
Beans O
Impact O
the O
Stool B-outcome ['Physiological-Clinical']
Metabolome I-outcome ['Physiological-Clinical']
and O
Metabolic B-outcome ['Physiological-Clinical']
Pathways O
for O
Colon O
Health O
in O
Cancer O
Survivors. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Conclusions O
and O
Relevance: O
Among O
patients O
with O
MI, O
provision O
of O
vouchers O
to O
offset O
medication O
co-payments O
for O
P2Y12 O
inhibitors, O
compared O
with O
no O
vouchers, O
resulted O
in O
a O
3.3% O
absolute O
increase O
in O
patient-reported O
persistence B-outcome ['Life-Impact']
with O
P2Y12 O
inhibitors O
and O
no O
significant O
reduction O
in O
1-year O
major B-outcome ['Physiological-Clinical', 'Mortality']
adverse I-outcome ['Physiological-Clinical', 'Mortality']
cardiovascular I-outcome ['Physiological-Clinical', 'Mortality']
events I-outcome ['Physiological-Clinical', 'Mortality']
(MACE) I-outcome ['Physiological-Clinical', 'Mortality']
outcomes. O
[['Life-Impact'], ['Physiological-Clinical', 'Mortality']]

Journal O
ID: O
101234168 O
[]

Background O
Intravenous O
sufentanil-midazolam O
and O
inhalational O
sevoflurane O
are O
widely O
used O
for O
anesthetic O
induction O
in O
children O
undergoing O
cardiac O
surgery. O
[]

There O
were O
56 O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
in O
total, O
including O
31 O
in O
the O
PICSI O
group O
and O
25 O
in O
the O
ICSI O
group; O
most O
were O
congenital B-outcome ['Physiological-Clinical']
abnormalities I-outcome ['Physiological-Clinical']
and O
none O
were O
attributed O
to O
treatment. O
[['Adverse-effects'], ['Physiological-Clinical']]

The O
duration B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
analgesia I-outcome ['Life-Impact']
was O
230.5 O
+/- O
40.5 O
minutes O
in O
Dex O
group O
and O
145.1 O
+/- O
28.5 O
minutes O
in O
Control O
group, O
respectively O
(P O
< O
.001). O
[['Life-Impact']]

Journal O
ID: O
2985248R O
[]

On O
the O
same O
task, O
average O
reaction B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
improved O
(treatment O
effect, O
p O
= O
0.036) O
with O
PSE O
at O
Day O
7 O
(PSE O
vs. O
PLA: O
0.5896 O
+/- O
0.060 O
vs. O
0.6141 O
+/- O
0.073 O
s; O
p O
= O
0.049) O
and O
Day O
30 O
(PSE O
vs. O
PLA: O
0.5811 O
+/- O
0.068 O
vs. O
0.6033 O
+/- O
0.055 O
s; O
p O
= O
0.049). O
[['Life-Impact']]

Similar O
changes O
were O
observed O
in O
some O
slight O
or O
more O
serious O
unintentional O
injuries B-outcome ['Physiological-Clinical']
(P=0.030). O
[['Physiological-Clinical']]

After O
12 O
months, O
the O
Combined-arm O
showed O
reduced O
intensity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
low I-outcome ['Physiological-Clinical']
back I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
(p O
= O
0.006; O
effect O
size O
0.70, O
confidence O
interval O
0.23 O
to O
1.17) O
and O
pain B-outcome ['Physiological-Clinical', 'Life-Impact']
interfering I-outcome ['Physiological-Clinical', 'Life-Impact']
with O
work O
(p O
= O
0.011) O
compared O
with O
the O
Control-arm. O
[['Physiological-Clinical'], ['Physiological-Clinical', 'Life-Impact']]

TRIAL O
REGISTRATION: O
Registered O
with O
Clinical O
Trials O
Registry- O
India O
at O
www.ctri.nic.in O
(Registration O
number: O
CTRI/2015/04/005682 O
) O
on O
8 O
April O
2015 O
(retrospectively O
registered). O
[]

Participants O
who O
were O
lost O
to O
follow-up O
or O
did O
not O
provide O
biochemical O
validation O
were O
considered O
to O
not O
be O
abstinent. O
[]

Objective: O
To O
determine O
whether O
a O
nurse-led O
preventive, O
complex O
psychological O
intervention, O
initiated O
in O
the O
ICU, O
reduces O
patient-reported O
posttraumatic B-outcome ['Physiological-Clinical', 'Life-Impact']
stress I-outcome ['Physiological-Clinical', 'Life-Impact']
disorder I-outcome ['Physiological-Clinical', 'Life-Impact']
(PTSD) I-outcome ['Physiological-Clinical', 'Life-Impact']
symptom I-outcome ['Physiological-Clinical', 'Life-Impact']
severity I-outcome ['Physiological-Clinical', 'Life-Impact']
at O
6 O
months. O
[['Physiological-Clinical', 'Life-Impact']]

The O
plasma O
concentrations O
of O
the O
NT O
marker O
were O
measured O
just O
before, O
immediately O
after O
and O
24 O
h O
after O
operation. O
[]

Title: O
[Effects O
of O
intranasal O
dexmedetomidine O
for O
children O
undergoing O
dental O
rehabilitation O
under O
general O
anesthesia: O
a O
double-blinded O
randomized O
controlled O
trial]. O
[]

Basis O
for O
sample O
size O
calculation O
was O
the O
rate O
of O
MACE O
from O
the O
ISAR O
TEST O
3 O
trial O
in O
which O
the O
absolute O
difference O
was O
10.25% O
with O
a O
standard O
deviation O
of O
0.24. O
[]

Journal O
ID: O
0374675 O
[]

INTRODUCTION: O
Joint O
hypermobility O
is O
common O
in O
childhood O
and O
can O
be O
associated O
with O
musculoskeletal O
pain O
and O
dysfunction. O
[]

Level O
of O
evidence O
II-2. O
[]

MATERIALS O
AND O
METHODS: O
Tumor O
specimens O
and O
clinical O
information O
were O
collected O
from O
patients O
enrolled O
in O
CLASSIC O
trial, O
a O
randomized O
controlled O
study O
of O
capecitabine O
plus O
oxaliplatin-based O
adjuvant O
chemotherapy. O
[]

Design, O
Setting, O
and O
Participants: O
Randomized, O
blinded, O
placebo-controlled, O
4-group O
trial O
in O
6 O
Danish O
hospitals O
with O
90-day O
follow-up O
that O
included O
556 O
patients O
undergoing O
total O
hip O
arthroplasty O
(THA) O
from O
December O
2015 O
to O
October O
2017. O
[]

Publication O
date: O
2019/01/08 O
06:00 O
[medline] O
[]

Title: O
Effectiveness O
of O
neuromuscular O
electrical O
stimulation O
therapy O
in O
patients O
with O
urinary O
incontinence O
after O
stroke: O
A O
randomized O
sham O
controlled O
trial. O
[]

BACKGROUND: O
and O
purpose: O
Different O
in O
vitro O
studies O
have O
reported O
the O
antimicrobial O
effects O
of O
green O
tea O
catechins O
and O
also O
their O
synergistic O
effects O
with O
trimethoprim-sulfamethoxazole O
against O
E. O
coli. O
[]

We O
investigated O
the O
effects O
of O
negative O
pressure O
wound O
therapy O
(NPWT) O
on O
short- O
and O
long-term O
wound O
outcomes O
in O
patients O
undergoing O
pancreatectomy. O
[]

TRIAL O
REGISTRATION: O
Prospectively O
registered O
at O
ClinicalTrials. O
[]

RESULTS: O
The O
FOLFIRI/erlotinib O
arm O
met O
the O
pre-specified O
response B-outcome ['Physiological-Clinical']
rate O
criteria O
of O
at O
least O
10% O
to O
expand O
accrual O
to O
the O
intended O
sample O
size. O
[['Physiological-Clinical']]

The O
e-cigarette O
group O
reported O
greater O
declines O
in O
the O
incidence O
of O
cough B-outcome ['Physiological-Clinical']
and O
phlegm B-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
from O
baseline O
to O
52 O
weeks O
than O
did O
the O
nicotine-replacement O
group O
(relative O
risk O
for O
cough, O
0.8; O
95% O
CI, O
0.6 O
to O
0.9; O
relative O
risk O
for O
phlegm, O
0.7; O
95% O
CI, O
0.6 O
to O
0.9). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Results: O
Among O
11001 O
enrolled O
patients O
(median O
age, O
62 O
years; O
3459 O
[31%] O
women), O
10102 O
patients O
were O
discharged O
with O
prescriptions O
for O
clopidogrel O
or O
ticagrelor O
(clopidogrel O
prescribed O
to O
2317 O
[36.0%] O
in O
the O
intervention O
group O
and O
2497 O
[54.7%] O
in O
the O
usual O
care O
group), O
4393 O
of O
6135 O
patients O
(72%) O
in O
the O
intervention O
group O
used B-outcome ['Life-Impact']
the O
voucher O
, O
and O
follow-up O
data O
at O
1 O
year O
were O
available O
for O
10802 O
patients O
(98.2%). O
[['Life-Impact']]

The O
EMID O
study O
is O
a O
randomized O
and O
controlled O
clinical O
trial O
with O
two O
parallel O
groups O
and O
a O
12-month O
follow-up O
period. O
[]

Samples O
were O
stable O
during O
storage O
at O
4 O
degrees O
C O
for O
15 O
days O
and O
during O
2 O
freeze-thaw O
cycles. O
[]

Title: O
Vitamin O
D O
Daily O
versus O
Monthly O
Administration: O
Bone B-outcome ['Physiological-Clinical']
Turnover I-outcome ['Physiological-Clinical']
and O
Adipose B-outcome ['Physiological-Clinical']
Tissue I-outcome ['Physiological-Clinical']
Influences. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Title: O
National O
quality O
improvement O
programmes O
need O
time O
and O
resources O
to O
have O
an O
impact. O
[]

The O
Monitoring O
+ O
Acceptance O
Theory O
(MAT) O
postulates O
that O
MBI O
improves O
cognition O
through O
monitoring, O
and O
psychological O
well-being, O
through O
acceptance. O
[]

The O
resulting O
data O
were O
used O
to O
calculate O
the O
metabolizable O
energy O
of O
cashews O
and O
the O
digestibility O
of O
macronutrients. O
[]

Statistical O
analysis O
were O
performed O
using O
the O
Statistical O
Package O
for O
the O
Social O
Sciences, O
version O
20. O
[]

Journal O
ID: O
101578780 O
[]

Publication O
Type: O
Multicenter O
Study O
[]

No O
complications B-outcome ['Adverse-effects']
were O
observed O
during O
the O
study. O
[['Adverse-effects']]

Journal O
ID: O
8610224 O
[]

The O
drainage B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
on O
the O
1st O
day O
and O
the O
2nd O
to O
4th O
day O
after O
operation O
in O
the O
AGS O
group O
was O
less O
than O
that O
in O
the O
control O
group O
(P O
= O
.015, O
P O
= O
.010). O
[['Physiological-Clinical']]

Publication O
date: O
2018/12/30 O
06:00 O
[entrez] O
[]

The O
development O
of O
complex O
communities, O
particularly O
involving O
Enterobacteriaceae O
and O
strict O
anaerobes, O
may O
be O
contributing O
to O
poor O
outcomes O
in O
DFUs O
and O
requires O
further O
investigation. O
[]

Baseline O
characteristics O
were O
comparable O
between O
both O
groups. O
[]

BACKGROUPD: O
This O
study O
investigated O
the O
plasma O
fentanyl O
concentration O
and O
efficacy O
of O
transdermal O
fentanyl O
patch O
(TFP) O
(25 O
mug/h) O
in O
the O
management O
of O
acute O
postoperative O
pain B-outcome ['Physiological-Clinical']
. O
METHODS: O
Patients O
undergoing O
laparoscopic O
cholecystectomy O
were O
randomly O
allocated O
to O
2 O
groups. O
[['Physiological-Clinical']]

The O
IG O
participants O
additionally O
took O
part O
in O
a O
food O
workshop, O
five O
walks O
and O
received O
a O
smartphone O
application O
for O
three O
months. O
[]

Publication O
Type: O
Comparative O
Study O
[]

Journal-Name:The O
New O
England O
journal O
of O
medicine O
[]

RESULTS: O
Fifty-two O
eyes O
from O
26 O
patients O
(mean O
age, O
57.7 O
years) O
were O
included. O
[]

Background: O
Although O
community O
engagement O
has O
been O
promoted O
as O
a O
strategy O
for O
health O
systems O
strengthening, O
there O
is O
need O
for O
more O
evidence O
for O
effectiveness O
of O
this O
approach. O
[]

TRIAL O
REGISTRATION: O
ClinicalTrials.gov O
NCT02666872 O
(Retrospectively O
registered O
as O
January O
28, O
2016). O
[]

METHODS: O
A O
cross-sectional O
study O
was O
carried O
out O
among O
healthy O
controls O
(HCs, O
n O
= O
65), O
diabetes O
patients O
without O
kidney O
disease O
(DCs, O
n O
= O
48) O
and O
DKD O
patients O
(n O
= O
60). O
[]

Publication O
date: O
2018/11/20 O
00:00 O
[revised] O
[]

108 O
(27%) O
of O
394 O
patients O
in O
the O
ixazomib O
group O
and O
51 O
(20%) O
of O
259 O
patients O
in O
the O
placebo O
group O
experienced O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
. O
During O
the O
treatment O
period, O
one O
patient O
died B-outcome ['Mortality']
in O
the O
ixazomib O
group O
and O
none O
died B-outcome ['Mortality']
in O
the O
placebo O
group. O
[['Adverse-effects'], ['Mortality'], ['Mortality']]

Publication O
date: O
2019/03/06 O
06:00 O
[medline] O
[]

RESULTS: O
The O
incidence O
of O
involuntary B-outcome ['Physiological-Clinical']
movement I-outcome ['Physiological-Clinical']
and O
spontaneous B-outcome ['Physiological-Clinical']
movement I-outcome ['Physiological-Clinical']
were O
measured O
as O
significantly O
lower O
in O
group O
I O
(P O
< O
.05). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

RESULTS: O
Both O
the O
ALS O
and O
control O
group O
(CG) O
showed O
better O
performance B-outcome ['Life-Impact']
on O
the O
computer O
task O
when O
using O
the O
touchscreen O
device, O
but O
there O
was O
limited O
transfer B-outcome ['Life-Impact']
of O
performance O
onto O
the O
task O
performed O
on O
the O
Finger O
Motion O
control O
or O
motion O
tracking. O
[['Life-Impact'], ['Life-Impact']]

Results O
will O
be O
disseminated O
through O
workshops, O
conferences O
and O
peer-reviewed O
publications. O
[]

Journal O
ID: O
101521595 O
[]

Yi O
xue O
ban O
= O
Journal O
of O
Central O
South O
University. O
[]

Participants O
rated O
their O
gastrointestinal B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
on O
an O
adapted O
version O
of O
the O
Irritable B-outcome ['Physiological-Clinical']
Bowel I-outcome ['Physiological-Clinical']
Syndrome-Severity I-outcome ['Physiological-Clinical']
Scoring O
System O
(IBS-SSS) O
questionnaire O
before O
and O
at O
the O
end O
of O
each O
dietary O
period. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

To O
this O
end, O
we O
tested O
the O
effects O
of O
two O
commercially-available O
drinks O
on O
strength O
in O
a O
field-based O
setting O
with O
both O
male O
and O
female O
high O
school O
athletes O
completing O
a O
summer O
training O
program. O
[]

RESULTS: O
Thirty-five O
patients O
were O
assigned O
to O
the O
AG O
and O
thirty-four O
patients O
were O
assigned O
to O
the O
CG. O
[]

INTERPRETATION: O
Ixazomib O
maintenance O
prolongs O
progression-free B-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
(PFS) I-outcome ['Physiological-Clinical', 'Mortality']
and O
represents O
an O
additional O
option O
for O
post-transplant O
maintenance O
therapy O
in O
patients O
with O
newly O
diagnosed O
multiple O
myeloma. O
[['Physiological-Clinical', 'Mortality']]

Determining O
whether O
levodopa O
also O
has O
a O
disease-modifying O
effect O
could O
provide O
guidance O
as O
to O
when O
in O
the O
course O
of O
the O
disease O
the O
treatment O
with O
this O
drug O
should O
be O
initiated. O
[]

There O
was O
no O
significant O
difference O
in O
anteversion B-outcome ['Physiological-Clinical']
and O
abduction B-outcome ['Physiological-Clinical']
between O
2 O
groups O
( O
P>0.05) O
according O
to O
the O
X-ray O
film O
at O
1 O
year. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

as O
found O
in O
the O
fresh O
wild O
amla O
fruit) O
in O
patients O
with O
dyslipidemia. O
[]

Serum O
corticosterone B-outcome ['Physiological-Clinical']
in O
group O
D O
were O
sharply O
less O
than O
them O
in O
group O
C O
at O
T(2), O
T(3), O
T(4), O
T(5) O
(t=16.364, O
15.306, O
12.153, O
12.592, O
respectively; O
all O
P<0.05), O
but O
at O
T(0), O
T(1), O
T(6), O
T(7), O
T(8), O
there O
were O
no O
difference O
between O
these O
two O
groups O
(all O
P>0.05). O
[['Physiological-Clinical']]

Therefore, O
in O
this O
setting, O
ATLG O
plus O
standard O
GVHD O
prophylaxis O
should O
be O
preferred O
over O
the O
standard O
GVHD O
prophylaxis O
alone. O
[]

Publication O
date: O
['2019/10/17 O
06:00' O
[]

There O
was O
a O
slightly O
higher O
incidence O
of O
ovarian B-outcome ['Physiological-Clinical']
hyperstimulation I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
(OHSS) I-outcome ['Physiological-Clinical']
in O
Group O
2 O
compared O
to O
Group O
1 O
although O
the O
difference O
was O
not O
statistically O
significant O
(3/31, O
9.7% O
versus O
1/26, O
3.8%). O
[['Physiological-Clinical']]

Journal O
ID: O
101281800 O
[]

Adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
of O
grade O
3 O
or O
4 O
occurred O
in O
75.9% O
of O
the O
patients O
in O
the O
modified-FOLFIRINOX O
group O
and O
in O
52.9% O
of O
those O
in O
the O
gemcitabine O
group. O
[['Adverse-effects']]

Title: O
Effect O
of O
infant O
stimulation O
on O
the O
adaptation B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
birth I-outcome ['Physiological-Clinical']
: O
a O
randomized O
trial. O
[['Physiological-Clinical']]

These O
patients O
were O
enrolled O
at O
17 O
medical O
centres O
in O
the O
USA. O
[]

METHODS: O
Current O
soft O
contact O
lens O
wearers O
with O
-0.75 O
to O
-1.75 O
D O
astigmatism O
in O
each O
eye O
were O
binocularly O
fitted O
with O
toric O
(1-Day O
ACUVUE O
MOIST O
for O
astigmatism) O
and O
spherical O
(1-Day O
ACUVUE O
MOIST) O
contact O
lenses O
in O
random O
order. O
[]

Study O
models O
and O
cephalograms O
were O
taken O
at O
baseline O
and O
after O
12 O
months O
of O
treatment. O
[]

This O
study O
therefore O
investigated O
the O
effect O
of O
two O
betaA O
dosing O
strategies O
on O
30-min O
rowing B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
subsequent X ['Physiological-Clinical', 'Physiological-Clinical']
sprint B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
performance E1-outcome ['Physiological-Clinical', 'Physiological-Clinical']
. O
METHODS: O
Following O
University O
Ethics O
approval, O
twenty-seven O
healthy, O
male O
rowers O
(age: O
24 O
+/- O
2 O
years; O
body-height: O
1.81 O
+/- O
0.02 O
m; O
body-mass: O
82.3 O
+/- O
2.5 O
kg; O
body-fat: O
14.2 O
+/- O
1.0%) O
were O
randomised O
in O
a O
double-blind O
manner O
to O
4 O
weeks O
of: O
i) O
betaA O
(2.4 O
g.d(- O
1), O
betaA1); O
ii) O
matched O
total O
betaA O
(4.8 O
g O
on O
alternate O
days, O
betaA2); O
or O
iii) O
cornflour O
placebo O
(2.4 O
g.d(- O
1), O
PL). O
[['Physiological-Clinical', 'Physiological-Clinical']]

Journal O
ID: O
9708388 O
[]

Intensive O
BP O
control O
significantly O
reduced O
the O
risk O
of O
mild O
cognitive B-outcome ['Life-Impact']
impairment I-outcome ['Life-Impact']
(14.6 O
vs O
18.3 O
cases O
per O
1000 O
person-years; O
HR, O
0.81; O
95% O
CI, O
0.69-0.95) O
and O
the O
combined O
rate O
of O
mild O
cognitive B-outcome ['Physiological-Clinical', 'Life-Impact']
impairment I-outcome ['Physiological-Clinical', 'Life-Impact']
or O
probable O
dementia O
(20.2 O
vs O
24.1 O
cases O
per O
1000 O
person-years; O
HR, O
0.85; O
95% O
CI, O
0.74-0.97). O
[['Life-Impact'], ['Physiological-Clinical', 'Life-Impact']]

TRIAL O
REGISTRATION: O
The O
project O
is O
approved O
by O
Iranian O
Registry O
of O
Clinical O
Trial O
with O
no. O
[]

CONCLUSIONS: O
Among O
patients O
with O
TTP, O
treatment O
with O
caplacizumab O
was O
associated O
with O
faster O
normalization B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the O
platelet O
count O
; O
a O
lower O
incidence O
of O
a O
composite O
of O
TTP-related B-outcome ['Mortality']
death I-outcome ['Mortality']
, O
recurrence B-outcome ['Physiological-Clinical']
of O
TTP, O
or O
a O
thromboembolic B-outcome ['Physiological-Clinical']
event I-outcome ['Physiological-Clinical']
during O
the O
trial O
treatment O
period; O
and O
a O
lower O
rate O
of O
recurrence B-outcome ['Physiological-Clinical']
of O
TTP O
during O
the O
trial O
than O
placebo. O
( O
[['Physiological-Clinical'], ['Mortality'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

The O
results O
have O
contributed O
to O
the O
establishing O
of O
an O
HA O
vaccination O
policy O
in O
Korea O
and O
will O
be O
informative O
to O
countries O
that O
plan O
to O
initiate O
vaccination O
programs O
against O
HAV. O
[]

Most O
subjects O
were O
vitD(3) O
deficient O
at O
enrolment, O
but O
a O
gradual O
and O
significant O
improvement O
of O
vitD(3) B-outcome ['Physiological-Clinical']
status O
was O
demonstrated O
in O
the O
vitD(3) O
+ O
PBA O
group O
compared O
with O
placebo O
(p O
< O
0.0001) O
from O
week O
0 O
to O
16 O
(median O
37.5 O
versus O
115.5 O
nmol/L). O
[['Physiological-Clinical']]

Maternal B-outcome ['Physiological-Clinical']
outcomes O
and O
other O
obstetric B-outcome ['Resource-use']
interventions I-outcome ['Resource-use']
did O
not O
differ O
between O
the O
strategies. O
[['Physiological-Clinical'], ['Resource-use']]

There O
is O
evidence O
that O
supplementation O
with O
L-methylfolate O
augments O
antidepressant O
agent O
effects O
and O
thus O
might O
also O
augment O
ADHD O
treatment O
effects O
by O
a O
common O
catecholaminergic O
mechanism. O
[]

INTERPRETATION: O
In O
older O
patients O
with O
newly O
diagnosed O
acute O
myeloid O
leukaemia, O
efficacy O
and O
safety O
did O
not O
differ O
by O
the O
5-day O
or O
the O
10-day O
decitabine O
schedule. O
[]

Title: O
Reduction O
of O
postendodontic O
pain B-outcome ['Physiological-Clinical']
after O
one-visit O
root O
canal O
treatment O
using O
three O
irrigating O
regimens O
with O
different O
temperature. O
[['Physiological-Clinical']]

The O
primary O
outcome O
was O
assessed O
by O
the O
post-voiding B-outcome ['Physiological-Clinical']
residual I-outcome ['Physiological-Clinical']
urine I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
(PV-VRU) I-outcome ['Physiological-Clinical']
. O
The O
secondary O
outcomes O
were O
evaluated O
by O
the O
voided B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
, O
maximum B-outcome ['Physiological-Clinical']
urinary I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
rate O
(Qmax), O
and O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
, O
as O
assessed O
by O
Barthel O
Index O
(BI) O
scale. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact']]

We O
found O
significant O
positive O
correlations O
of O
Delta O
insulin-like B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
factor-1 I-outcome ['Physiological-Clinical']
with O
initial O
and O
Delta O
values O
of: O
HOMA-IR B-outcome ['Physiological-Clinical']
, O
triglyceride/high-density B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
, O
visceral B-outcome ['Physiological-Clinical']
adiposity I-outcome ['Physiological-Clinical']
index O
(VAI). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

BACKGROUND: O
Oscillatory O
positive O
expiratory O
pressure O
(OPEP) O
training O
is O
a O
kind O
of O
breathing O
exercise O
with O
Acapella. O
[]

Journal-Name:Cornea O
[]

Journal-Name:JAMA O
[]

Outcomes O
will O
be O
assessed O
at O
baseline O
and O
at O
3, O
6, O
and O
10 O
weeks O
after O
screening. O
[]

The O
primary O
safety O
outcome O
was O
a O
protocol-defined O
decrease O
in O
the O
hemoglobin B-outcome ['Physiological-Clinical']
level O
(>3.0 O
g O
per O
deciliter O
or O
>/=30% O
from O
baseline O
or O
to O
a O
level O
of O
<6.0 O
g O
per O
deciliter). O
[['Physiological-Clinical']]

Title: O
Impact O
of O
a O
Local O
Vision O
Care O
Center O
on O
Glasses B-outcome ['Life-Impact']
Ownership I-outcome ['Life-Impact']
and O
Wearing B-outcome ['Life-Impact']
Behavior I-outcome ['Life-Impact']
in O
Northwestern O
Rural O
China: O
A O
Cluster-Randomized O
Controlled O
Trial. O
[['Life-Impact'], ['Life-Impact']]

Journal-Name:The O
New O
England O
journal O
of O
medicine O
[]

The O
participants O
in O
the O
treatment O
group O
received O
lactulose, O
while O
the O
subjects O
in O
the O
placebo O
group O
received O
placebo O
intervention. O
[]

On O
intention-to-treat O
analysis, O
Hp B-outcome ['Physiological-Clinical']
eradication I-outcome ['Physiological-Clinical']
rates O
in O
FZD O
and O
CLA O
groups O
were O
90.22% O
and O
86.02% O
(P O
= O
.378); O
in O
per-protocol O
analysis, O
their O
eradication B-outcome ['Physiological-Clinical']
rates O
were O
93.26% O
and O
87.91%, O
respectively O
(P O
= O
.220). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

At O
3 O
years, O
the O
mean O
marginal B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
level O
(MBL) O
change O
at O
CI, O
FI, O
and O
PS O
implants O
was O
-0.12, O
-1.02, O
and O
-1.04 O
mm, O
respectively O
(P O
= O
.014). O
" O
[['Physiological-Clinical']]

METHODS: O
In O
this O
mixed-methods O
pilot O
trial, O
participants O
with O
quiescent O
or O
mildly-active O
CD O
were O
randomly O
assigned O
1:1:1 O
to O
HIIT, O
MICT O
or O
usual O
care O
control, O
and O
followed O
up O
for O
6 O
months. O
[]

The O
primary O
end O
point O
was O
definitive O
treatment B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
within O
1 O
year O
after O
randomization. O
[['Physiological-Clinical']]

After O
the O
intervention, O
only O
the O
exercise O
group O
had O
a O
significantly O
lower O
BMI B-outcome ['Physiological-Clinical']
z-score O
than O
the O
baseline O
score O
by O
about O
0.1 O
(p O
= O
0.03), O
but O
no O
significant O
group O
by O
time O
interaction O
effects O
were O
observed. O
[['Physiological-Clinical']]

Furthermore, O
there O
were O
no O
statistically O
significant O
differences O
between O
all O
measured O
variables O
for O
the O
EG O
and O
the O
CG O
at O
the O
final O
assessment. O
[]

However, O
self-testing O
is O
only O
a O
partial O
solution O
to O
increasing O
testing B-outcome ['Life-Impact']
rates O
in O
this O
hard O
to O
reach O
population. O
[['Life-Impact']]

CONCLUSION: O
While O
methohexital O
was O
shown O
to O
confer O
greater O
hemodynamic B-outcome ['Physiological-Clinical']
stability O
in O
patients O
taking O
ACEi/ARB, O
the O
measured O
hormone B-outcome ['Physiological-Clinical']
levels O
could O
not O
explain O
the O
mechanism O
for O
this O
effect. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Journal O
ID: O
101249598 O
[]

METHODS: O
Cricothyroidotomy-naive O
residents O
were O
recruited O
and O
randomly O
assigned O
to O
2 O
groups, O
including O
simulation O
training O
with O
a O
conventional O
simulator O
(Group O
C) O
and O
with O
a O
high-fidelity O
simulator O
(Group O
3D). O
[]

BACKGROUND: O
Total O
knee O
arthroplasty O
(TKA) O
is O
a O
surgical O
procedure O
to O
replace O
the O
weight-bearing O
surfaces O
of O
the O
knee O
joint O
to O
relieve O
pain O
and O
disability. O
[]

Title: O
Effects O
of O
botulinum O
toxin O
type O
A O
on O
the O
treatment O
of O
dry O
eye O
disease O
and O
tear O
cytokines. O
[]

Journal-Name:Medicine O
[]

POC O
patients O
were O
randomly O
divided O
into O
group O
A O
(n=40) O
and O
group O
B O
(n=39). O
[]

RESULTS: O
The O
mean O
age O
(+/-SD) O
of O
the O
60 O
participants O
was O
27.5+/-5.0 O
years, O
spherical O
refractive O
error O
was O
-3.68+/-2.01 O
D, O
and O
cylinder O
was O
-1.28+/-0.36 O
D. O
High- O
and O
low-contrast O
visual B-outcome ['Physiological-Clinical']
acuities I-outcome ['Physiological-Clinical']
with O
toric O
lenses O
were O
better O
than O
with O
spherical O
lenses O
at O
both O
fitting O
(toric O
high-contrast: O
-0.065+/-0.078 O
and O
low-contrast: O
0.133+/-0.103 O
vs. O
spherical O
high-contrast: O
0.001+/-0.104 O
and O
low-contrast: O
0.224+/-0.107) O
and O
follow-up O
(toric O
high-contrast: O
-0.083+/-0.087 O
and O
low-contrast: O
0.108+/-0.107 O
vs. O
spherical O
high-contrast: O
-0.015+/-0.095 O
and O
low-contrast: O
0.211+/-0.104) O
(all O
P<0.0001). O
[['Physiological-Clinical']]

Publication O
date: O
2019/03/01 O
06:00 O
[medline] O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

However, O
Kruskal O
Wallis O
test O
did O
not O
show O
a O
significant O
relationship O
between O
the O
three O
positions O
under O
study O
and O
the O
mean O
gastric B-outcome ['Physiological-Clinical']
residual I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
. O
CONCLUSION: O
Prone O
position O
was O
featured O
with O
the O
lowest O
gastric B-outcome ['Physiological-Clinical']
residual I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
and O
highest O
possibility O
of O
absorbing B-outcome ['Physiological-Clinical']
nutrient I-outcome ['Physiological-Clinical']
. O
Still, O
given O
the O
fact O
that O
no O
significant O
difference O
was O
found O
in O
the O
three O
groups, O
further O
and O
deeper O
studies O
are O
needed. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Title: O
Three-Year O
Prospective O
Randomized O
Comparative O
Assessment O
of O
Anterior O
Maxillary O
Single O
Implants O
with O
Different O
Abutment O
Interfaces. O
[]

This O
study O
was O
conducted O
to O
assess O
the O
safety O
and O
efficacy O
of O
sclerotherapy O
versus O
cyanoacrylate O
injection O
for O
management O
of O
actively O
bleeding O
esophageal O
varices O
in O
cirrhotic O
patients. O
[]

Secondary O
outcomes O
were O
organ B-outcome ['Physiological-Clinical']
dysfunction I-outcome ['Physiological-Clinical']
at O
72 O
hours O
after O
randomization, O
as O
assessed O
by O
Sequential O
Organ B-outcome ['Physiological-Clinical']
Failure I-outcome ['Physiological-Clinical']
Assessment O
(SOFA) O
score O
(range, O
0 O
[best] O
to O
24 O
[worst]); O
death B-outcome ['Mortality']
within O
90 O
days; O
mechanical B-outcome ['Resource-use', 'Resource-use', 'Resource-use', 'Resource-use']
ventilation-, I-outcome ['Resource-use', 'Resource-use', 'Resource-use', 'Resource-use']
renal B-outcome ['Resource-use', 'Resource-use', 'Resource-use', 'Resource-use']
replacement I-outcome ['Resource-use', 'Resource-use', 'Resource-use', 'Resource-use']
therapy-, I-outcome ['Resource-use', 'Resource-use', 'Resource-use', 'Resource-use']
and Seperator ['Resource-use', 'Resource-use', 'Resource-use', 'Resource-use']
vasopressor- B-outcome ['Resource-use', 'Resource-use', 'Resource-use', 'Resource-use']
free I-outcome ['Resource-use', 'Resource-use', 'Resource-use', 'Resource-use']
days E2-outcome ['Resource-use', 'Resource-use', 'Resource-use', 'Resource-use']
within O
28 O
days; O
intensive B-outcome ['Resource-use']
care I-outcome ['Resource-use']
unit I-outcome ['Resource-use']
and O
hospital O
length O
of O
stay O
. O
Results: O
Among O
424 O
patients O
randomized O
(mean O
age, O
63 O
years; O
226 O
[53%] O
women), O
416 O
(98%) O
completed O
the O
trial. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Mortality'], ['Resource-use', 'Resource-use', 'Resource-use', 'Resource-use'], ['Resource-use']]

BACKGROUND: O
Community-based O
organizations O
(CBOs) O
are O
key O
partners O
in O
supporting O
care, O
but O
health O
systems O
and O
CBOs O
operate O
in O
silos. O
[]

REGISTRATION: O
This O
trial O
was O
registered O
at O
ClinicalTrials.govNCT01925924. O
[]

A O
transition O
to O
oral O
omadacycline O
(300 O
mg O
every O
24 O
hours) O
or O
oral O
linezolid O
(600 O
mg O
every O
12 O
hours) O
was O
allowed O
after O
3 O
days; O
the O
total O
treatment O
duration O
was O
7 O
to O
14 O
days. O
[]

Journal-Name:Medicine O
[]

The O
purpose O
of O
this O
study O
was O
to O
examine O
the O
feasibility B-outcome ['Life-Impact']
and O
potential O
effectiveness O
of O
an O
active, O
music-instruction O
intervention O
in O
improving O
psychological B-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
and O
social B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
among O
Veterans O
suffering O
from O
moderate O
to O
severe O
PTSD. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

Results O
may O
be O
used O
to O
tailor O
structural, O
organizational, O
provider, O
patient, O
and O
innovation O
factors O
prior O
to O
future O
implementations O
of O
the O
mhGAP-based O
training O
in O
Tunisia. O
[]

TRIAL O
REGISTRATION: O
Current O
Controlled O
Trials O
ChiCTR-INR-16008863 O
(Date O
of O
registration: O
20 O
July O
2016). O
[]

There O
were O
173 O
with O
complete O
before-and O
after-digital O
images O
of O
the O
teeth. O
[]

CONCLUSIONS: O
Once-monthly O
injections O
of O
givosiran O
in O
patients O
who O
had O
recurrent O
porphyria B-outcome ['Physiological-Clinical']
attacks O
resulted O
in O
mainly O
low-grade O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
, O
reductions O
in O
induced O
ALAS1 B-outcome ['Physiological-Clinical']
mRNA I-outcome ['Physiological-Clinical']
levels, O
nearly O
normalized O
levels O
of O
the O
neurotoxic O
intermediates O
delta B-outcome ['Physiological-Clinical']
aminolevulinic I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
and O
porphobilinogen B-outcome ['Physiological-Clinical']
, O
and O
a O
lower O
attack B-outcome ['Physiological-Clinical']
rate O
than O
that O
observed O
with O
placebo. O
( O
[['Physiological-Clinical'], ['Adverse-effects'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Objective: O
The O
aim O
of O
the O
study O
was O
to O
assess O
the O
effectiveness O
of O
ExMI O
in O
the O
treatment O
of O
stress O
UI O
in O
women. O
[]

INTERVENTION(S): O
We O
randomly O
assigned O
participants O
to O
1 O
of O
4 O
groups: O
rigid O
taping, O
Kinesio O
taping, O
placebo, O
or O
control O
(no O
taping). O
[]

FINDINGS: O
Between O
Jan O
24, O
2013, O
and O
Nov O
7, O
2016, O
601 O
patients O
assessed O
for O
eligibility, O
of O
whom O
452 O
patients O
were O
enrolled O
and O
226 O
were O
randomly O
assigned O
to O
both O
the O
A+CHP O
group O
and O
the O
CHOP O
group. O
[]

We O
investigated O
SPC O
and O
the O
status O
of O
MSI O
and O
Epstein-Barr O
virus O
(EBV) O
as O
combinatory O
biomarkers O
to O
predict O
the O
prognosis O
and O
responsiveness O
of O
adjuvant O
chemotherapy O
for O
stage O
II/III O
gastric O
cancer. O
[]

There O
were O
slight O
transient O
increases O
in O
scaling B-outcome ['Physiological-Clinical']
and O
burning B-outcome ['Physiological-Clinical']
over O
the O
first O
four O
weeks. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Overjets B-outcome ['Physiological-Clinical']
were O
reduced O
by O
7 O
mm O
(SD, O
2.92) O
in O
the O
PT O
group O
and O
6.5 O
mm O
(SD, O
2.62) O
in O
the O
FT O
group, O
with O
no O
statistical O
difference O
between O
the O
groups O
(P O
= O
0.587; O
95% O
CI, O
-1.01, O
1.78). O
[['Physiological-Clinical']]

This O
interaction O
is O
capable O
of O
creating O
toxic O
species O
that O
generate O
cell O
death. O
[]

The O
3-year O
survival B-outcome ['Mortality']
rate O
of O
group O
A O
was O
higher O
than O
that O
of O
group O
BP<0.05. O
[['Mortality']]

Genotypes O
were O
associated O
with O
plasma O
arachidonic B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
levels O
and, O
if O
considered O
together O
with O
the O
levels O
of O
the O
precursor O
alpha-linolenic O
acid, O
also O
with O
DHA B-outcome ['Physiological-Clinical']
. O
Functional B-outcome ['Life-Impact']
outcomes O
and O
supplementation O
effects O
were O
not O
significantly O
associated O
with O
genotype. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact']]

For O
the O
comparison O
of O
the O
Ocular B-outcome ['Physiological-Clinical']
Surface I-outcome ['Physiological-Clinical']
Disease I-outcome ['Physiological-Clinical']
Index O
(OSDI)], O
subjective O
evaluation O
scores, O
tear B-outcome ['Physiological-Clinical']
breakup I-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
(TBUT) I-outcome ['Physiological-Clinical']
and O
fluorescein B-outcome ['Physiological-Clinical']
staining I-outcome ['Physiological-Clinical']
, O
statistically O
significant O
improvements O
were O
noted O
in O
the O
BCL O
group, O
especially O
on O
days O
7 O
and O
14 O
(P O
< O
0.001, O
P O
< O
0.001; O
P O
= O
0.031, O
P O
= O
0.009; O
P O
= O
0.021, O
P O
= O
0.028; O
and O
P O
= O
0.03, O
P O
= O
0.032, O
respectively). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

RESULTS: O
Forced B-outcome ['Physiological-Clinical']
vital I-outcome ['Physiological-Clinical']
capacity I-outcome ['Physiological-Clinical']
(FVC) I-outcome ['Physiological-Clinical']
, O
maximum B-outcome ['Physiological-Clinical']
voluntary I-outcome ['Physiological-Clinical']
ventilation I-outcome ['Physiological-Clinical']
(MVV) I-outcome ['Physiological-Clinical']
, O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
(QOL) I-outcome ['Life-Impact']
, O
and O
self-reported O
health B-outcome ['Physiological-Clinical']
status O
were O
significantly O
increased O
(P O
< O
.05) O
in O
the O
group O
receiving O
joint O
Baduanjin O
and O
CBT O
intervention O
at O
3 O
months O
and O
6 O
months, O
as O
compared O
to O
the O
Baduanjin O
only O
group O
or O
the O
CBT O
only O
group. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact'], ['Physiological-Clinical']]

Title: O
A O
Fully O
Automated O
Method O
for O
the O
Determination O
of O
Serum O
Belatacept O
and O
Its O
Application O
in O
a O
Pharmacokinetic O
Investigation O
in O
Renal O
Transplant O
Recipients. O
[]

At O
23 O
years, O
a O
mean O
of O
2.9 O
extra O
years O
of O
life O
were O
gained O
with O
radical O
prostatectomy. O
[]

The O
mean O
reduction O
in O
total B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
(TC) I-outcome ['Physiological-Clinical']
, O
low B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
lipoprotein-cholesterol I-outcome ['Physiological-Clinical']
(LDL-C) I-outcome ['Physiological-Clinical']
and O
non-high B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
lipoprotein-cholesterol I-outcome ['Physiological-Clinical']
(HDL-C) I-outcome ['Physiological-Clinical']
was O
significantly O
higher O
in O
DR O
group, O
whereas O
mean O
reduction O
in O
triglycerides B-outcome ['Physiological-Clinical']
(TG) I-outcome ['Physiological-Clinical']
and O
increase O
in O
non-high B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
lipoprotein-cholesterol I-outcome ['Physiological-Clinical']
(HDL-C) I-outcome ['Physiological-Clinical']
was O
similar O
in O
both O
the O
groups. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Having O
no O
hope O
for O
the O
future O
was O
independently O
associated O
with O
a O
range O
of O
factors, O
including O
recent O
"eve-teasing" O
(AOR O
1.5 O
(1.0-2.4)), O
being O
engaged O
(AOR O
2.9 O
(0.9-9.7)), O
not O
participating O
in O
groups O
(AOR O
0.5 O
(0.4-0.6)) O
and O
a O
lack O
of O
emotional O
support O
(AOR O
0.6 O
(0.4-0.7)). O
[]

These O
meetings, O
called O
Community O
Health O
Data O
Review O
(CHDR) O
meetings, O
were O
attended O
by O
community O
leaders, O
including O
members O
of O
the O
Ward O
Development O
Committee O
(WDC) O
and O
Health O
Management O
Committee O
(HMC), O
by O
the O
CHW O
Peer O
Supervisors, O
and O
by O
representatives O
of O
the O
Peripheral O
Health O
Unit. O
[]

This O
study O
is O
designed O
to O
evaluate O
the O
effect O
of O
high-dose O
remifentanil O
on O
the O
incidence O
of O
postoperative B-outcome ['Physiological-Clinical']
sore I-outcome ['Physiological-Clinical']
throat I-outcome ['Physiological-Clinical']
(POST) I-outcome ['Physiological-Clinical']
in O
patients O
after O
general O
anesthesia. O
[['Physiological-Clinical']]

RESULTS: O
The O
diet O
and O
exercise O
plus O
diet O
group O
lost O
6.1 O
and O
6.9% O
body B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
, O
respectively. O
[['Physiological-Clinical']]

Journal-Name:The O
New O
England O
journal O
of O
medicine O
[]

Using O
this O
approach, O
repellent O
(N,N-diethyl-benzamide O
- O
12% O
w/w, O
cream) O
is O
distributed O
by O
VHVs O
in O
villages O
sequentially O
throughout O
the O
malaria O
transmission O
season. O
[]

The O
effectiveness O
is O
satisfactory. O
[]

All O
together O
219 O
women O
were O
randomized O
within O
each O
sub-study, O
of O
whom O
74 O
and O
68% O
had O
adequate O
questionnaire O
data O
at O
6 O
and O
12 O
months, O
respectively. O
[]

The O
optimal O
duration O
of O
maintenance O
of O
the O
ACB O
is O
still O
questionable. O
[]

The O
results O
indicate O
that O
these O
vaccines O
were O
safe O
and O
immunogenic B-outcome ['Physiological-Clinical']
in O
ethnic O
Korean O
children. O
[['Physiological-Clinical']]

The O
mean O
time B-outcome ['Life-Impact']
required I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
complete I-outcome ['Life-Impact']
test-1 I-outcome ['Life-Impact']
was O
84.6 O
+/- O
26.6 O
seconds O
in O
training O
group O
and O
90.7 O
+/- O
43.9 O
seconds O
in O
the O
control O
group O
(95% O
CI O
-34.0 O
to O
21.7; O
P O
= O
.653); O
in O
test-2, O
the O
time B-outcome ['Life-Impact']
required O
was O
56.6 O
+/- O
27.9 O
and O
91.2 O
+/- O
43.8 O
seconds O
(95% O
CI O
-63.0 O
to O
-6.2; O
P O
= O
.019), O
respectively. O
[['Life-Impact'], ['Life-Impact']]

Title: O
A O
dose-finding O
randomized O
Phase O
II O
study O
of O
oral O
netupitant O
in O
combination O
with O
palonosetron O
.75 O
mg O
intravenous O
for O
the O
prevention O
of O
chemotherapy-induced O
nausea B-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
in O
Japanese O
patients O
receiving O
highly O
emetogenic O
chemotherapy. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
date: O
2019/03/08 O
06:00 O
[medline] O
[]

Journal O
ID: O
101521595 O
[]

The O
primary O
outcomes O
were O
hospitalized B-outcome ['Mortality']
death I-outcome ['Mortality']
, O
severe B-outcome ['Life-Impact']
disability I-outcome ['Life-Impact']
at O
15 O
months O
of O
age, O
neonatal B-outcome ['Life-Impact']
behavioral I-outcome ['Life-Impact']
neurological I-outcome ['Life-Impact']
assessment O
(NBNA) O
score O
at O
28 O
days O
of O
age, O
and O
Bayley O
scales O
of O
infant B-outcome ['Life-Impact', 'Life-Impact']
development I-outcome ['Life-Impact', 'Life-Impact']
(BSID) O
score O
(including O
mental B-outcome ['Life-Impact']
development I-outcome ['Life-Impact']
index O
(MDI) O
score O
and O
psychomotor B-outcome ['Life-Impact']
development I-outcome ['Life-Impact']
index O
(PDI) O
score) O
at O
15 O
months O
of O
age O
at O
follow-up. O
[['Mortality'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact', 'Life-Impact'], ['Life-Impact'], ['Life-Impact']]

Title: O
Wellbeing O
intervention O
for O
chronic O
kidney O
disease O
(WICKD): O
a O
randomised O
controlled O
trial O
study O
protocol. O
[]

These O
results O
confirm O
retrospective O
studies O
and O
add O
that O
histopathology O
subtype O
is O
a O
strong O
determinant O
of O
disease-free B-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
(DFS) I-outcome ['Physiological-Clinical', 'Mortality']
in O
resected O
MAGE-A3-positive O
NSCLC. O
[['Physiological-Clinical', 'Mortality']]

PE O
teachers O
assigned O
to O
the O
intervention O
condition O
will O
receive O
a O
two-week, O
12-h O
training O
program O
comprising O
basic O
information O
on O
how O
to O
promote O
out-of-school O
physical B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
and O
theory-based O
training O
on O
strategies O
to O
promote O
students' O
autonomous O
motivation B-outcome ['Life-Impact']
toward O
physical O
activity. O
[['Life-Impact'], ['Life-Impact']]

Journal O
ID: O
101521595 O
[]

CONCLUSIONS: O
This O
study O
revealed O
that O
teachers O
believed O
classroom O
based O
activities O
were O
most O
feasible B-outcome ['Life-Impact']
and O
acceptable B-outcome ['Life-Impact']
due O
to O
the O
reduced O
implementation O
barriers O
of O
sufficient O
time O
and O
space. O
[['Life-Impact'], ['Life-Impact']]

METHODS: O
An O
open-label, O
randomised O
controlled O
trial O
will O
be O
conducted O
in O
school-aged O
children O
(5 O
to O
18 O
years) O
from O
the O
region O
of O
Taabo, O
Cote O
d'Ivoire, O
an O
area O
endemic O
for O
S. O
mansoni. O
[]

RESULTS: O
We O
randomized O
210 O
participants, O
and O
197 O
completed O
the O
trial. O
[]

Journal-Name:Lancet O
(London, O
England) O
[]

The O
prevalence O
of O
atelectasis O
was O
10% O
for O
the O
PAR-G O
and O
30% O
for O
the O
1PO-G O
(p=0.0027). O
[]

METHODS: O
This O
trial O
was O
a O
multicenter O
(6 O
centers: O
2 O
teaching O
hospitals, O
4 O
specialist O
orthodontic O
practices), O
single-blinded, O
randomized O
controlled O
trial O
with O
2 O
parallel O
groups. O
[]

There O
was O
a O
statistically O
significant O
higher O
success B-outcome ['Physiological-Clinical']
rate O
regarding O
complete O
success B-outcome ['Physiological-Clinical']
in O
patients O
that O
received O
Ologen(R) O
implant O
(p O
= O
0.04). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

We O
observed O
no O
differences O
among O
groups O
for O
the O
change O
in O
the O
pectoralis B-outcome ['Physiological-Clinical']
minor I-outcome ['Physiological-Clinical']
index O
(P O
> O
.05). O
[['Physiological-Clinical']]

Title: O
Lactulose O
for O
the O
treatment O
of O
Chinese O
children O
with O
chronic O
constipation: O
A O
randomized O
controlled O
trial. O
[]

Both O
techniques O
created O
the O
same O
level O
of O
epithelial B-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
increase O
and O
variation, O
with O
a O
significantly O
higher O
mid-peripheral B-outcome ['Physiological-Clinical']
epithelial I-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
increase. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Importance: O
Microvascular O
obstruction O
commonly O
affects O
patients O
with O
acute O
ST-segment O
elevation O
myocardial O
infarction O
(STEMI) O
and O
is O
associated O
with O
adverse O
outcomes. O
[]

Further O
study O
of O
pegbelfermin O
is O
warranted O
in O
patients O
with O
non-alcoholic O
steatohepatitis. O
[]

Bilateral O
strength O
training O
did O
not O
correct O
the O
unilateral O
strength B-outcome ['Life-Impact']
deficit I-outcome ['Life-Impact']
observed O
in O
this O
group O
of O
survivors O
of O
breast O
cancer. O
[['Life-Impact']]

The O
dose B-outcome ['Resource-use']
of O
propofol O
and O
remifentanil O
were O
also O
statisticed. O
[['Resource-use']]

Title: O
Effect O
of O
Magnetic O
Resonance O
Imaging O
vs O
Conventional O
Treat-to-Target O
Strategies O
on O
Disease B-outcome ['Physiological-Clinical']
Activity I-outcome ['Physiological-Clinical']
Remission I-outcome ['Physiological-Clinical']
and O
Radiographic B-outcome ['Physiological-Clinical']
Progression I-outcome ['Physiological-Clinical']
in O
Rheumatoid O
Arthritis: O
The O
IMAGINE-RA O
Randomized O
Clinical O
Trial. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Title: O
[Evaluation O
of O
intervention O
program O
for O
risk O
behaviors O
of O
unintentional O
injury O
among O
school O
age O
children]. O
[]

Journal O
ID: O
2985248R O
[]

Publication O
date: O
2019/01/13 O
00:00 O
[accepted] O
[]

These O
results O
show O
that O
the O
amla O
extract O
used O
in O
the O
study O
is O
potentially O
a O
hypoglycaemic O
as O
well. O
[]

BACKGROUND: O
Today, O
the O
ever-expanding O
technology O
is O
inevitably O
shadowing O
on O
all O
aspects O
of O
human O
life. O
[]

MAIN O
OUTCOME O
MEASURES: O
The O
primary O
outcome O
was O
the O
Roland-Morris O
Disability B-outcome ['Life-Impact']
Questionnaire O
(RMDQ) O
score O
(range O
0-24) O
at O
one O
year O
follow-up O
in O
the O
intention O
to O
treat O
population. O
[['Life-Impact']]

PATIENTS O
OR O
OTHER O
PARTICIPANTS: O
Seventy-two O
elite O
asymptomatic O
overhead O
athletes O
(age O
= O
17.00 O
+/- O
4.09 O
years, O
height O
= O
1.75 O
+/- O
0.11 O
m, O
mass O
= O
67.26 O
+/- O
15.25 O
kg, O
body O
mass O
index O
= O
21.80 O
+/- O
3.00). O
[]

Registered O
June O
16, O
2015. O
[]

This O
trial O
is O
registered O
with O
ClinicalTrials.gov, O
number O
NCT01777152. O
[]

BACKGROUND: O
Implantation O
failure O
is O
the O
main O
factor O
affecting O
the O
success O
rate O
of O
in O
vitro O
fertilization O
(IVF) O
procedures. O
[]

Title: O
Oral O
ixazomib O
maintenance O
following O
autologous O
stem O
cell O
transplantation O
(TOURMALINE-MM3): O
a O
double-blind, O
randomised, O
placebo-controlled O
phase O
3 O
trial. O
[]

CONCLUSIONS: O
Our O
results O
suggest O
that O
the O
efficacy O
of O
EHF O
is O
potentially O
inferior O
to O
that O
of O
MHF O
and O
that O
further O
studies O
are O
warranted, O
therefore, O
to O
confirm O
these O
findings. O
[]

Journal O
ID: O
2985248R O
[]

Journal O
ID: O
101643584 O
[]

Journal-Name: O
BMJ O
(Clinical O
research O
ed.) O
[]

Under O
PCV O
mode, O
with O
the O
increase O
in O
atomized O
oxygen O
flow, O
inspiratory B-outcome ['Physiological-Clinical']
tidal I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
monitored O
by O
ventilator O
in O
different O
preset O
suction O
pressure O
groups O
was O
decreased O
gradually, O
and O
exhaled B-outcome ['Physiological-Clinical']
tidal I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
was O
increased O
gradually, O
but O
peak B-outcome ['Physiological-Clinical']
airway I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
monitored O
by O
ventilator O
did O
not O
changed O
significantly. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Conclusions O
and O
Relevance: O
Among O
older O
adults O
undergoing O
major O
surgery, O
EEG-guided O
anesthetic O
administration, O
compared O
with O
usual O
care, O
did O
not O
decrease O
the O
incidence O
of O
postoperative O
delirium B-outcome ['Physiological-Clinical', 'Life-Impact']
. O
This O
finding O
does O
not O
support O
the O
use O
of O
EEG-guided O
anesthetic O
administration O
for O
this O
indication. O
[['Physiological-Clinical', 'Life-Impact']]

There O
were O
no O
significant O
between-group O
differences O
in O
the O
incidence O
of O
wheezing B-outcome ['Physiological-Clinical']
or O
shortness B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
breath I-outcome ['Physiological-Clinical']
. O
CONCLUSIONS: O
E-cigarettes O
were O
more O
effective O
for O
smoking B-outcome ['Physiological-Clinical']
cessation I-outcome ['Physiological-Clinical']
than O
nicotine-replacement O
therapy, O
when O
both O
products O
were O
accompanied O
by O
behavioral O
support. O
( O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

The O
physiological B-outcome ['Physiological-Clinical']
adaptive I-outcome ['Physiological-Clinical']
mode I-outcome ['Physiological-Clinical']
( O
activity B-outcome ['Life-Impact']
and O
exercise B-outcome ['Life-Impact']
and O
neonatal B-outcome ['Life-Impact']
nutrition I-outcome ['Life-Impact']
) O
and O
the O
interdependence B-outcome ['Life-Impact']
adaptive I-outcome ['Life-Impact']
mode I-outcome ['Life-Impact']
(appropriate O
affection B-outcome ['Life-Impact']
and O
proper O
development B-outcome ['Life-Impact']
); O
and O
statistically O
significant O
differences O
were O
found O
in O
favor O
of O
the O
experimental O
group. O
[['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

METHODS: O
The O
phase O
3, O
double-blind, O
placebo-controlled O
TOURMALINE-MM3 O
study O
took O
place O
in O
167 O
clinical O
or O
hospital O
sites O
in O
30 O
countries O
in O
Europe, O
the O
Middle O
East, O
Africa, O
Asia, O
and O
North O
and O
South O
America. O
[]

Our O
results O
were O
estimated O
as O
good O
or O
very O
good O
in O
93% O
of O
patients. O
[]

Among O
the O
men O
who O
underwent O
radical O
prostatectomy, O
extracapsular O
extension O
was O
associated O
with O
a O
risk O
of O
death B-outcome ['Mortality']
from I-outcome ['Mortality']
prostate I-outcome ['Mortality']
cancer I-outcome ['Mortality']
that O
was O
5 O
times O
as O
high O
as O
that O
among O
men O
without O
extracapsular O
extension, O
and O
a O
Gleason O
score O
higher O
than O
7 O
was O
associated O
with O
a O
risk O
that O
was O
10 O
times O
as O
high O
as O
that O
with O
a O
score O
of O
6 O
or O
lower O
(scores O
range O
from O
2 O
to O
10, O
with O
higher O
scores O
indicating O
more O
aggressive O
cancer). O
[['Mortality']]

Publication O
date: O
2019/01/01 O
06:00 O
[medline] O
[]

BMI B-outcome ['Physiological-Clinical']
, O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
body B-outcome ['Physiological-Clinical']
composition I-outcome ['Physiological-Clinical']
, O
pulse B-outcome ['Physiological-Clinical']
wave I-outcome ['Physiological-Clinical']
velocity I-outcome ['Physiological-Clinical']
, O
glycemic B-outcome ['Physiological-Clinical']
parameters O
and O
lipid B-outcome ['Physiological-Clinical']
profile O
were O
assessed O
3(-)8 O
years O
after O
randomization. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Compared O
with O
before O
treatment, O
serum O
SOD B-outcome ['Physiological-Clinical']
level O
were O
all O
increased O
and O
malondialdehyde B-outcome ['Physiological-Clinical']
(MDA) I-outcome ['Physiological-Clinical']
level O
were O
all O
decreased O
in O
the O
three O
groups O
after O
treatment O
P<0.05. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

OBJECTIVE: O
To O
investigate O
the O
effects O
of O
aerosol O
inhalation O
on O
respiratory B-outcome ['Physiological-Clinical']
mechanical I-outcome ['Physiological-Clinical']
parameters O
under O
different O
ventilation O
patterns O
and O
ventilator O
parameters O
in O
patients O
on O
mechanical O
ventilation O
and O
simulated O
model O
of O
aqualung O
in O
vitro. O
[['Physiological-Clinical']]

TRIAL O
REGISTRATION: O
Post O
hoc O
analysis O
of O
the O
FLAME O
study. O
[]

Whether O
positive-pressure O
ventilation O
with O
a O
bag-mask O
device O
(bag-mask O
ventilation) O
during O
tracheal O
intubation O
of O
critically O
ill O
adults O
prevents O
hypoxemia O
without O
increasing O
the O
risk O
of O
aspiration O
remains O
controversial. O
[]

CONCLUSIONS: O
Both O
techniques O
were O
effective O
in O
the O
short-term O
(18-30 O
months) O
in O
treatment O
of O
recurrent O
patellar O
dislocation. O
[]

The O
CM O
group O
(12.3% O
increase) O
had O
significantly O
greater O
improvements O
in O
composite O
strength B-outcome ['Life-Impact']
from O
pre- O
to O
post-test O
than O
CHO O
(2.7% O
increase). O
[['Life-Impact']]

METHODS: O
Subjects O
were O
randomized O
to O
receive O
HP O
(256 O
subjects) O
or O
G O
+ O
T O
(132 O
subjects) O
for O
treatment O
of O
minimal, O
mild, O
or O
moderate O
bleeding B-outcome ['Physiological-Clinical']
at O
20 O
investigational O
sites. O
[['Physiological-Clinical']]

This O
sample O
size O
achieves O
90% O
power O
to O
detect O
a O
difference O
of O
14.6% O
between O
the O
two O
groups O
survival O
using O
a O
one-sided O
binomial O
test. O
[]

There O
was O
no O
significant O
(p O
= O
0.774) O
difference, O
however, O
between O
the O
low O
dose O
and O
placebo O
groups. O
[]

Journal-Name:Zhonghua O
nei O
ke O
za O
zhi O
[]

Journal O
ID: O
0135043 O
[]

However, O
the O
employees O
were O
influenced O
by O
several O
factors, O
such O
as O
their O
own O
health O
and O
weight O
loss, O
the O
pressure O
from O
the O
environment O
and O
their O
struggle O
for O
recognition. O
[]

METHODS: O
A O
total O
of O
46 O
eligible O
patients O
with O
acute O
tinnitus O
were O
entered O
and O
included O
in O
this O
randomized O
controlled O
trial. O
[]

RESULTS: O
0.2% O
bio-adhesive O
chlorhexidine O
gel O
used O
after O
mandibular O
third O
molar O
removal O
reduced O
incidence O
of O
alveolar B-outcome ['Physiological-Clinical']
osteitis I-outcome ['Physiological-Clinical']
by O
10% O
in O
comparison O
to O
control O
group O
with O
statistically O
significant O
difference, O
i.e., O
p=0.044.. O
CONCLUSIONS: O
2.3 O
times O
reduction O
in O
the O
incidence O
of O
alveolar B-outcome ['Physiological-Clinical']
osteitis I-outcome ['Physiological-Clinical']
was O
observed O
after O
use O
of O
0.2% O
bio-adhesive O
chlorhexidine O
gel. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

BACKGROUND: O
The O
lack O
of O
surveillance O
system O
is O
a O
major O
barrier O
in O
prevention O
and O
control O
of O
rheumatic O
fever/rheumatic O
heart O
disease O
(RF/RHD). O
[]

CONCLUSIONS: O
Ecabet O
sodium O
had O
a O
preventive O
effect O
on O
low-dose O
aspirin-induced O
small O
intestinal O
mucosal O
injury O
in O
the O
upper O
part O
of O
the O
small O
intestine. O
[]

Title: O
A O
multi-center, O
randomized O
controlled O
clinical O
trial O
of O
the O
application O
of O
a O
shortened O
protocol O
of O
long-acting O
Triptorelin O
down-regulated O
prior O
to O
IVF/ICSI O
among O
patients O
with O
endometriosis: O
A O
protocol. O
[]

By O
week O
8, O
HP/TAZ O
lotion O
achieved O
a O
63.5% O
reduction O
in O
mean O
IGAxBSA O
composite O
score O
(P<0.001 O
versus O
TAZ O
and O
vehicle), O
that O
was O
sustained O
four O
weeks O
posttreatment O
(P<0.001 O
versus O
TAZ O
and O
vehicle O
and O
P=0.003 O
versus O
HP). O
[]

OBJECTIVE: O
To O
observe O
the O
clinical O
efficacy O
of O
dopamine O
modulator O
methylphenidate O
(MPH) O
of O
extended-release O
formulations O
(MPH-ER) O
augmentation O
of O
ongoing O
fluvoxamine O
treatment O
in O
refractory O
obsessive-compulsive O
disorder O
(OCD) O
and O
its O
effects O
on O
patient's O
anxiety B-outcome ['Physiological-Clinical', 'Life-Impact']
and O
sleep B-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
. O
Methods: O
A O
pilot O
randomized, O
placebo-controlled, O
and O
double-blind O
trial O
was O
conducted O
at O
an O
outpatient, O
single-center O
academic O
setting. O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical']]

As O
a O
comparison O
control, O
26 O
advanced O
colorectal O
cancer O
patients O
with O
comparable O
clinical O
baseline O
characteristics O
including O
age, O
sex, O
Eastern O
Cooperative O
Oncology O
Group O
(ECOG) O
score, O
pathological O
type, O
carcinoembryonic O
antigen O
(CEA) O
level, O
tumor O
location, O
number O
and O
location(s) O
of O
metastasis, O
and O
previous O
chemotherapies O
were O
subject O
to O
observation. O
[]

The O
exercise O
protocol O
promoted O
slight O
muscle B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
, O
reflected O
in O
significant O
increases O
in O
total O
creatine B-outcome ['Physiological-Clinical']
kinase I-outcome ['Physiological-Clinical']
in O
all O
subjects O
after O
exercise. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
Type: O
Journal O
Article O
[]

Journal-Name:The O
New O
England O
journal O
of O
medicine O
[]

The O
tear B-outcome ['Physiological-Clinical']
film I-outcome ['Physiological-Clinical']
break-up I-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
was O
higher O
at O
2 O
weeks O
and O
at O
1 O
month O
in O
group O
A. O
The O
Schirmer O
I O
test O
and O
ocular B-outcome ['Physiological-Clinical']
surface I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
index O
scores O
were O
also O
better O
in O
group O
A O
for O
up O
to O
2 O
months. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

No O
significant O
differences O
were O
found O
between O
the O
direct O
and O
video O
groups. O
[]

antibiotic O
monotherapy O
with O
intravenous O
(i.v.) O
[]

Journal-Name:The O
New O
England O
journal O
of O
medicine O
[]

CONCLUSION: O
We O
developed O
a O
high-fidelity O
simulator O
for O
cricothyroidotomy O
from O
3D O
computed O
tomography O
data O
using O
a O
3D O
printer. O
[]

On O
each O
visit O
the O
participants O
consumed O
either O
a O
CA O
+ O
C O
(100 O
mg O
of O
CA O
and O
100 O
mg O
of O
C) O
or O
placebo O
(dextrose) O
capsule. O
[]

Journal O
ID: O
101307187 O
[]

A O
total O
of O
55 O
patients O
with O
histologically O
and O
clinically O
diagnosed O
stage O
IV O
colorectal O
carcinoma O
were O
enrolled O
between O
July O
2014 O
and O
July O
2017. O
[]

Journal O
ID: O
8208604 O
[]

RESULTS: O
At O
a O
median O
follow-up O
of O
33.6 O
months, O
the O
median O
disease-free B-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
was O
21.6 O
months O
in O
the O
modified-FOLFIRINOX O
group O
and O
12.8 O
months O
in O
the O
gemcitabine O
group O
(stratified O
hazard O
ratio O
for O
cancer-related B-outcome ['Physiological-Clinical']
event I-outcome ['Physiological-Clinical']
, O
second B-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
, O
or O
death B-outcome ['Mortality']
, O
0.58; O
95% O
confidence O
interval O
[CI], O
0.46 O
to O
0.73; O
P<0.001). O
[['Physiological-Clinical', 'Mortality'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Mortality']]

Participants O
in O
the O
control O
group O
were O
tested O
again O
after O
1 O
week O
(test-2). O
[]

METHODS: O
Patients O
who O
started O
riociguat O
treatment O
(1.0-2.5 O
mg O
tid) O
within O
the O
trials O
phase O
II, O
PATENT, O
PATENTplus, O
EAS, O
CHEST O
and O
continued O
treatment O
for O
3-12 O
months O
were O
included O
in O
this O
study. O
[]

Within O
7 O
days O
after O
surgery O
(or, O
if O
the O
infection O
was O
being O
managed O
without O
surgery, O
within O
7 O
days O
after O
the O
start O
of O
antibiotic O
treatment), O
participants O
were O
randomly O
assigned O
to O
receive O
either O
intravenous O
or O
oral O
antibiotics O
to O
complete O
the O
first O
6 O
weeks O
of O
therapy. O
[]

Trial O
Registration: O
ClinicalTrials.gov O
Identifier: O
NCT02257294. O
[]

Conclusion: O
Further O
trials O
are O
needed O
to O
determine O
optimal O
treatment O
protocols O
for O
various O
UI O
types O
and O
to O
evaluate O
long-term O
outcomes O
of O
the O
ExMI O
treatment. O
[]

Journal-Name:Medicine O
[]

Publication O
Type: O
Comparative O
Study, O
Journal O
Article, O
Multicenter O
Study, O
Randomized O
Controlled O
Trial, O
Research O
Support, O
U.S. O
Gov't, O
Non-P.H.S., O
[]

Title: O
[A O
comparison O
study O
of O
cognitive-behavioral O
therapy O
alone O
versus O
combination O
with O
tapered O
hypnotic O
agents O
in O
patients O
with O
chronic O
insomnia]. O
[]

Furthermore, O
in O
both O
groups, O
mean B-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
preoperative O
PR B-outcome ['Physiological-Clinical']
interval I-outcome ['Physiological-Clinical']
were O
similar O
at O
various O
times. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

This O
increase O
was O
higher O
in O
women O
who O
conceived O
in O
PRP O
group O
(p O
value: O
0.031). O
[]

PARTICIPANTS: O
13 O
046 O
women O
aged O
16 O
years O
or O
older O
with O
a O
low O
risk O
singleton O
pregnancy. O
[]

We O
enrolled O
522 O
patients O
with O
microscopically O
confirmed O
P. O
vivax O
infection O
(>100 O
to O
<100,000 O
parasites O
per O
microliter) O
and O
normal O
glucose-6-phosphate O
dehydrogenase O
(G6PD) O
activity O
(with O
normal O
activity O
defined O
as O
>/=70% O
of O
the O
median O
value O
determined O
at O
each O
trial O
site O
among O
36 O
healthy O
male O
volunteers O
who O
were O
otherwise O
not O
involved O
in O
the O
trial). O
[]

This O
study O
was O
performed O
in O
a O
double-blind, O
randomized O
crossover O
fashion O
consisting O
of O
two O
exhaustive O
exercise O
protocols. O
[]

The O
assay O
was O
successfully O
applied O
in O
a O
pharmacokinetic O
study O
in O
renal O
transplant O
recipients O
receiving O
belatacept O
infusions. O
[]

The O
primary O
outcome O
was O
the O
fit B-outcome ['Physiological-Clinical']
factor I-outcome ['Physiological-Clinical']
, O
and O
the O
secondary O
outcomes O
were O
overall B-outcome ['Physiological-Clinical']
fit I-outcome ['Physiological-Clinical']
factor I-outcome ['Physiological-Clinical']
, O
adequate O
protection B-outcome ['Life-Impact']
rate, O
and O
respiratory O
preference B-outcome ['Life-Impact']
. O
RESULTS: O
Fit B-outcome ['Physiological-Clinical']
factors I-outcome ['Physiological-Clinical']
, O
overall B-outcome ['Physiological-Clinical']
fit I-outcome ['Physiological-Clinical']
factor I-outcome ['Physiological-Clinical']
, O
and O
adequate B-outcome ['Life-Impact']
protection I-outcome ['Life-Impact']
rate O
were O
higher O
after O
training O
than O
before O
training O
for O
the O
3 O
types O
of O
respirators O
(all O
P O
< O
.05). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact']]

Journal O
ID: O
0255562 O
[]

OBJECTIVE: O
To O
determine O
and O
compare O
the O
short-term O
effects O
of O
rigid O
and O
Kinesio O
taping O
on O
scapular B-outcome ['Physiological-Clinical']
dyskinesis I-outcome ['Physiological-Clinical']
, O
scapular B-outcome ['Physiological-Clinical']
upward I-outcome ['Physiological-Clinical']
rotation I-outcome ['Physiological-Clinical']
, O
and O
pectoralis B-outcome ['Physiological-Clinical']
minor I-outcome ['Physiological-Clinical']
length I-outcome ['Physiological-Clinical']
in O
asymptomatic O
overhead O
athletes. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Flushing B-outcome ['Physiological-Clinical']
and O
flushing-related B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
, O
and O
gastrointestinal B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
were O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
related O
to O
DMF O
treatment. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Adverse-effects']]

Publication O
Type: O
Journal O
Article O
[]

Journal O
ID: O
101474849 O
[]

Publication O
date: O
2019/02/23 O
06:00 O
[medline] O
[]

The O
mean O
age O
of O
enrolled O
subjects O
was O
51 O
years O
old O
[range: O
22 O
to O
76]. O
The O
majority O
was O
male O
(90%). O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Within O
24 O
h O
after O
operation, O
the O
sufentanil B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
in O
group O
D[(35.86+/-8.65)mug]was O
significantly O
less O
than O
that O
in O
group O
C[(59.53+/-15.26) O
mug, O
t=7.061, O
P<0.05], O
and O
the O
number O
of O
patient O
controlled O
analgesia B-outcome ['Resource-use']
pressing O
in O
group O
D(2.15+/-1.38) O
was O
obviously O
less O
than O
that O
in O
group O
C(5.85+/-2.16, O
t=4.971, O
P<0.05). O
[['Resource-use'], ['Resource-use']]

Nonetheless, O
the O
positive O
results O
achieved O
in O
the O
area O
of O
functionality O
of O
the O
CHW O
intervention O
and O
community O
structure O
capacity O
are O
encouraging. O
[]

RESULTS: O
Thirty-four O
patients O
completed O
the O
study. O
[]

The O
average O
age O
was O
65.41 O
years O
(+/-SD O
4.08). O
[]

The O
probabilities O
of O
decompression O
being O
cost-effective O
compared O
with O
no O
treatment O
at O
a O
willingness-to-pay O
threshold O
of O
pound20 O
000 O
per O
QALY O
were O
close O
to O
0% O
at O
six O
months O
and O
approximately O
50% O
at O
one O
year, O
with O
this O
probability O
potentially O
increasing O
for O
the O
extrapolation O
to O
two O
years. O
[]

CONCLUSION: O
The O
1 O
year O
MACE B-outcome ['Physiological-Clinical', 'Mortality']
rates O
are O
comparable O
in O
patients O
who O
underwent O
elective O
coronary O
revascularization O
using O
sirolimus O
eluting O
polymer-free O
and O
biodegradable O
polymer O
stents. O
[['Physiological-Clinical', 'Mortality']]

Journal-Name:Journal O
of O
medical O
microbiology O
[]

OBJECTIVES: O
To O
study O
if O
four O
cycles O
of O
remote O
ischemic O
preconditioning O
(RIPC) O
could O
offer O
protection O
against O
contrast B-outcome ['Physiological-Clinical']
induced I-outcome ['Physiological-Clinical']
nephropathy I-outcome ['Physiological-Clinical']
(CIN) I-outcome ['Physiological-Clinical']
and O
post O
procedural O
renal B-outcome ['Physiological-Clinical']
dysfunction I-outcome ['Physiological-Clinical']
in O
high O
risk O
patients O
undergoing O
percutaneous O
coronary O
intervention O
(PCI). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Title: O
Metabolizable O
Energy B-outcome ['Physiological-Clinical']
from O
Cashew O
Nuts O
is O
Less O
than O
that O
Predicted O
by O
Atwater O
Factors. O
[['Physiological-Clinical']]

Title: O
FOLFIRINOX O
or O
Gemcitabine O
as O
Adjuvant O
Therapy O
for O
Pancreatic O
Cancer. O
[]

Journal O
ID: O
101510759 O
[]

Publication O
date: O
2019/01/18 O
06:00 O
[entrez] O
[]

The O
primary O
endpoint O
of O
the O
study O
was O
between O
group O
difference O
in O
child O
reported O
pain B-outcome ['Physiological-Clinical']
from O
baseline O
to O
12 O
months O
as O
assessed O
using O
the O
Wong O
Baker O
faces O
pain B-outcome ['Physiological-Clinical']
scale]. O
Secondary O
endpoints O
were O
parent O
reported O
pain B-outcome ['Physiological-Clinical']
(100 O
mm O
visual O
analogue O
scale), O
parent O
reported O
function B-outcome ['Life-Impact']
( O
child O
health B-outcome ['Physiological-Clinical']
assessment O
questionnaire]), O
child O
reported O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
( O
child O
health B-outcome ['Physiological-Clinical']
utility O
9-dimensional O
assessment]), O
coordination B-outcome ['Life-Impact']
( O
movement B-outcome ['Life-Impact']
assessment O
battery O
for O
children O
version O
2]) O
and O
grip B-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
(handheld O
dynamometer). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact'], ['Physiological-Clinical'], ['Life-Impact'], ['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

Late O
first-trimester O
high O
adherence O
to O
the O
predefined O
six O
food O
targets O
is O
associated O
with O
a O
reduction O
in O
the O
risk O
of O
gestational B-outcome ['Physiological-Clinical']
diabetes I-outcome ['Physiological-Clinical']
mellitus I-outcome ['Physiological-Clinical']
(GDM) I-outcome ['Physiological-Clinical']
, O
emergency B-outcome ['Resource-use']
C-section I-outcome ['Resource-use']
, O
perineal B-outcome ['Physiological-Clinical']
trauma I-outcome ['Physiological-Clinical']
, O
pregnancy-induced B-outcome ['Physiological-Clinical']
hypertension I-outcome ['Physiological-Clinical']
and O
preeclampsia O
, O
prematurity B-outcome ['Physiological-Clinical']
, O
large-for-gestational-age B-outcome ['Physiological-Clinical']
, O
and/or O
small-for-gestational-age B-outcome ['Physiological-Clinical']
, O
urinary B-outcome ['Physiological-Clinical']
tract I-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
(UTI) I-outcome ['Physiological-Clinical']
, O
prematurity B-outcome ['Physiological-Clinical']
, O
and O
small-for-gestational-age B-outcome ['Physiological-Clinical']
(SGA) I-outcome ['Physiological-Clinical']
newborns. O
[['Physiological-Clinical'], ['Resource-use'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Process O
evaluations O
can O
provide O
information O
on O
which O
aspects O
of O
an O
intervention O
were O
delivered O
and O
how. O
[]

The O
exercise O
session O
attendance B-outcome ['Life-Impact']
rate O
was O
62% O
for O
HIIT O
(288/465) O
and O
75% O
for O
MICT O
(320/429), O
with O
62% O
of O
HIIT O
participants O
(8/13) O
and O
67% O
of O
MICT O
participants O
(8/12) O
completing O
at O
least O
24 O
of O
36 O
sessions. O
[['Life-Impact']]

Journal O
ID: O
101521595 O
[]

The O
participants O
were O
randomly O
assigned O
to O
one O
of O
two O
treatment O
groups O
for O
dry O
needling O
or O
sham O
dry O
needling, O
delivered O
in O
3 O
sessions O
a O
week O
for O
2 O
weeks. O
[]

Hybrid O
surgery O
comprised O
a O
two-field O
abdominal-thoracic O
operation O
(also O
called O
an O
Ivor-Lewis O
procedure) O
with O
laparoscopic O
gastric O
mobilization O
and O
open O
right O
thoracotomy. O
[]

Journal O
ID: O
101266132 O
[]

By O
the O
end O
of O
the O
10-year O
follow-up, O
11 O
patients O
(36.7%) O
in O
the O
CC O
group O
had O
experienced O
local B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
versus O
11 O
patients O
(36.7%) O
in O
the O
RC O
group O
(P O
> O
0.999). O
[['Physiological-Clinical']]

OBJECTIVE: O
To O
evaluate O
the O
efficacy O
and O
safety O
of O
selective O
brain O
hypothermia O
(SBH) O
in O
the O
treatment O
of O
neonates O
with O
moderate O
or O
severe O
neonatal O
hypoxic-ischemic O
encephalopathy O
(HIE), O
and O
the O
effect O
of O
SBH O
treatment O
on O
serum O
levels O
of O
neuron-specific B-outcome ['Physiological-Clinical']
enolase I-outcome ['Physiological-Clinical']
(NSE) I-outcome ['Physiological-Clinical']
and O
central B-outcome ['Physiological-Clinical']
nervous I-outcome ['Physiological-Clinical']
specific I-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
S100 I-outcome ['Physiological-Clinical']
. O
METHODS: O
A O
prospective O
randomized O
controlled O
trial O
was O
conducted. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Changes O
in O
the O
100-mm O
visual O
analogue O
scale O
(VAS) O
for O
low B-outcome ['Physiological-Clinical']
back I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
after O
6 O
weeks O
from O
baseline O
will O
be O
assessed O
as O
the O
primary O
outcome. O
[['Physiological-Clinical']]

The O
data O
of O
age, O
sex, O
and O
laterality O
were O
analyzed O
through O
pairwise O
comparison. O
[]

Journal O
ID: O
100968555 O
[]

Interestingly, O
the O
main O
determinant O
of O
vitamin O
D O
at O
baseline O
was O
the O
waist O
circumference. O
[]

In O
the O
5 O
PCBHIS O
communities, O
the O
findings O
from O
monthly O
reports O
submitted O
by O
community O
health O
workers O
(CHWs) O
and O
verbal O
autopsy O
findings O
for O
deaths O
of O
children O
who O
died O
before O
reaching O
5 O
years O
of O
age, O
were O
processed O
and O
shared O
at O
bimonthly O
meetings O
in O
each O
community. O
[]

BACKGROUND: O
This O
study O
evaluated O
the O
impact O
of O
an O
exercise O
program O
on O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
in O
older O
breast O
cancer O
survivors O
undergoing O
aromatase O
inhibitor O
therapy. O
[['Life-Impact']]

Both O
inspiratory B-outcome ['Physiological-Clinical']
tidal I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
and O
exhaled B-outcome ['Physiological-Clinical']
tidal I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
monitored O
by O
ventilator O
could O
not O
reflect O
the O
patient's O
tidal B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
under O
either O
VCV O
or O
PCV O
mode. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Journal O
ID: O
101213819 O
[]

METHOD: O
Thirty O
individuals O
with O
ALS O
(18 O
men O
and O
12 O
women, O
mean O
age O
59 O
years, O
range O
44-74 O
years) O
with O
a O
mean O
score O
of O
26, O
(minimum O
score O
of O
14 O
and O
maximum O
41) O
on O
the O
Revised O
Amyotrophic O
Lateral O
Sclerosis O
Functional O
Rating O
Scale O
(ALSFRS-R) O
and O
30 O
healthy O
controls O
matched O
for O
age O
and O
gender, O
participated. O
[]

The O
range B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
motion I-outcome ['Physiological-Clinical']
, O
functional B-outcome ['Life-Impact']
score O
( O
Harris O
score]), O
visual O
analogue O
scale O
(VAS) O
score, O
and O
prosthesis B-outcome ['Physiological-Clinical']
position I-outcome ['Physiological-Clinical']
were O
recorded. O
[['Physiological-Clinical'], ['Life-Impact'], ['Physiological-Clinical']]

Publication O
date: O
2019/01/10 O
06:00 O
[entrez] O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

The O
objective O
of O
this O
study O
was O
to O
evaluate O
right B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
heart I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
size I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
function S2-outcome ['Physiological-Clinical', 'Physiological-Clinical']
assessed O
by O
echocardiography O
during O
long O
term O
treatment O
with O
riociguat. O
[['Physiological-Clinical', 'Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Thus, O
the O
present O
study O
was O
conducted O
with O
the O
aim O
to O
determine O
the O
effect O
of O
lavender O
aromatherapy O
on O
the O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
(QOL) I-outcome ['Life-Impact']
of O
postmenopausal O
women. O
[['Life-Impact']]

RESULTS: O
At O
the O
end O
of O
8-week O
treatment, O
the O
patients O
in O
the O
treatment O
group O
did O
not O
achieve O
better O
outcomes O
in O
post-voiding B-outcome ['Physiological-Clinical']
residual I-outcome ['Physiological-Clinical']
urine I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
(PV-VRU) I-outcome ['Physiological-Clinical']
(P O
= O
.66), O
voided B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
(P O
= O
.59), O
maximum B-outcome ['Physiological-Clinical']
urinary I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
rate O
(Qmax) O
(P O
= O
.53), O
and O
Barthel O
Index O
(BI) O
scores O
(P O
= O
.67), O
than O
patients O
in O
the O
control O
group. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Hence, O
the O
primary O
objective O
was O
to O
study O
the O
hypothesis O
that O
methohexital O
confers O
a O
better O
hemodynamic B-outcome ['Physiological-Clinical']
profile O
than O
propofol O
for O
anesthetic O
induction, O
in O
patients O
receiving O
AAB. O
[['Physiological-Clinical']]

Relevant O
participants' O
data O
will O
be O
collected O
at O
enrolment O
and O
at O
delivery. O
[]

Journal O
ID: O
0255562 O
[]

Overall O
incidence O
of O
total O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
in O
FZD O
and O
CLA O
groups O
was O
19.57% O
and O
13.98%, O
and O
their O
severe B-outcome ['Adverse-effects']
side I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
3.26% O
and O
2.15%, O
respectively O
(P O
> O
.05). O
[['Adverse-effects'], ['Adverse-effects']]

RESULTS: O
A O
statistically O
significant O
difference O
was O
observed O
between O
the O
mean O
self-efficacy B-outcome ['Life-Impact']
indices O
in O
the O
experimental O
group O
(p=0.001). O
[['Life-Impact']]

Journal-Name:Medicine O
[]

Clinical B-outcome ['Physiological-Clinical']
attachment I-outcome ['Physiological-Clinical']
level I-outcome ['Physiological-Clinical']
was O
improved O
but O
the O
results O
were O
not O
statically O
significant. O
[['Physiological-Clinical']]

The O
proposed O
trial O
aims O
to O
provide O
evidence O
for O
the O
effectiveness O
of O
repellent O
distributed O
through O
VHVs O
in O
reducing O
malaria B-outcome ['Physiological-Clinical']
. O
METHODS: O
The O
study O
is O
an O
open O
stepped-wedge O
cluster-randomised O
controlled O
trial O
randomised O
at O
the O
village O
level. O
[['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Publication O
date: O
2019/01/23 O
06:00 O
[medline] O
[]

The O
administration O
of O
gonadotrophin-releasing O
hormone O
(GnRH) O
agonists O
prior O
to O
IVF/ICSI O
can O
improve O
the O
successful O
pregnancy O
rate. O
[]

They O
were O
randomly O
assigned O
to O
an O
experimental O
group O
and O
a O
control O
group O
(14 O
individuals O
in O
each O
group) O
and O
then O
were O
post-tested O
after O
two O
months. O
[]

Osteoporosis O
is O
a O
common O
complication O
of O
transfusion O
dependent O
beta-thalassemia O
(TDT) O
and O
denosumab O
has O
been O
recently O
emerged O
as O
a O
promising O
therapeutic O
option. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

For O
the O
project O
manager, O
achieving O
good O
scientific O
results O
was O
highlighted O
as O
well. O
[]

Publication O
Type: O
Journal O
Article O
[]

Publication O
Type: O
Journal O
Article, O
Multicenter O
Study, O
Pragmatic O
Clinical O
Trial, O
Randomized O
Controlled O
Trial, O
Research O
Support, O
Non-U.S. O
Gov't, O
[]

MATERIALS O
AND O
METHODS: O
In O
this O
randomized O
clinical O
trial, O
83 O
women O
with O
poor O
endometrial O
response O
to O
standard O
hormone O
replacement O
therapy O
(HRT) O
(endometrium O
thickness O
< O
7 O
mm) O
in O
the O
13th O
day O
of O
the O
cycle O
in O
a O
frozen-thawed O
embryo O
transfer O
(FET) O
were O
entered O
in O
two O
groups. O
[]

Fourteen O
patients O
in O
both O
the O
placebo-dexmedetomidine O
and O
acetaminophen-propofol O
groups O
(46% O
and O
45%) O
and O
7 O
in O
the O
acetaminophen-dexmedetomidine O
and O
placebo-propofol O
groups O
(24% O
and O
23%) O
had O
hypotension B-outcome ['Physiological-Clinical']
. O
Conclusions O
and O
Relevance: O
Among O
older O
patients O
undergoing O
cardiac O
surgery, O
postoperative O
scheduled O
IV O
acetaminophen, O
combined O
with O
IV O
propofol O
or O
dexmedetomidine, O
reduced O
in-hospital O
delirium B-outcome ['Physiological-Clinical', 'Life-Impact']
vs O
placebo. O
[['Physiological-Clinical'], ['Physiological-Clinical', 'Life-Impact']]

The O
level B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the O
root O
canal O
filling O
was O
better O
in O
the O
Calen(R)/ZO O
group. O
[['Physiological-Clinical']]

Journal O
ID: O
101476450 O
[]

BACKGROUND: O
Occupational O
radiation O
exposureis O
a O
growing O
problem O
due O
to O
increasing O
number O
and O
complexity O
of O
interventional O
procedures. O
[]

Objectives: O
To O
compare O
foot O
and O
ankle O
mobility, O
foot O
posture, O
and O
dynamic O
knee O
valgus, O
measured O
as O
the O
frontal O
plane O
projection O
angle O
(FPPA) O
during O
single-leg O
squatting, O
between O
individuals O
with O
and O
without O
PFOA. O
[]

The O
intention-to-treat O
analysis O
showed O
a O
difference O
in O
the O
risk O
of O
definitive O
treatment B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
(oral O
group O
vs. O
intravenous O
group) O
of O
-1.4 O
percentage O
points O
(90% O
confidence O
interval O
[CI], O
-4.9 O
to O
2.2; O
95% O
CI, O
-5.6 O
to O
2.9), O
indicating O
noninferiority. O
[['Physiological-Clinical']]

High O
ECOG O
scores, O
cancer O
localization O
to O
the O
right O
side O
of O
colon O
and O
lymph O
node O
metastasis O
were O
associated O
with O
increased O
risk O
of O
death B-outcome ['Mortality']
and O
all O
remained O
independent O
factors O
affecting O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
. O
The O
most O
common O
grade O
3/4 O
treatment-related O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
hypertension B-outcome ['Physiological-Clinical']
and O
hand-foot B-outcome ['Physiological-Clinical']
skin I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
. O
Apatinib O
treatment O
for O
patients O
with O
advanced O
colorectal O
cancer O
who O
had O
failed O
chemotherapy O
achieved O
better O
disease B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
and O
prolonged O
progression-free B-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
relative O
to O
untreated O
controls. O
[['Mortality'], ['Mortality'], ['Adverse-effects'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical', 'Mortality']]

FINDINGS: O
Between O
Feb O
28, O
2013, O
and O
April O
12, O
2018, O
71 O
patients O
were O
enrolled. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

BACKGROUND: O
Mental O
health O
disorders O
among O
adolescents O
have O
emerged O
as O
a O
major O
public O
health O
issue O
in O
many O
low O
and O
middle-income O
countries, O
including O
India. O
[]

Discussion: O
Short-term O
use O
of O
IQOS(TM) O
has O
a O
minimal O
impact O
on O
exhaled B-outcome ['Physiological-Clinical']
CO I-outcome ['Physiological-Clinical']
, O
is O
equally O
effective O
in O
reducing O
cigarette B-outcome ['Physiological-Clinical']
craving I-outcome ['Physiological-Clinical']
and O
withdrawal B-outcome ['Physiological-Clinical', 'Life-Impact', 'Life-Impact']
symptoms I-outcome ['Physiological-Clinical', 'Life-Impact', 'Life-Impact']
as O
an O
e-cigarette, O
and O
is O
slightly O
preferred B-outcome ['Life-Impact']
. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical', 'Life-Impact', 'Life-Impact'], ['Life-Impact']]

Publication O
date: O
2019/01/05 O
06:00 O
[medline] O
[]

Patients O
from O
the O
1st O
group O
were O
to O
take O
nicorandil O
2 O
days O
and O
1 O
day O
before O
the O
PCI O
at O
the O
30 O
mg/day O
dose, O
then O
20 O
mg O
orally O
2 O
hours O
just O
before O
PCI, O
and O
one O
more O
time O
6 O
hours O
after O
the O
PCI O
- O
10 O
mg O
nicorandil. O
[]

METHODS: O
Sixteen O
healthy O
volunteers O
were O
randomly O
assigned O
in O
a O
crossover O
design O
manner O
to O
either O
a O
LOWFODMAP O
(16.06 O
+/- O
1.79 O
g.d(- O
1)) O
or O
HIGHFODMAP O
(38.65 O
+/- O
6.66 O
g.d(- O
1)) O
diet O
for O
7 O
days, O
with O
a O
one O
week O
washout O
period O
followed O
by O
a O
further O
7 O
days O
on O
the O
alternate O
diet. O
[]

Final O
date O
of O
follow-up O
was O
January O
1, O
2018. O
[]

Journal-Name:Medicine O
[]

Journal O
ID: O
101090633 O
[]

PURPOSE: O
The O
goal O
of O
this O
investigation O
was O
to O
define O
time-dependent O
peri-implant B-outcome ['Physiological-Clinical']
tissue I-outcome ['Physiological-Clinical']
changes O
at O
implants O
with O
different O
abutment O
interface O
designs. O
[['Physiological-Clinical']]

METHODS: O
Older O
breast O
cancer O
survivors O
were O
randomized O
into O
two O
groups: O
combined O
training: O
resistance O
+ O
aerobic O
exercise O
program O
for O
nine O
months O
(n O
= O
18) O
or O
control O
group O
(n O
= O
18). O
[]

Thirty O
patients O
(50%) O
received O
prophylactic O
powdered O
GLN O
orally O
at O
a O
dose O
of O
10 O
g/8 O
h. O
The O
prescribed O
radiation O
dose O
to O
the O
planning O
target O
volume O
was O
30 O
Gy O
in O
2-Gy O
fractions. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

PATIENTS: O
A O
total O
of O
97 O
patients O
suffering O
from O
LBP. O
[]

PURPOSE: O
To O
evaluate O
3-dimensional O
epithelial O
remodeling O
in O
patients O
undergoing O
myopic O
laser O
in O
situ O
keratomileusis O
(LASIK) O
versus O
small O
incision O
lenticule O
extraction O
(SMILE). O
[]

Publication O
date: O
2018/12/23 O
06:00 O
[entrez] O
[]

Title: O
Live O
Music O
Therapy O
During O
Rehabilitation O
After O
Total O
Knee O
Arthroplasty: O
A O
Randomized O
Controlled O
Trial. O
[]

Therefore, O
it O
can O
be O
concluded O
that O
MBCT O
is O
effective O
on O
illness B-outcome ['Life-Impact']
perceptions I-outcome ['Life-Impact']
and O
psychological B-outcome ['Life-Impact']
syndrome I-outcome ['Life-Impact']
and O
can O
be O
used O
as O
an O
MBI O
method O
to O
reduce O
the O
illness B-outcome ['Life-Impact']
perceptions I-outcome ['Life-Impact']
in O
people O
with O
RA. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

Title: O
Effect O
of O
a O
Nurse-Led O
Preventive O
Psychological O
Intervention O
on O
Symptoms O
of O
Posttraumatic B-outcome ['Physiological-Clinical', 'Life-Impact']
Stress I-outcome ['Physiological-Clinical', 'Life-Impact']
Disorder O
Among O
Critically O
Ill O
Patients: O
A O
Randomized O
Clinical O
Trial. O
[['Physiological-Clinical', 'Life-Impact']]

This O
will O
help O
to O
determine O
if O
routine O
selenium O
supplementation O
in O
HIV-infected O
pregnant O
women O
will O
contribute O
to O
the O
improvement O
in O
the O
major O
adverse B-outcome ['Adverse-effects']
pregnancy I-outcome ['Adverse-effects']
outcomes I-outcome ['Adverse-effects']
such O
as O
preterm B-outcome ['Physiological-Clinical']
birth I-outcome ['Physiological-Clinical']
and O
low B-outcome ['Physiological-Clinical']
birth I-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
and O
the O
HIV B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
surrogate O
markers O
such O
as O
CD4+ B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
and O
viral B-outcome ['Physiological-Clinical']
load I-outcome ['Physiological-Clinical']
. O
TRIAL O
REGISTRATION: O
PACTR, O
PACTR201809756724274. O
[['Adverse-effects'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

The O
preventive, O
complex O
psychological O
intervention O
comprised O
promotion O
of O
a O
therapeutic O
ICU O
environment O
plus O
3 O
stress O
support O
sessions O
and O
a O
relaxation O
and O
recovery O
program O
delivered O
by O
trained O
ICU O
nurses O
to O
high-risk O
(acutely O
stressed) O
patients. O
[]

Journal-Name:The O
New O
England O
journal O
of O
medicine O
[]

The O
children O
in O
routine O
treatment O
group O
were O
given O
the O
traditional O
symptomatic O
supportive O
treatment, O
supplemented O
by O
drugs O
to O
promote O
nerve O
cell O
growth. O
[]

Journal-Name:Medicine O
[]

It O
was O
found O
that O
exhausted O
terminal O
programmed O
cell O
death O
1 O
(PD1)+ O
CD8+ O
T O
cells O
in O
the O
peripheral O
blood O
are O
independently O
associated O
with O
worse O
progression B-outcome ['Physiological-Clinical', 'Mortality']
free I-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
(PFS) I-outcome ['Physiological-Clinical', 'Mortality']
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
(OS) I-outcome ['Mortality']
. O
Notably, O
hydrogen O
gas O
decreased O
the O
abundance O
of O
exhausted O
terminal O
PD1+ B-outcome ['Physiological-Clinical']
CD8+ I-outcome ['Physiological-Clinical']
T I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
, O
increased O
that O
of O
active O
terminal O
PD1 B-outcome ['Physiological-Clinical']
CD8+ I-outcome ['Physiological-Clinical']
T I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
, O
and O
improved O
progression B-outcome ['Physiological-Clinical', 'Mortality']
free I-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
(PFS) I-outcome ['Physiological-Clinical', 'Mortality']
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
(OS) I-outcome ['Mortality']
times, O
suggesting O
that O
the O
balance O
between O
terminal O
PD1+ B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
PD1 B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
CD8+ I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
cells E3-outcome ['Physiological-Clinical', 'Physiological-Clinical']
is O
critical O
for O
cancer O
prognosis. O
[['Physiological-Clinical', 'Mortality'], ['Mortality'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical', 'Mortality'], ['Mortality'], ['Physiological-Clinical', 'Physiological-Clinical']]

Acute O
GU B-outcome ['Physiological-Clinical']
Toxicities I-outcome ['Physiological-Clinical']
were O
more O
common O
in O
the O
MHF O
than O
the O
EHF O
group O
(85 O
vs. O
57%, O
p O
= O
0.009), O
but O
late O
GI B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
GU B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
toxicities E1-outcome ['Physiological-Clinical', 'Physiological-Clinical']
did O
not O
differ O
between O
groups. O
[['Physiological-Clinical'], ['Physiological-Clinical', 'Physiological-Clinical']]

The O
patients O
were O
randomly O
assigned O
to O
1 O
of O
2 O
groups: O
Group O
1 O
patients O
received O
curettage O
plus O
NCH O
gel O
(intervention O
group), O
and O
group O
2 O
patients O
received O
curettage O
alone O
(control O
group). O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Main O
Outcomes O
and O
Measures: O
The O
primary O
outcome O
was O
12-month O
change O
in O
adherence B-outcome ['Life-Impact']
based O
on O
the O
energy-reduced O
Mediterranean O
diet O
(er-MedDiet) O
score O
(range, O
0-17; O
higher O
scores O
indicate O
greater O
adherence; O
minimal O
clinically O
important O
difference, O
1 O
point). O
[['Life-Impact']]

FUNDING: O
Neovii O
Biotech. O
[]

Compared O
with O
the O
preoperative O
levels, O
serum O
cortisol B-outcome ['Physiological-Clinical']
level O
at O
the O
end O
of O
the O
operation O
was O
increased O
in O
the O
sedation O
group O
but O
lowered O
in O
the O
control O
group, O
and O
the O
variations O
of O
serum O
cortisol B-outcome ['Physiological-Clinical']
level O
differed O
significantly O
between O
the O
two O
groups O
(t=4.75, O
P O
&lt; O
0.01). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Conclusion: O
Nursing O
intervention O
can O
effectively O
improve O
forced B-outcome ['Physiological-Clinical']
expiratory I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
in O
1 O
second O
(FEV(1) O
, O
forced B-outcome ['Physiological-Clinical']
vital I-outcome ['Physiological-Clinical']
capacity I-outcome ['Physiological-Clinical']
(FVC) I-outcome ['Physiological-Clinical']
, O
arterial B-outcome ['Physiological-Clinical']
partial I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
(PaO(2) I-outcome ['Physiological-Clinical']
, O
and O
6-minute O
walking B-outcome ['Physiological-Clinical']
distance I-outcome ['Physiological-Clinical']
in O
patients O
with O
silicosis O
complicated O
by O
stable O
COPD. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Title: O
Does O
Doctor O
Race O
Affect O
the O
Health O
of O
Black O
Men? O
[]

CONCLUSIONS: O
Direct O
and O
video O
instructions O
are O
equally O
effective O
in O
teaching O
parents O
to O
perform O
simple O
whole B-outcome ['Life-Impact']
motor I-outcome ['Life-Impact']
tasks O
in O
the O
NICU, O
and O
parents O
welcome B-outcome ['Life-Impact']
the O
instruction O
. O
[['Life-Impact'], ['Life-Impact']]

This O
trial O
is O
registered, O
number O
ISRCTN99214271. O
[]

When O
sex O
was O
considered, O
females O
had O
lower O
urine B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
[UV] I-outcome ['Physiological-Clinical']
, O
elevated O
urine B-outcome ['Physiological-Clinical']
osmolality I-outcome ['Physiological-Clinical']
(UOsm) I-outcome ['Physiological-Clinical']
(p O
< O
0.05), O
trends O
for O
higher O
Delta O
Body B-outcome ['Physiological-Clinical']
Weight I-outcome ['Physiological-Clinical']
[BW] I-outcome ['Physiological-Clinical']
), O
urine B-outcome ['Physiological-Clinical']
specific I-outcome ['Physiological-Clinical']
gravity I-outcome ['Physiological-Clinical']
[USG] I-outcome ['Physiological-Clinical']
, O
but O
similar O
salivary B-outcome ['Physiological-Clinical']
osmolality I-outcome ['Physiological-Clinical']
(SOsm) I-outcome ['Physiological-Clinical']
. O
Analysis O
of O
beverages O
and O
urine O
for O
antioxidant B-outcome ['Physiological-Clinical']
potential I-outcome ['Physiological-Clinical']
(AP) I-outcome ['Physiological-Clinical']
revealed O
a O
four-fold O
greater O
antioxidant B-outcome ['Physiological-Clinical']
potential I-outcome ['Physiological-Clinical']
(AP) I-outcome ['Physiological-Clinical']
in O
MW, O
which O
increased O
peak O
urine O
antioxidant B-outcome ['Physiological-Clinical']
potential I-outcome ['Physiological-Clinical']
(AP) I-outcome ['Physiological-Clinical']
(9.4 O
+/- O
0.7 O
vs. O
7.6 O
+/- O
1.0 O
mmol, O
MW O
vs. O
control, O
p O
< O
0.05). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Nd:YAG O
laser O
goniopuncture O
was O
done O
in O
cases O
where O
the O
intraocular O
pressure O
(IOP) O
was O
elevated O
above O
21 O
mmHg O
after O
discontinuation O
of O
corticosteroid O
eye O
drops O
at O
any O
follow-up O
visit. O
[]

Baseline O
characteristics O
differed O
between O
genders, O
with O
women O
being O
younger, O
having O
better O
lung O
function O
and O
more O
often O
experiencing O
>/=2 O
exacerbations O
in O
the O
previous O
year. O
[]

Minor B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
was O
significantly O
less O
in O
group O
B O
[Bleeding O
Academic O
Research O
Consortium O
1, O
A O
= O
6.63% O
vs O
B O
= O
1.81%, O
odds O
ratio O
(OR) O
= O
3.86, O
95% O
confidence O
interval O
(CI) O
= O
1.06-14.08, O
P O
= O
0.05]. O
Major B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
was O
higher O
in O
group O
A O
(A O
= O
3.61%, O
vs O
B O
= O
1.81%, O
OR O
= O
2.04, O
95% O
CI O
= O
0.50-8.29, O
P O
= O
0.50). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

The O
present O
study O
was O
aimed O
to O
evaluate O
the O
effect O
of O
TEAS O
on O
the O
effective O
concentration B-outcome ['Life-Impact']
(EC50) O
of O
remifentanil O
suppressing O
tracheal O
extubation O
response O
in O
elderly O
patients. O
[['Life-Impact']]

This O
study O
aimed O
to O
evaluate O
the O
effects O
of O
a O
12-week O
high-intensity O
interval O
exercise O
(HIIT) O
training O
program O
involving O
suspension O
exercises O
(TRX) O
on O
the O
muscle B-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
, O
body B-outcome ['Physiological-Clinical']
composition I-outcome ['Physiological-Clinical']
, O
gait B-outcome ['Life-Impact']
speed I-outcome ['Life-Impact']
, O
and O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
of O
older O
adults. O
[['Life-Impact'], ['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact']]

The O
Ocular B-outcome ['Physiological-Clinical']
Surface I-outcome ['Physiological-Clinical']
Disease I-outcome ['Physiological-Clinical']
Index O
(OSDI) O
questionnaire, O
evaluation O
of O
subjective O
symptoms B-outcome ['Physiological-Clinical']
and O
evaluation O
of O
the O
best-corrected B-outcome ['Physiological-Clinical']
visual I-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
(BCVA) I-outcome ['Physiological-Clinical']
were O
conducted O
preoperatively O
and O
postoperatively O
on O
days O
1, O
7, O
14, O
30 O
and O
90. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

METHODS: O
In O
a O
multicenter, O
double-blind, O
placebo-controlled, O
delayed-start O
trial, O
we O
randomly O
assigned O
patients O
with O
early O
Parkinson's O
disease O
to O
receive O
levodopa O
(100 O
mg O
three O
times O
per O
day) O
in O
combination O
with O
carbidopa O
(25 O
mg O
three O
times O
per O
day) O
for O
80 O
weeks O
(early-start O
group) O
or O
placebo O
for O
40 O
weeks O
followed O
by O
levodopa O
in O
combination O
with O
carbidopa O
for O
40 O
weeks O
(delayed-start O
group). O
[]

Publication O
date: O
['2019/10/18 O
06:00' O
[]

Title: O
Physiological, O
hyaluronan-selected O
intracytoplasmic O
sperm O
injection O
for O
infertility O
treatment O
(HABSelect): O
a O
parallel, O
two-group, O
randomised O
trial. O
[]

The O
measures O
represent O
the O
exposure O
in O
a O
normal O
workload O
schedule O
of O
ninety O
randomly O
selected O
workers O
over O
a O
3-month O
period, O
extrapolated O
to O
1 O
year. O
[]

p<0.001). O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

CONCLUSIONS: O
There O
was O
no O
difference O
in O
either O
dental B-outcome ['Physiological-Clinical']
or O
skeletal B-outcome ['Physiological-Clinical']
changes O
achieved O
with O
PT O
or O
FT O
wear O
of O
a O
Twin-block O
appliance O
over O
12 O
months. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

The O
G1 O
presented O
a O
higher O
average O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
in O
relation O
to O
the O
G2, O
such O
differences O
were O
not O
significant O
(p> O
0.05). O
[['Resource-use']]

A O
prespecified O
interim O
analysis O
at O
week O
8 O
showed O
a O
greater O
than O
expected O
change O
in O
the O
primary O
outcome O
and O
supported O
early O
closing O
of O
patient O
enrolment, O
since O
this O
analysis O
indicated O
that O
the O
full O
planned O
sample O
size O
was O
not O
needed. O
[]

Efficacy O
and O
safety O
results O
in O
the O
Japanese O
subgroup O
and O
the O
East O
Asian O
subgroup O
(which O
included O
patients O
from O
Japan, O
Taiwan, O
and O
South O
Korea) O
were O
consistent O
with O
the O
overall O
study O
population. O
[]

At O
the O
16-week O
follow-up, O
significant O
group O
by O
time O
interaction O
effects O
were O
observed O
in O
percentage O
body B-outcome ['Physiological-Clinical']
fat I-outcome ['Physiological-Clinical']
(%BF) O
(beta O
= O
-1.52, O
95%CI O
= O
-2.58(-)-0.45), O
lean B-outcome ['Physiological-Clinical']
body I-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
(LM) I-outcome ['Physiological-Clinical']
(beta O
= O
1.20, O
95%CI O
= O
0.12(-)2.29), O
diastolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
(beta O
= O
-5.24, O
95%CI O
= O
-9.66(-)-0.83), O
high-sensitivity B-outcome ['Physiological-Clinical']
C-reactive I-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
(beta O
= O
-1.67, O
95%CI O
= O
-2.77(-)-1.01), O
and O
wall O
sit O
test O
score O
(beta O
= O
50.74, O
95%CI O
= O
32.30(-)69.18). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Four O
of O
the O
6 O
care-seeking O
behaviors O
judged O
to O
be O
amenable O
to O
promotion O
by O
CHWs O
improved O
more O
in O
the O
intervention O
area O
than O
in O
the O
comparison O
area, O
and O
1 O
was O
statistically O
significant O
(treatment O
of O
diarrhea O
with O
ORS O
and O
zinc). O
[]

Moreover, O
gastrocnemius B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
medialis I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
biceps B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
femoris I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
peak I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
activation E3-outcome ['Physiological-Clinical', 'Physiological-Clinical']
during O
loading O
response O
decreased O
by O
8.36%MVIC O
(95% O
CI O
= O
2.71, O
14.02) O
and O
3.54%MVIC O
(95% O
CI O
= O
1.08, O
6.01), O
respectively, O
in O
the O
control O
group O
overtime. O
[['Physiological-Clinical', 'Physiological-Clinical']]

Control O
group O
received O
general O
education. O
[]

None O
of O
the O
intervention-arms O
was O
cost-effective O
for O
sickness B-outcome ['Life-Impact']
absence I-outcome ['Life-Impact']
. O
There O
was O
85% O
probability O
of O
exercise-arm O
being O
cost-effective O
if O
willing O
to O
pay O
euro3550 O
for O
QALY O
gained. O
[['Life-Impact']]

PMID: O
31623042 O
[]

Nervous O
tissues O
may O
be O
less O
prone O
to O
low O
DHA B-outcome ['Physiological-Clinical']
levels O
after O
infancy, O
or O
higher O
doses O
might O
be O
required O
to O
impact O
neurological B-outcome ['Life-Impact']
functions I-outcome ['Life-Impact']
. O
In O
situations O
of O
minimal O
dietary O
DHA, O
endogenous O
synthesis O
of O
DHA O
from O
alpha-linolenic O
acid O
could O
relevantly O
contribute O
to O
DHA B-outcome ['Physiological-Clinical']
status. O
[['Physiological-Clinical'], ['Life-Impact'], ['Physiological-Clinical']]

Ferric B-outcome ['Physiological-Clinical']
reducing I-outcome ['Physiological-Clinical']
ability O
of O
plasma O
and O
vitamin B-outcome ['Physiological-Clinical']
C I-outcome ['Physiological-Clinical']
levels O
in O
AA O
cohort O
significantly O
increased O
after O
exercise O
(p O
< O
0.05). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

In O
Study O
1, O
this O
effect O
was O
observed O
in O
end-of-day B-outcome ['Life-Impact']
positive I-outcome ['Life-Impact']
affect I-outcome ['Life-Impact']
. O
In O
Study O
2, O
this O
effect O
was O
found O
in O
both O
end-of-day B-outcome ['Life-Impact', 'Life-Impact']
and Seperator ['Life-Impact', 'Life-Impact']
momentary B-outcome ['Life-Impact', 'Life-Impact']
positive I-outcome ['Life-Impact', 'Life-Impact']
affect E2-outcome ['Life-Impact', 'Life-Impact']
outcomes. O
[['Life-Impact'], ['Life-Impact', 'Life-Impact']]

Journal-Name:Complementary O
therapies O
in O
clinical O
practice O
[]

We O
divided O
45 O
subjects O
into O
3 O
groups: O
those O
with O
expert O
proctoring O
(group O
I), O
those O
who O
watched O
only O
an O
educational O
video O
(group O
II), O
and O
those O
with O
independent O
training O
(group O
III; O
n O
= O
15 O
per O
group). O
[]

Furthermore, O
the O
24 O
elite O
football O
players O
were O
randomly O
assigned O
to O
either O
a O
dark O
chocolate O
(>85% O
cocoa) O
intake O
(n O
= O
12) O
or O
a O
control O
group O
(n O
= O
12) O
for O
30 O
days O
in O
a O
randomized O
controlled O
trial. O
[]

The O
forearm O
band O
showed O
better O
scores O
on O
joint B-outcome ['Physiological-Clinical']
position I-outcome ['Physiological-Clinical']
reproduction I-outcome ['Physiological-Clinical']
at O
70 O
degrees O
compared O
with O
the O
elbow O
sleeve O
(P O
= O
.006), O
whereas O
the O
elbow O
sleeve O
showed O
better O
scores O
at O
110 O
degrees O
(P O
< O
.001). O
[['Physiological-Clinical']]

Over O
the O
36-month O
period, O
there O
were O
no O
significant O
changes O
in O
the O
location B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
mesial I-outcome ['Physiological-Clinical']
or O
distal O
papilla O
in O
any O
group. O
[['Physiological-Clinical']]

They O
were O
randomly O
divided O
into O
placebo, O
D1, O
and O
D2 O
groups, O
respectively. O
[]

The O
postinduction O
systolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
(P O
= O
.03), O
diastolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
(P O
< O
.001) O
and O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
(P O
= O
.03) O
were O
significantly O
higher O
in O
the O
methohexital O
group. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

CONCLUSIONS: O
L-Methylfolate O
was O
associated O
with O
no O
change O
in O
efficacy O
on O
measures O
relevant O
to O
neuropsychiatric B-outcome ['Life-Impact', 'Life-Impact']
function I-outcome ['Life-Impact', 'Life-Impact']
in O
adults O
with O
ADHD, O
other O
than O
suggestion O
of O
reduced O
efficacy O
of O
methylphenidate. O
[['Life-Impact', 'Life-Impact']]

The O
intervention O
period O
lasted O
30 O
days O
(1 O
session O
every O
10 O
days). O
[]

Funded O
by O
Vanderbilt O
Institute O
for O
Clinical O
and O
Translational O
Research O
and O
others; O
PreVent O
ClinicalTrials.gov O
number, O
NCT03026322.). O
[]

The O
primary O
outcome O
was O
the O
24th O
hour O
tramadol B-outcome ['Resource-use']
consumption. O
[['Resource-use']]

Adverse B-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
were O
analyzed O
by O
the O
incidence O
rate, O
type, O
and O
severity. O
[['Adverse-effects']]

BACKGROUND: O
The O
increasing O
multidrug O
resistance O
among O
gram-negative O
uropathogens O
necessitates O
new O
treatments O
for O
serious O
infections. O
[]

Although O
none O
of O
our O
patient O
had O
significant O
elevation O
of O
CPK B-outcome ['Physiological-Clinical']
. O
CONCLUSION: O
This O
study O
concluded O
that O
both O
doses O
of O
atorvastatin O
(40 O
& O
80mg) O
are O
equally O
efficacious O
in O
improving O
dyslipidemia B-outcome ['Physiological-Clinical']
but O
higher O
dose O
leads O
to O
more O
incidence O
of O
myalgia B-outcome ['Physiological-Clinical']
. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Both O
groups O
were O
treated O
and O
followed O
up O
for O
six O
months. O
[]

BACKGROUND: O
Proprietary O
spearmint O
extract O
(PSE) O
containing O
a O
minimum O
14.5% O
rosmarinic O
acid O
and O
24% O
total O
phenolic O
content, O
has O
evinced O
positive O
effects O
on O
cognition O
in O
individuals O
aged O
50-70 O
with O
memory O
impairment O
after O
chronic O
supplementation. O
[]

Vaping O
did O
not O
affect O
exhaled B-outcome ['Physiological-Clinical']
CO I-outcome ['Physiological-Clinical']
. O
Cigarette B-outcome ['Physiological-Clinical']
craving I-outcome ['Physiological-Clinical']
reduced O
significantly O
after O
product O
use, O
with O
the O
decline O
being O
stronger O
for O
smoking O
than O
for O
e-cigarettes O
or O
IQOS(TM). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Unhealthy O
food O
sponsorship O
also O
led O
to O
greater O
perceived O
event-sponsor B-outcome ['Life-Impact', 'Life-Impact']
fit I-outcome ['Life-Impact', 'Life-Impact']
and Seperator ['Life-Impact', 'Life-Impact']
transfer B-outcome ['Life-Impact', 'Life-Impact']
of I-outcome ['Life-Impact', 'Life-Impact']
perceptions E1-outcome ['Life-Impact', 'Life-Impact']
of O
the O
sporting O
event O
to O
the O
unhealthy O
food O
sponsor O
brands, O
relative O
to O
the O
control O
group. O
[['Life-Impact', 'Life-Impact']]

In O
a O
double-blind O
multicentric O
trial, O
109 O
PKU O
patients O
were O
randomized O
to O
DHA O
doses O
from O
0 O
to O
7 O
mg/kg&amp;day O
for O
six O
months. O
[]

A O
total O
of O
21 O
patients O
(10.9%) O
in O
the O
bag-mask O
ventilation O
group O
had O
severe B-outcome ['Physiological-Clinical']
hypoxemia I-outcome ['Physiological-Clinical']
, O
as O
compared O
with O
45 O
patients O
(22.8%) O
in O
the O
no-ventilation O
group O
(relative O
risk, O
0.48; O
95% O
confidence O
interval O
[CI], O
0.30 O
to O
0.77). O
[['Physiological-Clinical']]

Publication O
date: O
2019/01/29 O
06:00 O
[medline] O
[]

Journal O
ID: O
101213729 O
[]

In O
experimental O
group, O
patients O
received O
delayed-start O
GnRH O
antagonist O
protocol O
with O
estrogen O
priming O
followed O
by O
early O
follicular-phase O
GnRH O
antagonist O
treatment O
for O
7 O
days O
before O
ovarian O
stimulation O
with O
gonadotropin O
and O
in O
control O
group, O
patients O
treated O
with O
estrogen O
priming O
antagonist O
protocol. O
[]

Title: O
Changes O
in O
Unilateral O
Upper B-outcome ['Life-Impact']
Limb I-outcome ['Life-Impact']
Muscular I-outcome ['Life-Impact']
Strength I-outcome ['Life-Impact']
and O
Electromyographic B-outcome ['Physiological-Clinical']
Activity O
After O
a O
16-Week O
Strength O
Training O
Intervention O
in O
Survivors O
of O
Breast O
Cancer. O
[['Life-Impact'], ['Physiological-Clinical']]

Journal O
ID: O
7501160 O
[]

There O
was O
a O
statistically O
significant O
improvement O
in O
the O
post O
procedure O
creatinine B-outcome ['Physiological-Clinical']
values O
at O
24h O
(p=0.013), O
48h O
(p=0.015), O
2 O
weeks O
(p=0.003), O
6 O
weeks O
(p=0.003) O
and O
post O
procedure O
glomerular B-outcome ['Physiological-Clinical']
filtration I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
(eGFR) I-outcome ['Physiological-Clinical']
values O
at O
24h O
(p=0.026), O
48h O
(p=0.044), O
2 O
weeks O
(p=0.015) O
and O
6 O
weeks O
(p=0.011) O
in O
study O
group O
compared O
to O
control O
group. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

PMID: O
31597806 O
[]

We O
have O
developed O
a O
drug-capture O
assay O
(using O
drug O
target) O
to O
measure O
belatacept O
in O
serum O
and O
applied O
this O
assay O
in O
a O
pharmacokinetic O
study O
in O
renal O
transplant O
recipients. O
[]

All O
patients O
presented O
with O
a O
vital O
maxillary O
or O
mandibular O
molar, O
premolar, O
or O
front O
teeth O
designated O
for O
intentional O
endodontic O
RCT O
for O
prosthetic O
reasons. O
[]

2015;35(3): O
R17-R34). O
[]

Title: O
Efficacy O
of O
antibiotic O
treatment O
in O
patients O
with O
chronic O
low O
back O
pain O
and O
Modic O
changes O
(the O
AIM O
study): O
double O
blind, O
randomised, O
placebo O
controlled, O
multicentre O
trial. O
[]

The O
postprandial O
insulin B-outcome ['Physiological-Clinical']
and O
GLP-1 B-outcome ['Physiological-Clinical']
responses O
were O
not O
significantly O
different. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Funded O
by O
Paratek O
Pharmaceuticals; O
OASIS-1 O
ClinicalTrials.gov O
number, O
NCT02378480 O
.). O
[]

After O
12 O
months, O
patients O
receiving O
riociguat O
therapy O
showed O
a O
significant O
reduction O
in O
right B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
atrial I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
(- X ['Physiological-Clinical', 'Physiological-Clinical']
2.6 X ['Physiological-Clinical', 'Physiological-Clinical']
+/- X ['Physiological-Clinical', 'Physiological-Clinical']
4.4 X ['Physiological-Clinical', 'Physiological-Clinical']
cm2, X ['Physiological-Clinical', 'Physiological-Clinical']
95% X ['Physiological-Clinical', 'Physiological-Clinical']
CI X ['Physiological-Clinical', 'Physiological-Clinical']
-3.84, X ['Physiological-Clinical', 'Physiological-Clinical']
- X ['Physiological-Clinical', 'Physiological-Clinical']
1.33; X ['Physiological-Clinical', 'Physiological-Clinical']
p X ['Physiological-Clinical', 'Physiological-Clinical']
< X ['Physiological-Clinical', 'Physiological-Clinical']
0.001, X ['Physiological-Clinical', 'Physiological-Clinical']
n X ['Physiological-Clinical', 'Physiological-Clinical']
= X ['Physiological-Clinical', 'Physiological-Clinical']
49) X ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
right B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
(RV) I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
area E1-outcome ['Physiological-Clinical', 'Physiological-Clinical']
(- O
3.5 O
+/- O
5.2 O
cm2, O
95% O
CI O
-5.1, O
- O
1.9; O
p O
< O
0.001; O
n O
= O
44), O
RV B-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
(- O
0.76 O
+/- O
2.2 O
mm, O
95% O
CI O
-1.55, O
0.03; O
n O
= O
32), O
and O
a O
significant O
increase O
in O
TAPSE B-outcome ['Physiological-Clinical']
(2.95 O
+/- O
4.78 O
mm, O
95% O
CI O
1.52, O
4.39; O
n O
= O
45) O
and O
RV B-outcome ['Physiological-Clinical']
fractional I-outcome ['Physiological-Clinical']
area I-outcome ['Physiological-Clinical']
change O
(8.12 O
+/- O
8.87 O
mm, O
95% O
CI O
4.61, O
11.62; O
n O
= O
27). O
[['Physiological-Clinical', 'Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Title: O
Observation O
of O
the O
curative O
effect O
of O
device-guided O
rehabilitation O
on O
respiratory B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
stable O
patients O
with O
chronic O
obstructive O
pulmonary O
disease. O
[['Physiological-Clinical']]

Physical O
exercise O
remains O
a O
potentially O
useful O
adjunct O
therapy O
in O
CD. O
[ O
[]

INTRODUCTION: O
N95 O
or O
higher O
filtering O
respirators O
have O
been O
recommended O
in O
healthcare O
settings, O
although O
there O
is O
still O
a O
risk O
of O
infection O
due O
to O
the O
improper O
selection O
and O
wearing O
of O
respirators. O
[]

Secondary O
objectives O
were O
to O
compare O
the O
effects O
of O
atorvastatin O
40mg O
vs O
80mg O
on O
HDL-C B-outcome ['Physiological-Clinical']
and O
triglycerides B-outcome ['Physiological-Clinical']
and O
also O
comparing O
of O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
( O
myopathy B-outcome ['Physiological-Clinical']
, O
hepatotoxicity B-outcome ['Physiological-Clinical']
and O
new B-outcome ['Physiological-Clinical']
onset I-outcome ['Physiological-Clinical']
diabetes I-outcome ['Physiological-Clinical']
mellitus I-outcome ['Physiological-Clinical']
) O
of O
both O
doses. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Adverse-effects'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Preliminary O
evidence O
suggests O
that O
patients' O
beliefs O
and O
perceptions O
may O
influence O
their O
prognosis. O
[]

RESULTS: O
A O
total O
of O
388 O
subjects O
were O
included O
in O
the O
primary O
efficacy O
analysis. O
[]

Journal-Name:The O
international O
journal O
of O
behavioral O
nutrition O
and O
physical O
activity O
[]

The O
ETView O
tracheoscopic O
ventilation O
tube O
(TVT) O
is O
a O
tracheal O
tube O
(TT) O
incorporating O
a O
video O
camera O
and O
a O
light O
source O
in O
its O
tip. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

The O
cumulative O
opioid B-outcome ['Resource-use']
dose I-outcome ['Resource-use']
administered O
at O
6, O
12, O
24, O
and O
48 O
h O
after O
surgery O
were O
recorded. O
[['Resource-use']]

Journal O
ID: O
101234168 O
[]

Mixed O
model O
ANOVAs O
and O
ANCOVAs O
were O
used O
to O
statistically O
analyze O
the O
dependent O
variables O
for O
the O
total O
groups O
(n O
= O
21 O
per O
group) O
as O
well O
as O
dichotomized O
groups. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Publication O
Type: O
Journal O
Article O
[]

During O
induction O
chemotherapy, O
the O
incidence O
rates O
of O
leukocytopenia B-outcome ['Physiological-Clinical']
(43.3% O
vs. O
80%, O
P O
= O
0.003), O
thrombocytopenia B-outcome ['Physiological-Clinical']
(26.7% O
vs. O
56.7%, O
P O
= O
0.018), O
and O
nausea/vomiting B-outcome ['Physiological-Clinical']
(40% O
vs. O
66.7%, O
P O
= O
0.038) O
were O
significantly O
lower O
in O
the O
CC O
group O
than O
in O
the O
RC O
group. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Background O
& O
objectives: O
: O
Three O
doses O
of O
intermittent O
preventive O
treatment O
with O
sulphadoxine-pyrimethamine O
(IPTp-SP) O
has O
been O
adopted O
as O
the O
new O
recommendation O
for O
prevention O
of O
malaria B-outcome ['Physiological-Clinical']
in O
pregnancy. O
[['Physiological-Clinical']]

Journal-Name:Taiwanese O
journal O
of O
obstetrics O
& O
gynecology O
[]

Publication O
Type: O
Journal O
Article, O
Randomized O
Controlled O
Trial, O
[]

Journal O
ID: O
100967802 O
[]

OBJECTIVE: O
This O
study O
aimed O
to O
evaluate O
the O
effectiveness O
of O
Kinesio O
tape O
(KT) O
on O
lower O
limb O
muscle B-outcome ['Physiological-Clinical']
activation I-outcome ['Physiological-Clinical']
pattern O
in O
children O
with O
developmental O
coordination O
disorder O
(DCD) O
during O
walking. O
[['Physiological-Clinical']]

Taking O
effective O
preventive O
measures O
is O
particularly O
important O
for O
control O
of O
HFMD O
infection. O
[]

The O
curative O
effect O
was O
compared O
before O
and O
after O
treatment, O
including O
ulcer B-outcome ['Physiological-Clinical']
surface I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
(VAS O
score), O
time B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
ulcer I-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
, O
and O
the O
changes O
of O
T B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
subsets I-outcome ['Physiological-Clinical']
( O
CD3(+) B-outcome ['Physiological-Clinical']
, O
CD4(+) B-outcome ['Physiological-Clinical']
, O
CD8(+) B-outcome ['Physiological-Clinical']
and O
CD4(+)/CD8(+) B-outcome ['Physiological-Clinical']
) O
before O
and O
after O
treatment O
were O
compared O
by O
SPSS O
22 O
software O
package. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

The O
initial O
3 O
mg O
dose O
was O
increased O
to O
4 O
mg O
from O
cycle O
5 O
if O
tolerated O
during O
cycles O
1-4. O
[]

Journal O
ID: O
2985248R O
[]

No O
additional O
significant O
benefit O
could O
be O
shown O
from O
the O
intervention O
compared O
to O
standard O
management. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

The O
primary O
outcome O
was O
microbiologically O
confirmed O
or O
clinically O
suspected O
late-onset O
infection B-outcome ['Physiological-Clinical']
(occurring O
>72 O
h O
after O
birth), O
which O
was O
assessed O
in O
all O
participants O
for O
whom O
primary O
outcome O
data O
was O
available O
by O
calculating O
the O
relative O
risk O
ratio O
with O
95% O
CI O
between O
the O
two O
groups. O
[['Physiological-Clinical']]

PURPOSE/BACKGROUND: O
Interventions O
for O
attention-deficit/hyperactivity O
disorder O
(ADHD) O
may O
be O
inadequate O
for O
some O
patients. O
[]

Publication O
Type: O
Journal O
Article O
[]

The O
analysis O
of O
which O
was O
conducted O
before O
PCI O
and O
24 O
hours O
after O
the O
surgery. O
[]

INTERPRETATION: O
Front-line O
treatment O
with O
A+CHP O
is O
superior O
to O
CHOP O
for O
patients O
with O
CD30-positive O
peripheral O
T-cell O
lymphomas O
as O
shown O
by O
a O
significant O
improvement O
in O
progression-free B-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
with O
a O
manageable O
safety O
profile. O
[['Physiological-Clinical', 'Mortality'], ['Mortality']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Journal-Name:Complementary O
therapies O
in O
clinical O
practice O
[]

The O
duration O
of O
treatment O
lasted O
for O
8 O
weeks. O
[]

The O
main O
outcomes O
were O
the O
rate O
and O
severity B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
of I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
intrauterine B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
adhesions E2-outcome ['Physiological-Clinical', 'Physiological-Clinical']
formation, O
which O
were O
assessed O
by O
follow-up O
hysteroscopy O
performed O
in O
the O
ensuing O
2-6 O
months. O
[['Physiological-Clinical', 'Physiological-Clinical']]

They O
were O
randomly O
divided O
into O
2 O
groups O
of O
120 O
each. O
[]

Journal-Name:Medicine O
[]

Publication O
date: O
2019/01/08 O
06:00 O
[medline] O
[]

CONCLUSIONS: O
The O
findings O
support O
the O
feasibility B-outcome ['Life-Impact']
and O
acceptability B-outcome ['Life-Impact']
of O
the O
exercise O
programmes O
and O
trial O
procedures. O
[['Life-Impact'], ['Life-Impact']]

CONCLUSIONS: O
We O
found O
that O
hybrid O
minimally O
invasive O
esophagectomy O
resulted O
in O
a O
lower O
incidence O
of O
intraoperative O
and O
postoperative O
major O
complications B-outcome ['Adverse-effects']
, O
specifically O
pulmonary B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
, O
than O
open O
esophagectomy, O
without O
compromising O
overall B-outcome ['Mortality', 'Physiological-Clinical']
and Seperator ['Mortality', 'Physiological-Clinical']
disease-free B-outcome ['Mortality', 'Physiological-Clinical']
survival E1-outcome ['Mortality', 'Physiological-Clinical']
over O
a O
period O
of O
3 O
years. O
( O
[['Adverse-effects'], ['Physiological-Clinical'], ['Mortality', 'Physiological-Clinical']]

The O
findings O
provide O
new O
insights O
on O
the O
effects O
and O
mechanisms O
of O
a O
MBI O
on O
aMCI O
symptoms. O
[]

METHODS/DESIGN: O
Eligible O
and O
consenting O
women O
will O
be O
randomly O
assigned O
to O
one O
of O
two O
treatments O
(one O
cycle O
of O
a O
GnRH O
agonist O
or O
two O
cycles O
of O
a O
GnRH O
agonist) O
prior O
to O
IVF/ICSI O
using O
a O
table O
of O
random O
numbers. O
[]

All O
patients O
received O
a O
3-day O
course O
of O
chloroquine O
(total O
dose O
of O
1500 O
mg). O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

The O
median O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
an O
objective O
response O
among O
patients O
who O
had O
a O
response O
was O
9.6 O
months O
(interquartile O
range, O
6.6 O
to O
16.7) O
in O
the O
sorafenib O
group O
and O
13.3 O
months O
(interquartile O
range, O
11.2 O
to O
31.1) O
in O
the O
placebo O
group. O
[['Physiological-Clinical']]

The O
time O
required O
for O
a O
change O
in O
TOFr O
values O
from O
0.25 O
to O
0.75 O
and O
0.9 O
was O
evaluated. O
[]

Osmotic-release O
oral O
system O
methylphenidate O
was O
dose O
optimized O
over O
the O
first O
6 O
weeks. O
[]

RESULTS: O
Data O
from O
55 O
of O
the O
62 O
participants O
were O
analyzed. O
[]

Results: O
At O
week O
12, O
mean O
percent O
reduction O
in O
inflammatory O
and O
noninflammatory O
lesion B-outcome ['Physiological-Clinical']
counts O
were O
60.1% O
and O
53.0%, O
respectively, O
compared O
with O
51.1% O
and O
38.7% O
with O
vehicle O
(P</=0.001) O
in O
the O
Hispanic O
population. O
[['Physiological-Clinical']]

2) O
Compared O
with O
the O
results O
at O
baseline, O
subjective O
sleep B-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
(SQ) I-outcome ['Physiological-Clinical']
, O
sleep B-outcome ['Physiological-Clinical']
onset I-outcome ['Physiological-Clinical']
latency I-outcome ['Physiological-Clinical']
(SOL) I-outcome ['Physiological-Clinical']
, O
sleep B-outcome ['Physiological-Clinical']
efficiency I-outcome ['Physiological-Clinical']
(SE) I-outcome ['Physiological-Clinical']
, O
sleep B-outcome ['Physiological-Clinical']
disturbance I-outcome ['Physiological-Clinical']
(SD) I-outcome ['Physiological-Clinical']
and O
used O
sleep B-outcome ['Resource-use']
medication I-outcome ['Resource-use']
(USM) O
in O
PSQI O
in O
combination O
group O
significantly O
decreased O
at O
week O
4 O
and O
8 O
(all O
P<0.05) O
. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Resource-use']]

A O
range O
of O
studies O
showed O
confusing O
data O
about O
the O
relationship O
between O
obesity, O
weight O
reduction O
and O
circulating O
total O
insulin-like O
growth O
factor O
-1 O
(IGF-1). O
[]

Clinical O
interventions O
to O
address O
greater O
foot O
mobility O
may O
be O
relevant O
for O
PFOA. O
[]

RESULTS: O
Analysis O
identified O
different O
views O
and O
considerations O
for O
engaging O
in O
a O
weight O
loss O
intervention O
at O
the O
workplace. O
[]

Publication O
date: O
2018/12/21 O
00:00 O
[accepted] O
[]

The O
primary O
outcome O
was O
the O
lowest O
oxygen B-outcome ['Physiological-Clinical']
saturation I-outcome ['Physiological-Clinical']
observed O
during O
the O
interval O
between O
induction O
and O
2 O
minutes O
after O
tracheal O
intubation. O
[['Physiological-Clinical']]

Twenty O
minutes O
before O
the O
end O
of O
surgery, O
single O
bolus O
injection O
of O
fentanyl, O
50 O
mug O
(fentanyl O
group O
[group O
F], O
n O
= O
23) O
or O
oxycodone, O
4 O
mg O
(oxycodone O
group O
[group O
O], O
n O
= O
23) O
was O
administered O
intravenously. O
[ O
[]

We O
quantified O
associations O
between O
macrolide B-outcome ['Life-Impact']
and O
fluoroquinolone B-outcome ['Life-Impact']
use O
and O
cardiac B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
in O
patients O
hospitalized O
with O
CAP O
in O
non-ICU O
wards. O
[['Life-Impact'], ['Life-Impact'], ['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

These O
findings O
may O
be O
explained O
by O
a O
reduction O
in O
indigestible O
carbohydrates O
available O
for O
fermentation O
in O
the O
gut. O
[]

Functional B-outcome ['Life-Impact']
outcomes O
were O
similar O
in O
all O
three O
groups O
in O
POD O
1 O
and O
POD O
2. O
[['Life-Impact']]

Title: O
The O
addition O
of O
simvastatin O
administration O
to O
cold O
storage O
solution O
of O
explanted O
whole O
liver O
grafts O
for O
facing O
ischemia/reperfusion O
injury O
in O
an O
area O
with O
a O
low O
rate O
of O
deceased O
donation: O
a O
monocentric O
randomized O
controlled O
double-blinded O
phase O
2 O
study. O
[]

We O
analyzed O
44 O
patients O
with O
hypovitaminosis O
at O
baseline O
and O
after O
six O
months O
of O
two O
different O
regimens O
of O
administration: O
seven O
drops O
(1750 O
IU)/day O
vs. O
50,000 O
IU/month. O
[]

Publication O
date: O
2018/12/15 O
06:00 O
[entrez] O
[]

OBJECTIVE: O
The O
study O
sought O
to O
compare O
the O
efficacy O
of O
a O
lower O
loading O
dose O
of O
prasugrel O
with O
conventional O
loading O
dose O
of O
prasugrel O
in O
Indian O
patients. O
[]

A O
total O
of O
82 O
children O
with O
spastic O
cerebral O
palsy O
were O
recruited, O
including O
43 O
children O
in O
treatment O
group O
and O
39 O
children O
in O
control O
group. O
[]

Publication O
date: O
2019/02/12 O
06:00 O
[medline] O
[]

BACKGROUND: O
Unhealthy O
foods O
are O
promoted O
heavily, O
through O
food O
company O
sponsorship O
of O
elite O
sport, O
resulting O
in O
extensive O
exposure O
among O
young O
adults O
who O
are O
avid O
sport O
spectators. O
[]

However, O
individuals O
who O
met O
in-person O
with O
a O
faculty O
member O
rated O
effectiveness O
of O
communication B-outcome ['Life-Impact']
higher O
than O
those O
who O
met O
via O
videoconference O
(p=0.0002), O
while O
those O
who O
met O
online O
rated O
convenience B-outcome ['Life-Impact']
higher O
than O
those O
who O
met O
in-person O
(p<0.0001). O
[['Life-Impact'], ['Life-Impact']]

Journal O
ID: O
2985248R O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

At O
baseline, O
mean O
(SD) O
duration O
of O
cry B-outcome ['Life-Impact', 'Life-Impact']
and Seperator ['Life-Impact', 'Life-Impact']
fuss B-outcome ['Life-Impact', 'Life-Impact']
time E1-outcome ['Life-Impact', 'Life-Impact']
was O
comparable O
in O
the O
probiotic O
and O
control O
groups: O
305 O
(81) O
vs. O
315 O
(90) O
min., O
[['Life-Impact', 'Life-Impact']]

Compared O
to O
MIIT O
and O
CG, O
participants O
of O
the O
HIIT O
group O
showed O
significant O
post-intervention O
improvements O
in O
BMI B-outcome ['Physiological-Clinical']
(p=.002 O
and O
p<.001, O
respectively) O
and O
gait B-outcome ['Life-Impact']
speed I-outcome ['Life-Impact']
(p<.001 O
for O
both). O
[['Physiological-Clinical'], ['Life-Impact']]

h(- O
1) O
followed O
by O
a O
maintenance O
dose O
with O
continuous O
infusion O
of O
3 O
mg.kg(- O
1). O
[]

Twenty-eight O
patients O
undergoing O
painless O
fiberbronchoscopy O
in O
Hangzhou O
First O
People's O
Hospital O
were O
randomly O
divided O
into O
2 O
groups(n=14): O
supraglottic O
tracheal O
tube O
ventilation(group O
A) O
and O
modified O
laryngeal O
mask O
airway(group O
B). O
[]

The O
patients O
received O
dry O
needling O
using O
sterile O
stainless-steel O
acupuncture O
needles O
of O
0.25 O
x O
40 O
mm O
and O
0.25 O
x O
25 O
mm O
dimensions. O
[]

Journal O
ID: O
101225531 O
[]

Journal-Name:Cellular O
physiology O
and O
biochemistry O
: O
international O
journal O
of O
experimental O
cellular O
physiology, O
biochemistry, O
and O
pharmacology O
[]

CLINICAL O
TRIAL O
REGISTRATION: O
NCT00788398. O
[]

Belatacept O
serum O
concentrations O
were O
determined O
at O
several O
time O
points O
between O
belatacept O
infusions. O
[]

We O
evaluated O
the O
use O
of O
bilateral O
internal-thoracic-artery O
grafts O
for O
CABG. O
[]

Journal-Name:Medicine O
[]

The O
toxicity B-outcome ['Adverse-effects']
were O
evaluated O
in O
all O
patients O
this O
study O
according O
to O
the O
National O
Cancer O
Institute O
Common O
Toxicity O
Criteria O
4 O
(NCI O
CTC O
version O
4.0).A O
total O
of O
53 O
well-matched O
patients O
with O
advanced O
colorectal O
cancer O
were O
retrospectively O
analyzed. O
[['Adverse-effects']]

Patients O
in O
group O
D O
received O
intravenous O
infusion O
of O
dexmedetomidine(1 O
mug/kg) O
20 O
min O
before O
anesthesia O
induction, O
followed O
by O
intravenous O
pumping O
of O
dexmedetomidine(0.2 O
mug.kg(-1).h(-1)) O
intraoperatively. O
[]

Last O
and O
baseline O
observation O
carried O
forward O
method O
(LOCF, O
BOCF) O
were O
performed O
as O
sensitivity O
analysis. O
[]

The O
sample O
had O
180 O
individuals O
with O
a O
pattern O
of O
hazardous O
or O
harmful O
alcohol O
use, O
recruited O
in O
a O
Basic O
Health O
Unit O
in O
the O
city O
of O
Sao O
Paulo. O
[]

PC O
may O
help O
prevent O
dangerous O
hyperthermia O
in O
athletes. O
[]

Tranexamic O
acid O
(TXA) O
is O
an O
efficient O
antifibrinolytic O
agent, O
but O
the O
mode O
and O
timing O
of O
its O
administration O
remain O
controversial. O
[]

The O
median O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
69.2 O
months O
in O
the O
no-lymphadenectomy O
group O
and O
65.5 O
months O
in O
the O
lymphadenectomy O
group O
(hazard O
ratio O
for O
death O
in O
the O
lymphadenectomy O
group, O
1.06; O
95% O
confidence O
interval O
[CI], O
0.83 O
to O
1.34; O
P O
= O
0.65), O
and O
median O
progression-free B-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
was O
25.5 O
months O
in O
both O
groups O
(hazard O
ratio O
for O
progression O
or O
death O
in O
the O
lymphadenectomy O
group, O
1.11; O
95% O
CI, O
0.92 O
to O
1.34; O
P O
= O
0.29). O
[['Mortality'], ['Physiological-Clinical', 'Mortality']]

Current O
management O
is O
delivered O
by O
a O
multidisciplinary O
team, O
but O
evidence O
of O
effectiveness O
is O
limited. O
[]

At O
6 O
months, O
the O
mean O
Posttraumatic B-outcome ['Physiological-Clinical', 'Life-Impact']
Stress I-outcome ['Physiological-Clinical', 'Life-Impact']
Disorder I-outcome ['Physiological-Clinical', 'Life-Impact']
(PTSD) I-outcome ['Physiological-Clinical', 'Life-Impact']
Symptom I-outcome ['Physiological-Clinical', 'Life-Impact']
Scale]-Self-Report O
questionnaire O
score O
in O
intervention O
ICUs O
was O
11.8 O
(baseline O
period) O
compared O
with O
11.5 O
(intervention O
period) O
(difference, O
-0.40 O
[95% O
CI, O
-2.46 O
to O
1.67]) O
and O
in O
control O
ICUs, O
10.1 O
(baseline O
period) O
compared O
with O
10.2 O
(intervention O
period) O
(difference, O
0.06 O
[95% O
CI, O
-1.74 O
to O
1.85]) O
between O
periods. O
[['Physiological-Clinical', 'Life-Impact']]

Before O
and O
at O
2 O
weeks, O
1 O
month, O
2 O
months, O
and O
4 O
months O
after O
injection, O
dry B-outcome ['Physiological-Clinical']
eye I-outcome ['Physiological-Clinical']
signs I-outcome ['Physiological-Clinical']
; O
tear B-outcome ['Physiological-Clinical']
film I-outcome ['Physiological-Clinical']
break-up I-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
(TBUT) I-outcome ['Physiological-Clinical']
, O
Schirmer O
I O
test], O
corneal B-outcome ['Physiological-Clinical']
fluorescein I-outcome ['Physiological-Clinical']
staining I-outcome ['Physiological-Clinical']
(CFS) I-outcome ['Physiological-Clinical']
, O
and O
symptoms B-outcome ['Physiological-Clinical']
; O
ocular B-outcome ['Physiological-Clinical']
surface I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
index O
(OSDI)]; O
and O
frequency O
of O
lubricants B-outcome ['Resource-use']
were O
assessed. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Resource-use']]

To O
address O
these O
lacunas, O
a O
training O
based O
on O
the O
Mental O
Health O
Gap O
Action O
Programme O
(mhGAP) O
Intervention O
Guide O
(IG) O
was O
offered O
to O
PCPs O
working O
in O
the O
Greater O
Tunis O
area O
between O
February O
and O
April O
2016. O
[]

Side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
(all O
mild) O
occurred O
in O
4.2% O
of O
the O
participants. O
[['Adverse-effects']]

Predilution O
extended O
the O
measurement O
range O
to O
130 O
mg/L O
with O
an O
accuracy O
of O
90% O
and O
coefficients O
of O
variation O
of O
3.8%. O
[]

Publication O
date: O
2018/09/05 O
00:00 O
[accepted] O
[]

PC O
significantly O
lowered O
sweat B-outcome ['Physiological-Clinical']
rate O
(PC O
= O
1.02 O
+/- O
0.31 O
L O
. O
[['Physiological-Clinical']]

Publication O
Type: O
Clinical O
Trial, O
Phase O
II O
[]

Publication O
date: O
2019/02/12 O
06:00 O
[medline] O
[]

This O
study O
evaluated O
clinical O
and O
radiographic O
twelve-month O
outcomes O
of O
root O
canal O
treatments O
(CT) O
with O
smear O
layer O
removal, O
performed O
in O
primary O
teeth, O
using O
two O
different O
root O
canal O
filling O
materials. O
[]

Participants O
recovered O
in O
a O
similar O
time-dependent O
manner O
in O
all O
markers O
of O
metabolism B-outcome ['Physiological-Clinical']
following O
the O
PLA O
and O
CA O
+ O
C O
trials. O
[['Physiological-Clinical']]

This O
trial O
was O
registered O
with O
ClinicalTrials.gov, O
number O
NCT02413372. O
[]

Efficacy O
was O
evaluated O
again O
at O
day O
58, O
after O
completion O
of O
treatment. O
[]

Main O
Outcomes O
and O
Measures: O
Independent O
coprimary O
outcomes O
were O
patient-reported O
persistence B-outcome ['Life-Impact']
with O
P2Y12 O
inhibitor O
(defined O
as O
continued O
treatment O
without O
gap O
in O
use O
>/=30 O
days) O
and O
major B-outcome ['Physiological-Clinical', 'Mortality']
adverse I-outcome ['Physiological-Clinical', 'Mortality']
cardiovascular I-outcome ['Physiological-Clinical', 'Mortality']
events I-outcome ['Physiological-Clinical', 'Mortality']
(MACE) I-outcome ['Physiological-Clinical', 'Mortality']
( O
death B-outcome ['Mortality']
, O
recurrent B-outcome ['Physiological-Clinical']
MI I-outcome ['Physiological-Clinical']
, O
or O
stroke B-outcome ['Physiological-Clinical']
) O
at O
1 O
year O
among O
patients O
discharged O
with O
a O
prescription O
for O
clopidogrel O
or O
ticagrelor. O
[['Life-Impact'], ['Physiological-Clinical', 'Mortality'], ['Mortality'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
date: O
['2019/10/17 O
06:00' O
[]

Whereas O
rigid O
and O
Kinesio O
taping O
are O
recommended O
for O
preventing O
these O
injuries, O
high-level O
evidence O
from O
clinical O
trials O
is O
still O
needed. O
[]

Trial O
Registration: O
ClinicalTrials.gov O
Identifier: O
NCT02406677. O
[]

Journal-Name:Lancet O
(London, O
England) O
[]

The O
incidence O
of O
new O
demineralized B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
was O
24%; O
but O
when O
the O
esthetic B-outcome ['Life-Impact']
impact O
was O
taken O
into O
account, O
this O
was O
considerably O
lower O
(9%). O
[['Physiological-Clinical'], ['Life-Impact']]

There O
was O
no O
significant O
difference O
between O
the O
two O
groups O
regarding O
the O
incidences O
of O
postoperative O
agitation B-outcome ['Life-Impact']
and O
oxygen B-outcome ['Physiological-Clinical']
saturation I-outcome ['Physiological-Clinical']
(SpO2) I-outcome ['Physiological-Clinical']
. O
Compared O
with O
control O
group, O
the O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
(HR) I-outcome ['Physiological-Clinical']
of O
DEX O
group O
was O
decreased O
after O
20 O
minutes O
of O
drug O
administration O
[(97.13+/-12.93) O
beats/min O
vs.(104.53+/-11.97) O
beats/min, O
P<0.05]. O
The O
changes O
of O
the O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
(HR) I-outcome ['Physiological-Clinical']
and O
oxygen B-outcome ['Physiological-Clinical']
saturation I-outcome ['Physiological-Clinical']
(SpO2) I-outcome ['Physiological-Clinical']
in O
the O
two O
groups O
were O
within O
the O
normal O
range. O
[['Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

RESULTS: O
Over O
17 O
months, O
53 O
patients O
were O
assessed O
for O
eligibility O
and O
36 O
(68%) O
were O
randomised O
(47% O
male; O
mean O
age O
36.9 O
[SD O
11.2 O
years); O
13 O
to O
HIIT, O
12 O
to O
MICT, O
and O
11 O
to O
control. O
[]

There O
were O
no O
statistically O
significant O
changes O
in O
the O
control O
group. O
[]

BACKGROUND/AIM: O
The O
analysis O
of O
prognostic O
factors O
is O
important O
to O
identify O
determinants O
of O
disease-free O
survival O
(DFS) O
and O
overall O
survival O
(OS) O
in O
resected O
non-small-cell O
lung O
cancer O
(NSCLC). O
[]

kg(-1).h(-1) O
for O
patients O
in O
group O
C, O
and O
sufentanil O
0.025 O
mug.kg(-1).h(-1) O
plus O
dexmedetomidine O
0.1 O
mug. O
[]

OBJECTIVE: O
To O
determine O
the O
efficacy O
of O
TENS O
in O
the O
treatment O
LBP O
when O
associated O
to O
a O
therapeutic O
education O
program O
(TEP). O
[]

This O
study O
was O
designed O
to O
determine O
the O
effects O
of O
ascorbic O
acid O
supplementation O
on O
circulating O
biomarkers O
of O
oxidative B-outcome ['Physiological-Clinical']
stress I-outcome ['Physiological-Clinical']
and O
muscle B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
following O
a O
single O
bout O
of O
exercise. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

3) O
Results: O
There O
were O
statistically O
significant O
(p O
< O
0.05) O
decreases O
in O
systolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
sVCAM-1 B-outcome ['Physiological-Clinical']
, O
sE-selectin B-outcome ['Physiological-Clinical']
and O
endothelin-1 B-outcome ['Physiological-Clinical']
levels, O
and O
increases O
in O
glutathione B-outcome ['Physiological-Clinical']
peroxidase I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
and O
oxidized B-outcome ['Physiological-Clinical']
glutathione I-outcome ['Physiological-Clinical']
levels. O
( O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

The O
conventional O
pulmonary O
rehabilitation O
treatments, O
including O
pursed O
lips O
breathing O
(PLB) O
and O
abdominal O
breathing O
training, O
were O
applied O
in O
the O
control O
group. O
[]

This O
semi-experimental O
study O
was O
conducted O
using O
a O
pretest-posttest O
and O
control O
group. O
[]

In O
as-treated O
analyses, O
participants O
in O
the O
decolonization O
group O
who O
adhered O
fully O
to O
the O
regimen O
had O
44% O
fewer O
MRSA B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
than O
the O
education O
group O
(hazard O
ratio, O
0.56; O
95% O
CI, O
0.36 O
to O
0.86) O
and O
had O
40% O
fewer O
infections B-outcome ['Physiological-Clinical']
from O
any O
cause O
(hazard O
ratio, O
0.60; O
95% O
CI, O
0.46 O
to O
0.78). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Journal O
ID: O
9424324 O
[]

Training O
was O
performed O
by O
lecture, O
real-time O
feedback, O
and O
fit O
check. O
[]

We O
hypothesized O
that O
Dex O
could O
enhance O
the O
efficiency O
of O
intrathecal O
bupivacaine O
for O
spinal O
anesthesia O
in O
cesarean O
section. O
[]

Asthma O
and O
body O
posture O
abnormalities O
in O
children O
and O
young O
people O
are O
major O
epidemiological O
problems O
worldwide. O
[]

Title: O
Evaluation O
of O
a O
Single O
Dose O
of O
Azithromycin O
for O
Trachoma O
in O
Low-Prevalence O
Communities. O
[]

Patients O
and O
Methods: O
Between O
2003 O
and O
2004, O
60 O
patients O
with O
pathologically O
confirmed O
NPC O
were O
included O
and O
randomly O
assigned O
to O
two O
groups. O
[]

In O
the O
treatment O
group, O
1 O
case O
had O
incision B-outcome ['Physiological-Clinical']
fat I-outcome ['Physiological-Clinical']
liquefaction I-outcome ['Physiological-Clinical']
and O
4 O
cases O
had O
bone B-outcome ['Physiological-Clinical']
cement I-outcome ['Physiological-Clinical']
leakage I-outcome ['Physiological-Clinical']
; O
in O
the O
control O
group, O
2 O
cases O
had O
screw B-outcome ['Physiological-Clinical']
loosening I-outcome ['Physiological-Clinical']
and O
1 O
case O
had O
unilateral O
connecting O
rod B-outcome ['Physiological-Clinical']
rupture I-outcome ['Physiological-Clinical']
; O
there O
was O
no O
significant O
difference O
in O
the O
incidence O
of O
complications B-outcome ['Adverse-effects']
between O
the O
two O
groups O
( O
chi O
(2)=0.504, O
P=0.478). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Adverse-effects']]

Publication O
date: O
2019/02/20 O
06:00 O
[entrez] O
[]

Publication O
Type: O
Journal O
Article O
[]

The O
total O
irradiation O
dose O
in O
each O
group O
was O
70 O
Gy O
for O
the O
whole O
nasopharynx. O
[]

Publication O
date: O
2019/03/01 O
06:00 O
[entrez] O
[]

The O
6-month O
values O
of O
the O
resin O
infiltration O
group O
were O
statistically O
lower O
than O
those O
of O
the O
fluoride O
varnish O
group O
(P O
= O
0.028, O
P O
< O
0.05). O
[]

A O
randomized O
controlled O
trial. O
[]

Serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
reported O
in O
124 O
patients O
(20.2%) O
in O
the O
guided O
and O
130 O
(21.0%) O
in O
the O
usual O
care O
group. O
[['Adverse-effects']]

The O
surgical B-outcome ['Physiological-Clinical']
findings I-outcome ['Physiological-Clinical']
and O
success B-outcome ['Physiological-Clinical']
rate O
in O
two O
subgroups O
were O
compared. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

There O
were O
no O
statistically O
significant O
regression-adjusted O
effects O
on O
other O
outcomes, O
although O
the O
direction O
of O
change O
was O
consistent O
with O
improvements. O
[]

RESULTS: O
No O
significant O
operative O
or O
postoperative O
complications B-outcome ['Adverse-effects']
(other O
than O
failure) O
were O
encountered O
in O
either O
group. O
[['Adverse-effects']]

Journal-Name:BMC O
ophthalmology O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Journal O
ID: O
8109958 O
[]

BACKGROUND: O
Many O
surgical O
procedures O
have O
been O
described O
to O
treat O
recurrent O
patellar O
dislocation, O
but O
none O
of O
these O
techniques O
has O
been O
successful O
in O
all O
patients. O
[]

Resulting O
data O
were O
then O
analyzed O
using O
t O
test, O
Pearson O
chi-square O
test, O
and O
Fisher O
exact O
test O
to O
compare O
outcomes O
between O
the O
2 O
groups. O
[]

Patient O
follow-up O
to O
3 O
months O
was O
completed O
on O
April O
12, O
2018. O
[]

The O
consumption B-outcome ['Resource-use']
of O
postoperative O
rescued O
sufentanil O
was O
significantly O
lower O
in O
Dex O
group O
than O
in O
the O
Control O
group O
(56.3 O
+/- O
9.4 O
vs O
65.9 O
+/- O
10.7 O
mug). O
[['Resource-use']]

The O
exercise O
group O
performed O
40 O
min O
of O
resistance O
exercises O
on O
machines O
followed O
by O
30 O
min O
of O
aerobic O
training O
on O
a O
treadmill O
3x/wk. O
[]

Reactive B-outcome ['Life-Impact']
agility I-outcome ['Life-Impact']
, O
our O
primary O
outcome, O
was O
determined O
by O
measuring O
the O
number O
of O
hits B-outcome ['Life-Impact']
and O
average O
reaction B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
(ART) O
on O
a O
Makoto O
Arena O
II, O
a O
360(0) O
audio-visual O
device O
that O
measures O
stationary, B-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
lateral, B-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
and Seperator ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
multi-directional B-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
active I-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
choice I-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
reaction I-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
performance E4-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
. O
Safety O
was O
evaluated O
using O
complete O
blood B-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
, O
comprehensive O
metabolic B-outcome ['Physiological-Clinical']
panel I-outcome ['Physiological-Clinical']
, O
and O
blood B-outcome ['Physiological-Clinical']
lipids I-outcome ['Physiological-Clinical']
. O
Measurements O
were O
evaluated O
on O
days O
7, O
30, O
and O
90 O
of O
supplementation. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

RESULTS: O
The O
mean O
+/- O
SD O
of O
total O
induction B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
was O
180.5 O
+/- O
49.0 O
s O
in O
Group O
N O
and O
246.3 O
+/- O
64.7 O
s O
in O
Group O
R O
(mean O
difference: O
65.8 O
seconds; O
95% O
CI: O
35.0-96.5 O
s, O
P O
< O
.01). O
[['Life-Impact']]

A O
randomized O
controlled O
trial O
comparing O
the O
effect O
of O
NPWT O
with O
standard O
surgical O
dressing O
(SSD) O
on O
wounds O
was O
performed O
in O
265 O
patients O
undergoing O
open O
gastrointestinal O
resections O
from O
2012 O
to O
2016. O
[]

The O
test O
groups O
showed O
significantly O
higher O
reductions O
in O
Gingival B-outcome ['Physiological-Clinical']
Index], O
probing B-outcome ['Physiological-Clinical']
depth I-outcome ['Physiological-Clinical']
, O
and O
clinical B-outcome ['Physiological-Clinical']
attachment I-outcome ['Physiological-Clinical']
level I-outcome ['Physiological-Clinical']
as O
well O
as O
reductions O
in O
Porphyromonas B-outcome ['Physiological-Clinical']
gingivalis I-outcome ['Physiological-Clinical']
and O
Aggregatibacter B-outcome ['Physiological-Clinical']
actinomycetemcomitans I-outcome ['Physiological-Clinical']
counts O
at O
1-, O
3-, O
6-, O
and O
9-month O
follow-ups O
when O
compared O
with O
the O
control O
group. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Date O
of O
enrolment O
of O
the O
first O
participant O
to O
the O
trial: O
02/02/2016. O
[]

CONCLUSIONS: O
Exercise-heat O
exposures O
every O
fifth O
day O
for O
25 O
days O
and O
regular O
intense O
physical O
activity O
after O
HA O
sustained O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
and O
Tre B-outcome ['Physiological-Clinical']
adaptations O
and O
reduced O
perceptual B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
Physiological B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
strain E1-outcome ['Physiological-Clinical', 'Physiological-Clinical']
during O
exercise-heat O
stress O
approximately O
1 O
month O
later. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical', 'Physiological-Clinical']]

Journal-Name: O
Einstein O
(Sao O
Paulo, O
Brazil) O
[]

However, O
data O
from O
randomized O
trials O
are O
limited. O
[]

The O
OSTAP O
group O
showed O
a O
statistically O
significant O
reduction O
at O
the O
postoperative O
24th O
hour O
tramadol B-outcome ['Resource-use']
consumption O
(mean O
difference O
22 O
mg, O
95% O
confidence O
interval O
-38.4 O
to O
-5.6 O
mL; O
P O
= O
.009). O
[['Resource-use']]

Two O
hundred O
patients O
with O
RA O
in O
clinical O
remission O
(disease O
activity O
score O
in O
28 O
joints-C-reactive O
protein O
[DAS28-CRP] O
<3.2 O
and O
no O
swollen O
joints) O
were O
enrolled O
between O
April O
2012 O
and O
June O
2015. O
[]

METHODS: O
The O
study O
was O
a O
randomised, O
double-blinded, O
placebo-controlled O
intervention O
study O
with O
35 O
overweight O
subjects O
with O
mildly O
or O
moderately O
elevated O
blood O
pressure, O
who O
took O
4 O
g O
krill O
oil O
powder O
or O
4 O
g O
of O
placebo O
during O
an O
8-week O
follow-up O
period. O
[]

Data O
were O
from O
review O
of O
notes O
and O
minutes O
from O
meetings, O
and O
discussions O
with O
each O
CBO O
on O
value O
added O
by O
intervention O
elements O
and O
on O
impact O
of O
the O
project. O
[]

METHODS: O
The O
SHAPE-2 O
study O
is O
a O
three-armed O
randomised O
controlled O
trial O
conducted O
in O
2012-2013 O
in O
the O
Netherlands. O
[]

Local O
cutaneous O
safety O
and O
tolerability B-outcome ['Life-Impact']
assessments O
were O
generally O
mild-to-moderate O
at O
baseline O
and O
improved O
by O
week O
12. O
[['Life-Impact']]

Publication O
date: O
2018/11/04 O
00:00 O
[accepted] O
[]

METHODS: O
In O
this O
study, O
80 O
patients O
who O
underwent O
neuro O
intervention O
with O
MEP O
monitoring O
were O
randomly O
assigned O
into O
2 O
groups. O
[]

Journal O
ID: O
0255562 O
[]

The O
patients O
were O
randomly O
assigned, O
in O
a O
2:1 O
ratio, O
to O
receive O
a O
single O
300-mg O
dose O
of O
tafenoquine O
or O
15 O
mg O
of O
primaquine O
once O
daily O
for O
14 O
days O
(administered O
under O
supervision); O
all O
patients O
received O
a O
3-day O
course O
of O
chloroquine O
and O
were O
followed O
for O
180 O
days. O
[]

Title: O
Cost-effectiveness O
analysis O
of O
a O
placebo-controlled O
randomized O
trial O
evaluating O
the O
effectiveness O
of O
arthroscopic O
subacromial O
decompression O
in O
patients O
with O
subacromial O
shoulder O
pain. O
[]

Therefore, O
we O
conducted O
this O
study O
to O
determine O
the O
95% O
effective O
dose B-outcome ['Life-Impact']
(ED95) O
of O
intrathecal O
hyperbaric O
ropivacaine O
for O
cesarean O
section O
in O
parturients O
receiving O
prophylactic O
infusion O
of O
phenylephrine O
to O
prevent O
spinal-induced O
hypotension. O
[['Life-Impact']]

CONCLUSION: O
Patients O
under O
long-term O
treatment O
with O
riociguat O
show O
significantly O
reduced O
right B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
size I-outcome ['Physiological-Clinical']
and O
improved O
RV B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
PAH O
and O
CTEPH. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Health O
sciences O
[]

Adjuvant O
chemotherapy O
using O
S-1 O
was O
administered O
for O
6 O
months O
to O
patients O
with O
curative O
resection O
who O
fully O
recovered O
within O
10 O
weeks O
after O
surgery O
in O
both O
arms. O
[]

This O
study O
aimed O
to O
compare O
the O
effect O
of O
delayed-start O
GnRH O
antagonist O
protocol O
and O
standard O
GnRH O
antagonist O
in O
patients O
with O
poor O
ovarian O
response O
(POR) O
undergoing O
in O
vitro O
fertilization O
(IVF)/ O
intracytoplasmic O
sperm O
injection O
(ICSI). O
[]

Journal-Name:Journal O
of O
global O
health O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Journal-Name:Medicine O
[]

METHODS: O
A O
randomized, O
cross-over O
trial O
of O
eight O
weeks O
combined O
aerobic O
and O
resistance O
training O
on O
body B-outcome ['Physiological-Clinical']
composition I-outcome ['Physiological-Clinical']
assessed O
by O
Dual O
Energy O
X-ray O
Absorptiometry O
was O
performed. O
[['Physiological-Clinical']]

Journal O
ID: O
101248897 O
[]

After O
144 O
weeks O
of O
treatment, O
HBV B-outcome ['Physiological-Clinical']
DNA I-outcome ['Physiological-Clinical']
levels O
were O
similarly O
suppressed O
in O
both O
groups O
(ETV O
vs O
TDF; O
-6.6485 O
vs O
-6.692 O
log10IU/mL, O
P O
= O
.807). O
[['Physiological-Clinical']]

Title: O
Examining O
diabetic O
heel O
ulcers O
through O
an O
ecological O
lens: O
microbial O
community O
dynamics O
associated O
with O
healing O
and O
infection. O
[]

BACKGROUND: O
Based O
on O
epidemiological O
and O
clinical O
data O
acute O
appendicitis O
can O
present O
either O
as O
uncomplicated O
(70-80%) O
or O
complicated O
(20-30%) O
disease. O
[]

CONCLUSION: O
The O
results O
of O
this O
study O
found O
that O
lactulose O
is O
efficacious O
for O
Chinese O
children O
with O
chronic O
constipation O
after O
6-weeks O
of O
treatment. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Publication O
date: O
2019/01/01 O
06:00 O
[medline] O
[]

Both O
groups O
received O
brief O
advice O
about O
healthy O
eating O
and O
physical O
activity. O
[]

We O
randomly O
assigned O
clusters O
(1:1) O
using O
a O
computer O
generated O
random O
sequence. O
[]

The O
present O
study O
aimed O
to O
investigate O
the O
short-term O
effects O
of O
RS O
on O
appetite B-outcome ['Physiological-Clinical']
, O
satiety B-outcome ['Physiological-Clinical']
and O
postprandial O
metabolism B-outcome ['Physiological-Clinical']
in O
overweight/obese O
subjects. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

The O
changes O
of O
Self-rating O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
scale O
(SDS) O
and O
self-rating O
anxiety B-outcome ['Physiological-Clinical', 'Life-Impact']
scale O
SAS O
before O
and O
after O
the O
three O
groups O
were O
compared, O
and O
the O
changes O
of O
serum O
SOD O
and O
MDA O
were O
detected O
by O
immunoenzyme-linked O
adsorption O
for O
comparative O
analysis. O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact']]

We O
assessed O
the O
effectiveness O
of O
the O
interventions O
on O
intensity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
low I-outcome ['Physiological-Clinical']
back I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
pain B-outcome ['Physiological-Clinical', 'Life-Impact']
interfering I-outcome ['Physiological-Clinical', 'Life-Impact']
with O
work O
and O
fear O
avoidance O
beliefs B-outcome ['Life-Impact']
against O
the O
Control, O
and O
calculated O
the O
incremental O
cost-effectiveness O
ratios O
for O
sickness B-outcome ['Life-Impact']
absence I-outcome ['Life-Impact']
and O
QALY. O
[['Physiological-Clinical'], ['Physiological-Clinical', 'Life-Impact'], ['Life-Impact'], ['Life-Impact']]

Group O
receiving O
placebo O
had O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
only O
for O
first O
two O
weeks. O
[['Physiological-Clinical']]

The O
tendency O
to O
use O
different O
methods O
of O
complementary O
medicine O
to O
control O
menopausal O
symptoms O
is O
increasing. O
[]

Objective: O
Investigate O
beneficial O
and O
harmful O
effects O
of O
4 O
nonopioid O
analgesics O
regimens. O
[]

Sixty O
patients, O
aged O
50-70, O
undergoing O
elective O
surgery O
for O
unilateral O
lower O
extremity O
varicose O
vein O
at O
Ningbo O
No.2 O
Hospital, O
with O
American O
Society O
of O
Anesthesiologists O
(ASA) O
grade O
or O
, O
were O
enrolled O
and O
randomly O
allocated O
to O
two O
groups O
(n=30), O
general O
anesthesia O
group O
and O
spinal O
anesthesia O
group. O
[]

To O
reach O
these O
goals, O
we O
determined O
that O
we O
needed O
to O
recruit O
106 O
patients. O
[]

Journal O
ID: O
2985248R O
[]

The O
participants O
consumed O
either O
two O
packs O
a O
day O
for O
a O
total O
of O
132 O
g O
of O
WSP O
(WSP-MR O
group) O
or O
a O
normal O
diet O
daily O
(non-WSP O
group) O
for O
eight O
weeks. O
[]

Title: O
Effectiveness O
of O
repellent O
delivered O
through O
village O
health O
volunteers O
on O
malaria B-outcome ['Physiological-Clinical']
incidence O
in O
villages O
in O
South-East O
Myanmar: O
a O
stepped-wedge O
cluster-randomised O
controlled O
trial O
protocol. O
[['Physiological-Clinical']]

Conclusion: O
Therapeutic O
radiographer O
prostate O
contours O
are O
more O
accurate, O
show O
less O
interobserver O
variability O
and O
are O
more O
confidently O
and O
quickly O
outlined O
on O
MRI O
compared O
to O
CT, O
particularly O
using O
T2*W O
MRI. O
[]

Publication O
date: O
2019/02/26 O
06:00 O
[medline] O
[]

METHODS: O
In O
the O
original O
open-label O
study, O
patients O
with O
acute O
myeloid O
and O
lymphoblastic O
leukaemia O
in O
first O
or O
subsequent O
remission, O
having O
sibling O
HLA-identical O
allogeneic O
peripheral O
blood O
stem-cell O
transplantation, O
were O
randomly O
assigned O
(1:1) O
to O
receive O
ATLG O
plus O
standard O
GVHD O
prophylaxis O
with O
ciclosporin O
and O
short-term O
methotrexate O
(ATLG O
group) O
or O
standard O
GVHD O
prophylaxis O
without O
ATLG O
(non-ATLG O
group). O
[]

A O
dietary O
calcium O
intake O
of O
1 O
g O
per O
day O
was O
advised, O
but O
calcium O
supplements O
were O
not O
provided. O
[]

After O
in O
vitro O
GI O
digestion, O
intestinal O
bioaccessibility O
of O
RSV O
was O
92.3%. O
[]

There O
were O
significant O
differences O
favoring O
acetaminophen O
vs O
placebo O
for O
3 O
prespecified O
secondary O
outcomes: O
delirium B-outcome ['Physiological-Clinical', 'Life-Impact']
duration I-outcome ['Physiological-Clinical', 'Life-Impact']
(median, O
1 O
vs O
2 O
days; O
difference, O
-1 O
[95% O
CI, O
-2 O
to O
0]), O
ICU B-outcome ['Resource-use']
length I-outcome ['Resource-use']
of I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
(median, O
29.5 O
vs O
46.7 O
hours; O
difference, O
-16.7 O
[95% O
CI, O
-20.3 O
to O
-0.8]), O
and O
breakthrough O
analgesia B-outcome ['Resource-use']
(median, O
322.5 O
vs O
405.3 O
microg O
morphine O
equivalents; O
difference, O
-83 O
[95% O
CI, O
-154 O
to O
-14]). O
[['Physiological-Clinical', 'Life-Impact'], ['Resource-use'], ['Resource-use']]

The O
hazard O
ratio O
for O
the O
risk O
of O
recurrence B-outcome ['Physiological-Clinical']
was O
0.30 O
(95% O
CI, O
0.22 O
to O
0.40) O
with O
tafenoquine O
as O
compared O
with O
placebo O
(P<0.001) O
and O
0.26 O
(95% O
CI, O
0.18 O
to O
0.39) O
with O
primaquine O
as O
compared O
with O
placebo O
(P<0.001). O
[['Physiological-Clinical']]

A O
total O
of O
196 O
patients O
(98 O
per O
group) O
are O
required. O
[]

Journal-Name:Nutrients O
[]

BACKGROUND: O
In O
this O
randomized, O
double-blind, O
parallel-group O
trial, O
we O
aimed O
to O
explore O
the O
effectiveness O
of O
trigger O
point O
dry O
needling O
in O
patients O
with O
chronic O
tension-type O
headache O
in O
reducing O
headache B-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
frequency, I-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
duration S1-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
, O
and O
improvement O
of O
health-related B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
. O
METHODS: O
The O
168 O
patients O
in O
2 O
neurology O
clinics O
with O
chronic O
tension-type O
headache. O
[['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical'], ['Life-Impact']]

Journal-Name:Journal O
of O
athletic O
training O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Additionally, O
a O
39% O
reduction O
in O
atherogenic B-outcome ['Physiological-Clinical']
index O
of O
the O
plasma O
(AIP) O
(p O
= O
0.0177) O
was O
also O
noted O
in O
amla O
group. O
[['Physiological-Clinical']]

Journal-Name:BMC O
surgery O
[]

The O
assay O
was O
applied O
in O
a O
pilot O
pharmacokinetic O
study O
in O
renal O
transplanted O
patients O
receiving O
belatacept O
infusions. O
[]

Retrospectively O
registered: O
December O
3, O
2010, O
( O
http://www.drks.de/drks_web/setLocale_EN.do O
). O
[]

Publication O
date: O
2018/11/04 O
00:00 O
[accepted] O
[]

Such O
guidelines O
are O
made O
available O
for O
strength O
training O
(ST) O
using O
the O
1 O
repetition O
maximum O
(1RM), O
which O
has O
been O
linked O
to O
individuals' O
self-rated O
level O
of O
exertion O
using O
the O
Borg O
rating O
of O
perceived O
exertion O
(BRPE) O
scale. O
[]

Journal O
ID: O
9301647 O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Journal-Name:Medicine O
[]

Compared O
with O
SFC, O
IND/GLY O
treatment O
was O
associated O
with O
reductions O
in O
the O
annualized O
rates O
of O
moderate/severe O
exacerbations B-outcome ['Physiological-Clinical']
(rate O
ratio O
[95% O
CI]: O
0.81 O
[0.73-0.91], O
0.89 O
[0.74-1.07] O
in O
men O
and O
women, O
respectively). O
[['Physiological-Clinical']]

Similarly, O
fewer O
physical B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
breaks I-outcome ['Life-Impact']
in O
combination O
with O
other O
conditions O
impeded O
the O
program's O
success. O
[['Life-Impact']]

Publication O
Type: O
Journal O
Article O
[]

The O
follow-up O
was O
conducted O
during O
the O
first O
five O
weeks O
of O
life O
and O
the O
evaluation O
was O
carried O
at O
two O
different O
times. O
[]

Journal O
ID: O
7501160 O
[]

The O
difference O
in O
the O
incidence O
of O
treatment O
success O
between O
the O
active O
medical O
group O
and O
the O
control O
medical O
group O
was O
16 O
percentage O
points O
(95% O
confidence O
interval, O
-5 O
to O
38; O
P O
= O
0.17). O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

HIV O
self-testing O
may O
be O
a O
way O
to O
increase O
testing O
rates O
in O
this O
high-risk O
population. O
[]

While O
Atorvastatin O
80mg O
results O
in O
LDL B-outcome ['Physiological-Clinical']
reduction O
as O
50.11+/-15.85 O
& O
52.30+/-13.72. O
[['Physiological-Clinical']]

Palo O
Alto, O
CA, O
USA. O
[]

BACKGROUND: O
Induction O
of O
delta O
aminolevulinic O
acid O
synthase O
1 O
( O
ALAS1) O
gene O
expression O
and O
accumulation O
of O
neurotoxic O
intermediates O
result O
in O
neurovisceral O
attacks O
and O
disease O
manifestations O
in O
patients O
with O
acute O
intermittent O
porphyria, O
a O
rare O
inherited O
disease O
of O
heme O
biosynthesis. O
[]

Although O
the O
concentration B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
fentanyl I-outcome ['Life-Impact']
was O
higher O
than O
those O
of O
previous O
researches, O
there O
was O
no O
respiratory B-outcome ['Physiological-Clinical']
depression I-outcome ['Physiological-Clinical']
. O
But, O
there O
was O
no O
advantage O
of O
reducing O
pain B-outcome ['Physiological-Clinical']
score O
and O
the O
use B-outcome ['Resource-use']
of I-outcome ['Resource-use']
rescue I-outcome ['Resource-use']
analgesics I-outcome ['Resource-use']
. O
CLINICAL O
TRIAL O
REGISTRATION: O
(available O
at: O
http://cris.nih.go.kr, O
KCT0002221). O
[['Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Resource-use']]

Publication O
date: O
2018/12/15 O
06:00 O
[entrez] O
[]

Efficacy O
of O
school-based O
surveillance O
was O
evaluated O
for O
detection O
of O
acute B-outcome ['Physiological-Clinical']
pharyngitis I-outcome ['Physiological-Clinical']
and O
rheumatic B-outcome ['Physiological-Clinical']
fever/rheumatic I-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
(RF/RHD) I-outcome ['Physiological-Clinical']
in O
Shimla O
district, O
HP. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Diagnostic O
criteria O
for O
the O
diagnosis O
of O
patients O
with O
RA O
were O
all O
patients O
with O
RA O
who O
visited O
the O
clinic O
of O
Jam O
Rheumatology O
Centers O
and O
met O
other O
inclusion O
criteria O
in O
Mashhad O
in O
the O
spring O
of O
2018. O
[]

Title: O
Moderate-intensity O
aerobic O
and O
resistance O
exercise O
is O
safe O
and O
favorably O
influences O
body B-outcome ['Physiological-Clinical']
composition I-outcome ['Physiological-Clinical']
in O
patients O
with O
quiescent O
Inflammatory O
Bowel O
Disease: O
a O
randomized O
controlled O
cross-over O
trial. O
[['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Journal-Name:Nutrients O
[]

Five O
quasimonomorphic O
mononucleotide O
markers O
were O
used O
to O
assess O
tumor O
MSI O
status. O
[]

Journal-Name:Nutrients O
[]

OBJECTIVE: O
The O
objective O
of O
this O
study O
was O
to O
compare O
enhancement B-outcome ['Life-Impact']
of O
the O
aorta O
and O
liver O
on O
hepatic O
dynamic O
computed O
tomography O
scans O
acquired O
with O
contrast O
material O
doses O
based O
on O
the O
lean O
body O
weight O
(LBW) O
or O
the O
total O
body O
weight O
(TBW). O
[['Life-Impact']]

Group O
A O
(corneal O
group) O
included O
131 O
cases O
(135 O
eyes), O
receiving O
the O
3 O
layers O
of O
allogeneic O
cornea O
slices O
as O
graft. O
[]

RESULTS: O
L-Methylfolate O
was O
well O
tolerated B-outcome ['Life-Impact']
, O
with O
no O
significant O
effect O
over O
placebo O
except O
improvement O
from O
abnormal O
measures O
on O
the O
mean O
adaptive O
dimension O
of O
the O
Adult O
ADHD B-outcome ['Life-Impact', 'Life-Impact']
Self-report O
scale O
(chi O
= O
4.36, O
P O
= O
0.04). O
[['Life-Impact'], ['Life-Impact', 'Life-Impact']]

Omadacycline O
also O
was O
noninferior O
to O
linezolid O
with O
respect O
to O
investigator-assessed O
clinical B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
at O
the O
post-treatment O
evaluation O
in O
the O
modified O
intention-to-treat O
population O
(rate O
of O
response, O
86.1% O
and O
83.6%, O
respectively; O
difference, O
2.5 O
percentage O
points; O
95% O
CI, O
-3.2 O
to O
8.2) O
and O
in O
the O
clinical O
per-protocol O
population O
(96.3% O
and O
93.5%, O
respectively; O
difference, O
2.8 O
percentage O
points; O
95% O
CI, O
-1.0 O
to O
6.9). O
[['Physiological-Clinical']]

Title: O
Effectiveness O
of O
the O
Nutritional O
App O
"MyNutriCart" O
on O
Food B-outcome ['Life-Impact']
Choices I-outcome ['Life-Impact']
Related O
to O
Purchase B-outcome ['Life-Impact', 'Life-Impact']
and Seperator ['Life-Impact', 'Life-Impact']
Dietary B-outcome ['Life-Impact', 'Life-Impact']
Behavior E1-outcome ['Life-Impact', 'Life-Impact']
: O
A O
Pilot O
Randomized O
Controlled O
Trial. O
[['Life-Impact'], ['Life-Impact', 'Life-Impact']]

RESULTS: O
In O
the O
LASIK O
group, O
central B-outcome ['Physiological-Clinical']
epithelial I-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
increased O
from O
52.38 O
+/- O
2.57 O
mum O
to O
57.00 O
+/- O
4.23 O
mum O
and O
remained O
almost O
stable O
at O
this O
level O
for O
up O
to O
24 O
months. O
[['Physiological-Clinical']]

The O
likelihood O
for O
cost-effectiveness, O
based O
on O
a O
willingness O
to O
pay O
50,000 O
USD O
per O
QALY, O
was O
0.77-1.00. O
[]

T O
Ober O
test], O
the O
Thomas O
test], O
and O
transabdominal O
pelvic B-outcome ['Physiological-Clinical']
floor I-outcome ['Physiological-Clinical']
muscles I-outcome ['Physiological-Clinical']
(PFM) I-outcome ['Physiological-Clinical']
ultrasound O
measurements O
were O
performed O
in O
both O
groups. O
[['Physiological-Clinical']]

The O
data O
was O
analyzed O
via O
SPSS-21 O
using O
descriptive O
statistics O
such O
as O
mean, O
standard O
deviation, O
and O
frequency; O
and O
inferential O
statistics O
such O
as O
Chi O
Squared, O
Kruskal O
Wallis O
test, O
and O
Friedman O
test. O
[]

OBJECTIVE: O
To O
assess O
the O
efficacy O
of O
three O
months O
of O
antibiotic O
treatment O
compared O
with O
placebo O
in O
patients O
with O
chronic O
low O
back O
pain, O
previous O
disc O
herniation, O
and O
vertebral O
endplate O
changes O
(Modic O
changes). O
[]

The O
safety O
of O
BT-11 O
should O
be O
elucidated O
in O
younger O
person O
further. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Journal-Name:Kathmandu O
University O
medical O
journal O
(KUMJ) O
[]

Peripheral O
perfusion-targeted O
resuscitation O
was O
associated O
with O
less O
organ B-outcome ['Physiological-Clinical']
dysfunction I-outcome ['Physiological-Clinical']
at O
72 O
hours O
(mean O
SOFA O
score, O
5.6 O
[SD, O
4.3 O
vs O
6.6 O
[SD, O
4.7]; O
mean O
difference, O
-1.00 O
[95% O
CI, O
-1.97 O
to O
-0.02]; O
P O
= O
.045). O
[['Physiological-Clinical']]

PMID: O
31623051 O
[]

Journal O
ID: O
101230586 O
[]

The O
intervention O
will O
be O
guided O
by O
the O
trans-contextual O
model O
explaining O
the O
processes O
by O
which O
PE O
teachers' O
support O
for O
autonomous O
motivation O
in O
the O
classroom O
promotes O
students' O
motivation B-outcome ['Life-Impact']
to O
engage O
in O
out-of-school O
physical O
activity. O
[['Life-Impact']]

Evidence O
of O
Lack O
of O
Benefit O
From O
a O
Double-Blind, O
Placebo-Controlled, O
Randomized O
Clinical O
Trial. O
[]

CONCLUSIONS: O
QCA O
has O
potential O
for O
an O
in-depth O
analysis O
of O
complex O
interventions O
as O
it O
can O
rely O
on O
small O
to O
medium O
sample O
sizes O
and O
analyze O
pathways O
to O
success O
and O
non-success O
separately. O
[]

Title: O
Effect O
of O
lavender O
aromatherapy O
through O
inhalation O
on O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
among O
postmenopausal O
women O
covered O
by O
a O
governmental O
health O
center O
in O
Isfahan, O
Iran: O
A O
single-blind O
clinical O
trial. O
[['Life-Impact']]

And O
there O
were O
no O
significant O
differences O
in O
mean B-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
pulse B-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
saturation I-outcome ['Physiological-Clinical']
and O
bispectral O
index O
(BIS) O
every O
2 O
hours O
between O
the O
two O
groups O
from O
20: O
00 O
(the O
first O
day) O
to O
6: O
00 O
(the O
second O
day)(all O
P>0.05). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

There O
was O
not O
significantly O
different O
in O
the O
patient O
satisfaction B-outcome ['Life-Impact']
of O
analgesia, O
incidence O
of O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
, O
neonatal B-outcome ['Physiological-Clinical']
outcomes O
and O
neurological B-outcome ['Physiological-Clinical']
deficit I-outcome ['Physiological-Clinical']
between O
the O
2 O
groups. O
[['Life-Impact'], ['Adverse-effects'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Two O
blinded O
and O
standardized O
evaluators O
assessed O
the O
radiographic O
outcomes. O
[]

Using O
a O
theory-based O
approach, O
we O
hypothesized O
that O
learning O
acceptance O
skills O
in O
mindfulness O
interventions O
helps O
people O
notice O
more O
positive O
experiences O
in O
daily O
life, O
and O
tested O
whether O
removing O
acceptance O
training O
from O
mindfulness O
interventions O
would O
eliminate O
intervention-related O
boosts O
in O
positive O
affect. O
[]

Furthermore, O
we O
identified O
two O
different O
pathways O
characterizing O
ways O
to O
success O
(consistency: O
81%, O
coverage: O
52%). O
[]

METHODS: O
We O
conducted O
a O
multicenter, O
randomized, O
controlled O
trial O
of O
postdischarge O
hygiene O
education, O
as O
compared O
with O
education O
plus O
decolonization, O
in O
patients O
colonized O
with O
MRSA O
(carriers). O
[]

Follow-up O
was O
completed O
December O
2017. O
[]

Journal-Name:The O
heart O
surgery O
forum O
[]

Intensive O
physical O
exercise O
may O
cause O
increase O
oxidative O
stress O
and O
muscular O
injury O
in O
elite O
football O
athletes. O
[]

Journal-Name:BMC O
neurology O
[]

DISCUSSION: O
To O
our O
knowledge, O
APPAC O
II O
trial O
is O
the O
first O
randomised O
controlled O
trial O
comparing O
per O
oral O
antibiotic O
monotherapy O
with O
intravenous O
antibiotic O
therapy O
continued O
by O
per O
oral O
antibiotics O
in O
the O
treatment O
of O
uncomplicated O
acute O
appendicitis. O
[]

No O
significant O
differences O
were O
reported O
between O
dietary O
conditions O
for O
plasma O
intestinal B-outcome ['Physiological-Clinical']
fatty I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
binding I-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
(I-FABP) I-outcome ['Physiological-Clinical']
(P O
> O
0.05). O
[['Physiological-Clinical']]

Injecting O
a O
long O
acting O
steroid O
is O
a O
common O
practice O
to O
alleviate O
the O
symptoms O
of O
osteoarthritic O
knee. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Journal-Name:Medicine O
[]

Clinical O
data O
and O
biological O
parameters O
were O
detected O
and O
recorded. O
[]

The O
control O
group O
received O
an O
information O
leaflet O
about O
issues O
related O
to O
alcohol O
consumption. O
[]

Conclusion: O
Foot O
and O
ankle O
characteristics O
were O
different O
in O
individuals O
with O
PFOA O
compared O
to O
control O
participants, O
however O
there O
was O
no O
difference O
in O
dynamic O
knee O
valgus O
during O
single O
leg O
squat. O
[]

Retrospectively O
registered O
14th O
October O
2016. O
[]

Title: O
Randomized O
Controlled O
Trial O
of O
Simulation O
vs. O
Standard O
Training O
for O
Teaching O
Medical O
Students O
High-quality O
Cardiopulmonary O
Resuscitation. O
[]

Journal-Name:Zhonghua O
yi O
xue O
za O
zhi O
[]

CONCLUSIONS: O
The O
results O
of O
the O
present O
study O
demonstrated O
that O
8 O
weeks O
of O
PrimaVie(R) O
Shilajit O
supplementation O
at O
500 O
mg.d(- O
1) O
promoted O
the O
retention O
of O
maximal B-outcome ['Life-Impact']
muscular I-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
following O
the O
fatiguing O
protocol O
and O
decreased O
baseline O
HYP. O
[['Life-Impact']]

TPI O
or O
EMLA O
treatments O
decreased O
shoulder O
pain O
irrespective O
of O
exercise O
habit O
(P O
= O
.001 O
and O
P O
< O
.001, O
respectively), O
but O
decreased O
overall B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
only O
in O
patients O
without O
exercise O
habit O
(P O
= O
.019). O
[['Physiological-Clinical']]

Approximately O
6% O
of O
galcanezumab-treated O
patients O
maintained O
>/=75% O
response B-outcome ['Physiological-Clinical']
all O
6 O
months O
versus O
2% O
of O
placebo-treated O
patients. O
[['Physiological-Clinical']]

The O
objective O
of O
this O
randomized O
controlled O
trial O
was O
to O
assess O
whether O
informing O
truckers O
who O
do O
not O
test O
for O
HIV O
regularly O
about O
the O
availability O
of O
HIV O
self-testing O
kits O
at O
roadside O
wellness O
centers O
in O
Kenya O
using O
text O
messages O
would O
increase O
HIV B-outcome ['Life-Impact']
testing I-outcome ['Life-Impact']
rates O
compared O
to O
the O
current O
program O
in O
which O
they O
are O
sent O
text O
messages O
about O
the O
availability O
of O
HIV O
testing O
in O
general. O
[['Life-Impact']]

Journal-Name:JAMA O
[]

intrauterine B-outcome ['Physiological-Clinical']
adhesions I-outcome ['Physiological-Clinical']
were O
staged O
as O
mild O
in O
4 O
patients O
(14.28%) O
and O
moderate O
in O
2 O
patients O
(7.14%) O
in O
group O
2 O
according O
to O
the O
American O
Fertility O
Society O
classification O
of O
IUAs. O
[['Physiological-Clinical']]

Electromyography-measured O
eyestrain B-outcome ['Physiological-Clinical']
was O
less O
with O
toric O
versus O
spherical O
contact O
lenses O
at O
fitting O
(least-square O
ratio O
of O
toric O
over O
spherical=0.72; O
P=0.0019) O
but O
not O
at O
follow-up O
(ratio=0.86; O
P=0.11). O
[['Physiological-Clinical']]

The O
most O
relevant O
combination O
was O
good O
quality O
implementation O
of O
physical B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
breaks I-outcome ['Life-Impact']
, O
implemented O
by O
teachers O
with O
a O
high O
self-efficacy B-outcome ['Life-Impact']
, O
and O
a O
good O
previous O
knowledge B-outcome ['Life-Impact']
about O
the O
intervention. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

Title: O
Comparison O
of O
lower O
loading O
dose O
of O
prasugrel O
with O
conventional O
loading O
dose O
of O
prasugrel O
in O
Indian O
patients O
undergoing O
percutaneous O
coronary O
interventions. O
[]

In O
light O
of O
this, O
the O
present O
paper O
is O
an O
attempt O
to O
determine O
the O
effects O
of O
different O
positioning O
on O
gastric B-outcome ['Physiological-Clinical']
residual I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
in O
premature O
infants O
in O
NICU. O
[['Physiological-Clinical']]

Journal O
ID: O
0255562 O
[]

Publication O
date: O
2018/10/16 O
00:00 O
[accepted] O
[]

Results: O
One O
month O
after O
induction O
chemotherapy, O
the O
overall O
response B-outcome ['Physiological-Clinical']
rate O
was O
96.7% O
in O
the O
CC O
group O
versus O
73.3% O
in O
the O
RC O
group O
(P O
= O
0.011). O
[['Physiological-Clinical']]

Journal-Name:Radiation O
oncology O
(London, O
England) O
[]

Title: O
[Effect O
of O
Ronghuang O
Granule O
on O
serum O
FGF23 B-outcome ['Physiological-Clinical']
, O
FGFRs B-outcome ['Physiological-Clinical']
and O
Klotho B-outcome ['Physiological-Clinical']
in O
non-dialysis O
patients O
with O
CKD-MBD O
and O
kidney O
deficiency O
and O
damp-heat O
syndrome]. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Journal O
ID: O
2985248R O
[]

At O
Month O
6, O
there O
was O
no O
significant O
difference O
between O
the O
groups O
(P O
= O
.85) O
with O
regard O
to O
analgesics B-outcome ['Resource-use']
and O
social B-outcome ['Life-Impact']
impact. O
[['Resource-use'], ['Life-Impact']]

Objective O
To O
evaluate O
the O
clinical O
outcome O
of O
injecting O
Triamcinolone O
acetenoid O
in O
osteoarthritis O
of O
knee O
in O
a O
community O
set O
up O
over O
a O
randomized O
double-blind O
placebo O
control O
trial. O
[]

Patients O
in O
clinical O
remission O
and O
physically O
inactive O
with O
a O
mean O
age O
of O
25 O
+/- O
6.5 O
years O
and O
Body O
Mass O
Index O
of O
28.9 O
+/- O
3.8 O
were O
recruited O
from O
a O
dedicated O
Inflammatory O
Bowel O
Disease O
clinic. O
[]

Title: O
Effect O
of O
transcutaneous O
electrical O
acupoint O
stimulation O
on O
the O
effective O
concentration B-outcome ['Life-Impact']
(EC50) O
of O
remifentanil O
suppressing O
responses B-outcome ['Physiological-Clinical']
to O
tracheal O
extubation O
in O
elderly O
patients. O
[['Life-Impact'], ['Physiological-Clinical']]

TRIAL O
REGISTRATION: O
This O
trial O
has O
been O
assigned O
the O
following O
registry O
number: O
NCT03006406 O
. O
[]

The O
primary O
comparison O
was O
the O
alteplase O
20-mg O
group O
vs O
the O
placebo O
group; O
if O
not O
significant, O
the O
alteplase O
10-mg O
group O
vs O
the O
placebo O
group O
was O
considered O
a O
secondary O
analysis. O
[]

The O
patient's O
satisfaction B-outcome ['Life-Impact']
with O
anesthesia O
was O
assessed O
with O
the O
Visual O
Analog O
Scale O
(VAS) O
score O
on O
the O
first O
day O
after O
the O
operation. O
[['Life-Impact']]

OBJECTIVE: O
Deterioration O
in O
ventricular O
function O
is O
often O
observed O
in O
patients O
treated O
with O
anthracyclines O
for O
cancer. O
[]

The O
objective O
of O
the O
study O
was O
to O
assess O
if O
a O
combination O
of O
a O
lower O
dose O
of O
AmBisome O
with O
miltefosine O
would O
show O
acceptable O
efficacy O
at O
the O
end O
of O
treatment. O
[]

Journal-Name:Medicine O
[]

Hospitals O
randomized O
to O
usual O
care O
(n O
= O
156 O
[4565 O
patients]) O
did O
not O
provide O
study O
vouchers. O
[]

Treated O
teeth O
were O
restored O
with O
composite O
resin O
immediately O
after O
the O
root O
canal O
filling. O
[]

PATIENTS O
AND O
METHODS: O
The O
use B-outcome ['Resource-use']
of I-outcome ['Resource-use']
resources I-outcome ['Resource-use']
, O
costs B-outcome ['Resource-use']
, O
and O
quality-adjusted O
life-years O
(QALYs) O
were O
assessed O
in O
the O
trial O
at O
six O
months O
and O
one O
year. O
[['Resource-use'], ['Resource-use']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Participants O
completed O
1 O
week O
of O
pre- O
and O
post-testing, O
and O
4 O
days O
per O
week O
of O
strength O
and O
conditioning O
training O
for O
5 O
weeks. O
[]

Publication O
Type: O
Multicenter O
Study O
[]

METHODS: O
We O
randomly O
assigned O
patients O
scheduled O
for O
CABG O
to O
undergo O
bilateral O
or O
single O
internal-thoracic-artery O
grafting. O
[]

CONCLUSIONS: O
Single-dose O
tafenoquine O
resulted O
in O
a O
significantly O
lower O
risk O
of O
P. O
vivax O
recurrence O
than O
placebo O
in O
patients O
with O
phenotypically O
normal O
G6PD O
activity. O
( O
[]

CONCLUSION: O
SPC, O
MSI, O
and O
EBV O
statuses O
could O
be O
used O
in O
combination O
to O
predict O
the O
prognosis O
and O
responsiveness O
of O
adjuvant O
chemotherapy O
for O
stage O
II/III O
gastric O
cancer. O
[]

Patients O
received O
concomitant O
palonosetron O
(0.75 O
mg O
intravenously O
[i.v.] O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Title: O
Precooling, O
Exertional O
Heatstroke O
Risk O
Factors, O
and O
Postexercise O
Cooling O
Rates. O
[]

RESULTS: O
There O
were O
significant O
increases O
in O
the O
scores O
of O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
(QOL) I-outcome ['Life-Impact']
dimensions O
in O
the O
experimental O
group O
after O
the O
intervention O
(p</=0.05). O
[['Life-Impact']]

All O
the O
cases O
of O
OHSS O
in O
Group O
2 O
were O
moderate O
while O
the O
one O
case O
of O
OHSS O
in O
Group O
1 O
was O
mild. O
[]

Results: O
Operative B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
of O
the O
TAP O
group O
and O
parecoxib O
+ O
TAP O
group O
was O
significantly O
longer O
than O
that O
of O
the O
parecoxib O
group O
and O
control O
group. O
[['Life-Impact']]

Activities B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
daily I-outcome ['Life-Impact']
living I-outcome ['Life-Impact']
(ADL) I-outcome ['Life-Impact']
, O
self-evaluated O
loneliness B-outcome ['Life-Impact']
, O
and O
level O
of O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
were O
significantly O
lowered O
(P O
< O
.05) O
in O
the O
group O
receiving O
joint O
Baduanjin O
and O
CBT O
intervention O
at O
3 O
months O
and O
6 O
months, O
as O
compared O
to O
the O
Baduanjin O
only O
group O
or O
the O
CBT O
only O
group. O
[['Life-Impact'], ['Life-Impact'], ['Physiological-Clinical', 'Life-Impact']]

Title: O
[Can O
Perioperative O
Oscillating O
Positive O
Expiratory O
Pressure O
Practice O
Enhance O
Recovery B-outcome ['Physiological-Clinical']
in O
Lung O
Cancer O
Patients O
Undergoing O
Thorascopic O
Lobectomy? O
[['Physiological-Clinical']]

Sterol B-outcome ['Physiological-Clinical']
regulatory I-outcome ['Physiological-Clinical']
element-binding I-outcome ['Physiological-Clinical']
protein-1 I-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
was O
inhibited O
after O
treatment, O
while O
the O
inhibitory O
effects O
of O
combined O
treatment O
were O
stronger O
than O
those O
of O
clomifene O
citrate O
alone. O
[['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

RESULTS: O
Total O
30-min O
time-trial B-outcome ['Physiological-Clinical']
distance I-outcome ['Physiological-Clinical']
significantly O
increased O
from O
T1-T3 O
within O
betaA1 O
only O
(7397 O
+/- O
195 O
m O
to O
7580 O
+/- O
171 O
m, O
P O
= O
0.002, O
np(2) O
= O
0.196), O
including O
absolute O
average O
power B-outcome ['Physiological-Clinical']
(194.8 O
+/- O
18.3 O
W O
to O
204.2 O
+/- O
15.5 O
W, O
P O
= O
0.04, O
np(2) O
= O
0.115) O
and O
relative O
average O
power B-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
(2.28 O
+/- O
0.15 O
W.kg(- O
1) O
to O
2.41 O
+/- O
0.12 O
W.kg(- O
1), O
P O
= O
0.031, O
np(2) O
= O
0.122). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Journal-Name:American O
journal O
of O
orthodontics O
and O
dentofacial O
orthopedics O
: O
official O
publication O
of O
the O
American O
Association O
of O
Orthodontists, O
its O
constituent O
societies, O
and O
the O
American O
Board O
of O
Orthodontics O
[]

Publication O
date: O
2019/01/28 O
06:00 O
[entrez] O
[]

Journal-Name:Medicine O
[]

The O
present O
design O
is O
a O
clinical O
trial O
that O
uses O
the O
pre-test O
and O
post-test O
design O
with O
a O
control O
group. O
[]

RESULTS: O
The O
overall O
incidence O
of O
postoperative B-outcome ['Physiological-Clinical']
sore I-outcome ['Physiological-Clinical']
throat I-outcome ['Physiological-Clinical']
was O
higher O
in O
the O
HR O
group O
compared O
with O
that O
in O
the O
LR O
group O
[33 O
(72%) O
vs O
18 O
(39%), O
P O
= O
.022]. O
The O
incidence O
of O
postoperative B-outcome ['Physiological-Clinical']
sore I-outcome ['Physiological-Clinical']
throat I-outcome ['Physiological-Clinical']
at O
0, O
2, O
and O
24 O
hours O
after O
surgery O
was O
higher O
in O
the O
HR O
group O
compared O
with O
that O
in O
the O
LR O
group O
(P O
< O
.001, O
P O
= O
.001, O
and O
P O
= O
.001, O
respectively). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Pain B-outcome ['Physiological-Clinical']
, O
global B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
(GQoL) I-outcome ['Life-Impact']
and O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
specific O
for O
CD O
(QoLCD) O
were O
assessed O
before O
and O
after O
the O
intervention. O
[['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact']]

As O
predicted, O
across O
2 O
RCTs, O
Monitor O
+ O
Accept O
training O
increased O
positive B-outcome ['Life-Impact']
affect I-outcome ['Life-Impact']
compared O
with O
both O
Monitor O
Only O
and O
control O
groups. O
[['Life-Impact']]

Title: O
Using O
the O
Borg O
rating O
of O
perceived B-outcome ['Physiological-Clinical']
exertion I-outcome ['Physiological-Clinical']
scale O
to O
grade O
the O
intensity B-outcome ['Physiological-Clinical', 'Life-Impact']
of O
a O
functional O
training O
program O
of O
the O
affected O
upper O
limb O
after O
a O
stroke: O
a O
feasibility O
study. O
[['Physiological-Clinical'], ['Physiological-Clinical', 'Life-Impact']]

Publication O
date: O
2019/01/27 O
06:00 O
[entrez] O
[]

Publication O
date: O
2018/12/22 O
06:00 O
[entrez] O
[]

Precooling, O
exertional O
heatstroke O
risk O
factors, O
and O
postexercise O
cooling O
rates. O
[]

Publication O
date: O
2019/03/05 O
06:00 O
[medline] O
[]

Journal O
ID: O
9308586 O
[]

Repeated O
measures O
ANOVA O
was O
used O
to O
compare O
the O
groups O
over O
time. O
[]

Purpose: O
The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
efficacy O
and O
toxicities B-outcome ['Adverse-effects']
of O
induction O
chronomodulated O
chemotherapy O
in O
comparison O
with O
conventional O
induction O
chemotherapy O
for O
nasopharyngeal O
carcinoma O
(NPC). O
[['Adverse-effects']]

T O
Yale-Brown O
Obsessive B-outcome ['Physiological-Clinical', 'Life-Impact']
Compulsive I-outcome ['Physiological-Clinical', 'Life-Impact']
Scale O
(Y-BOCS)], O
Hamilton O
Anxiety B-outcome ['Physiological-Clinical', 'Life-Impact']
Scale O
(HAMA) O
were O
used O
to O
assess O
the O
efficacy, O
Pittsburgh O
Sleep B-outcome ['Physiological-Clinical']
Quality I-outcome ['Physiological-Clinical']
Index O
(PSQI) O
was O
used O
to O
evaluate O
the O
sleep B-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
, O
and O
Treatment O
Emergent O
Symptom O
Scale O
(TESS) O
was O
used O
to O
evaluate O
the O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
. O
Data O
were O
analyzed O
in O
the O
intention-to-treat O
sample. O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Adverse-effects']]

The O
primary O
outcome O
was O
MRSA B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
as O
defined O
according O
to O
Centers O
for O
Disease O
Control O
and O
Prevention O
(CDC) O
criteria. O
[['Physiological-Clinical']]

Publication O
Type: O
Journal O
Article O
[]

In O
this O
study, O
we O
investigated O
mtDNA B-outcome ['Physiological-Clinical']
, O
mitochondrial B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
dynamics I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
, Seperator ['Physiological-Clinical', 'Physiological-Clinical']
function S1-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and O
metabolic O
pathways O
to O
determine O
if O
mitochondrial O
damage O
plays O
a O
critical O
role O
in O
the O
development O
of O
tubular O
injury O
in O
DKD O
patients. O
[['Physiological-Clinical'], ['Physiological-Clinical', 'Physiological-Clinical']]

Department O
of O
Pharmacy O
Practice, O
Sri O
Adichunchanagiri O
College O
of O
Pharmacy, O
B. O
G. O
Nagara, O
Karnataka, O
India. O
[]

Data O
were O
analyzed O
using O
1-way O
repeated-measures O
analysis O
of O
variance O
for O
each O
outcome O
measure. O
[]

Hemodynamic B-outcome ['Physiological-Clinical']
variables O
were O
measured O
and O
blood O
samples O
were O
drawn O
before O
induction O
and O
for O
15 O
minutes O
afterwards. O
[['Physiological-Clinical']]

Australian O
adults O
(N O
= O
1132) O
aged O
18-24 O
years O
were O
recruited O
via O
a O
national O
online O
panel. O
[]

CONCLUSIONS: O
Ronghuang O
granule O
improves O
the O
clinical O
symptoms B-outcome ['Physiological-Clinical']
of O
non-dialysis O
CKD-MBD O
patients O
with O
kidney O
deficiency O
and O
dampness O
heat O
syndrome O
by O
reducing O
serum O
levels O
of O
fibroblast B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
factor I-outcome ['Physiological-Clinical']
23 I-outcome ['Physiological-Clinical']
(FGF23) I-outcome ['Physiological-Clinical']
, O
fibroblast B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
factor I-outcome ['Physiological-Clinical']
receptor I-outcome ['Physiological-Clinical']
(FGFRs) I-outcome ['Physiological-Clinical']
and O
Klotho B-outcome ['Physiological-Clinical']
, O
improving O
calcium B-outcome ['Physiological-Clinical']
and O
phosphorus O
metabolism O
disorder O
, O
and O
inhibiting O
secondary B-outcome ['Physiological-Clinical']
hyperparathyroidism I-outcome ['Physiological-Clinical']
. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

BACKGROUND/AIMS: O
The O
present O
study O
aimed O
to O
investigate O
the O
serum O
levels O
of O
adiponectin O
(APN) O
and O
adiponectin O
receptor O
1 O
(AdipoR1) O
in O
patients O
with O
type O
2 O
diabetes O
mellitus O
(T2DM) O
combined O
with O
macrovascular O
complications O
(MVC), O
as O
well O
as O
their O
correlation O
with O
clinical O
parameters. O
[]

Methods: O
Participants O
(n O
= O
30) O
came O
to O
the O
lab O
on O
three O
consecutive O
days O
after O
being O
overnight O
smoking O
abstinent. O
[]

Publication O
date: O
2019/02/27 O
06:00 O
[medline] O
[]

This O
trial O
began O
in O
January O
2013 O
and O
was O
registered O
with O
the O
UMIN O
Clinical O
Trials O
Registry O
(UMIN000009634). O
[]

Haematology O
[]

The O
duration O
of O
total B-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
and O
postoperative B-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
in O
the O
AG O
(10.86+/-5.64, O
5.09+/-4.55) O
d O
were O
significantly O
shorter O
than O
that O
in O
the O
CG O
(10.86+/-5.64, O
5.09+/-4.55) O
d O
(P=0.01, O
P=0.01). O
[['Resource-use'], ['Resource-use']]

PMID: O
31618286 O
[]

There O
was O
no O
significant O
difference O
in O
posttraumatic B-outcome ['Physiological-Clinical', 'Life-Impact']
stress I-outcome ['Physiological-Clinical', 'Life-Impact']
disorder I-outcome ['Physiological-Clinical', 'Life-Impact']
(PTSD) I-outcome ['Physiological-Clinical', 'Life-Impact']
symptom I-outcome ['Physiological-Clinical', 'Life-Impact']
severity I-outcome ['Physiological-Clinical', 'Life-Impact']
at O
6 O
months O
(treatment O
effect O
estimate O
[difference O
in O
differences O
of O
-0.03 O
[95% O
CI, O
-2.58 O
to O
2.52]; O
P O
= O
.98). O
[['Physiological-Clinical', 'Life-Impact']]

Considerations O
for O
feasibility O
and O
effectiveness, O
including O
barriers O
to O
attendance, O
are O
discussed. O
[]

RES O
was O
evaluated O
by O
two O
calibrated O
blind O
periodontists O
one O
year O
after O
the O
treatment. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

No O
statistical O
difference O
was O
also O
observed O
in O
safety O
laboratory O
tests, O
vital B-outcome ['Physiological-Clinical']
signs I-outcome ['Physiological-Clinical']
, O
and O
electrocardiogram B-outcome ['Physiological-Clinical']
(ECG) I-outcome ['Physiological-Clinical']
between O
two O
groups. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

The O
experimental O
group O
had O
a O
statistically O
significant O
reduction O
(p O
< O
0.01) O
of O
about O
10 O
points O
in O
Audit O
score O
after O
the O
brief O
group O
intervention O
[before O
BGI O
= O
15.89 O
(SD O
= O
6.62) O
- O
hazardous B-outcome ['Physiological-Clinical']
use I-outcome ['Physiological-Clinical']
; O
after O
BGI O
= O
6.40 O
(SD O
= O
5.05) O
- O
low O
hazardous B-outcome ['Physiological-Clinical']
use I-outcome ['Physiological-Clinical']
maintaining O
the O
low O
hazardous B-outcome ['Physiological-Clinical']
use I-outcome ['Physiological-Clinical']
in O
follow-up O
[6.69 O
(SD O
= O
6.38) O
- O
low O
hazardous B-outcome ['Physiological-Clinical']
use I-outcome ['Physiological-Clinical']
]. O
The O
control O
group O
had O
a O
statistically O
significant O
reduction O
(p O
</= O
0.01) O
of O
about O
three O
points O
in O
Audit O
score O
[before O
BGI O
= O
13.11 O
(SD O
= O
4.54) O
- O
hazardous B-outcome ['Physiological-Clinical']
use I-outcome ['Physiological-Clinical']
; O
after O
BGI O
= O
9.83 O
(SD O
= O
5.54) O
- O
hazardous B-outcome ['Physiological-Clinical']
use I-outcome ['Physiological-Clinical']
and O
in O
follow-up O
presented O
the O
mean O
score O
of O
13.00 O
(SD O
= O
5.70), O
indicative O
of O
hazardous B-outcome ['Physiological-Clinical']
use I-outcome ['Physiological-Clinical']
. O
Differences O
between O
the O
two O
groups O
(experimental O
group O
versus O
control O
group) O
in O
reduction O
of O
consumption B-outcome ['Physiological-Clinical']
were O
statistically O
significant O
(p O
</= O
0.01). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Journal O
ID: O
9415084 O
[]

The O
patients O
were O
followed O
up O
for O
12 O
weeks O
and O
efficacy O
of O
study O
medication O
was O
assessed O
by O
analyzing O
lipid B-outcome ['Physiological-Clinical']
profile. O
[['Physiological-Clinical']]

Three O
patients O
did O
not O
complete O
the O
study, O
leaving O
156 O
patients O
for O
final O
analysis. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

All O
patients O
that O
were O
operated O
returned O
to O
full B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
. O
However, O
median O
duration B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
operation I-outcome ['Life-Impact']
was O
longer O
and O
lasted O
1 O
hour O
and O
55 O
minutes. O
[['Life-Impact'], ['Life-Impact']]

Title: O
A O
randomized O
placebo-controlled O
trial O
of O
delayed-release O
dimethyl O
fumarate O
in O
patients O
with O
relapsing-remitting O
multiple O
sclerosis O
from O
East O
Asia O
and O
other O
countries. O
[]

RESULTS: O
At O
the O
end O
of O
6 O
weeks, O
and O
12 O
weeks, O
UGPRF O
showed O
more O
promising O
outcome O
results O
in O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
, O
as O
measured O
by O
VAS O
(P O
<.01), O
improvement O
of O
shoulder B-outcome ['Physiological-Clinical']
disorder I-outcome ['Physiological-Clinical']
, O
as O
assessed O
by O
shoulder B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
and O
disability B-outcome ['Life-Impact']
index O
(SPADI) O
score O
( O
pain B-outcome ['Physiological-Clinical']
, O
P O
<.01; O
disability B-outcome ['Life-Impact']
, O
P O
<.01; O
total, O
P O
<.01), O
and O
enhancement O
of O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
, O
as O
measured O
by O
the O
Short O
Form-36 O
questionnaire O
(SF-36) O
scale O
(PCS, O
P O
<.01; O
MCS, O
P O
<.01), O
compared O
with O
sham O
UGPRF O
in O
this O
study. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact'], ['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact']]

Journal-Name:Medicine O
[]

The O
baseline O
status O
of O
knees O
of O
two O
groups O
was O
comparable O
at O
the O
start O
of O
study. O
[]

The O
interruption O
of O
the O
blood O
supply O
to O
the O
donor O
liver O
during O
cold O
storage O
damages O
the O
liver, O
affecting O
how O
well O
the O
liver O
will O
function O
after O
transplant. O
[]

CONCLUSION: O
Intrathecal O
5 O
mug O
Dex O
enhances O
the O
efficacy O
of O
spinal O
bupivacaine O
by O
24% O
in O
patients O
undergoing O
cesarean O
section O
with O
spinal O
anesthesia. O
[]

There O
are O
no O
specific O
treatment O
drugs O
and O
vaccine O
for O
Hand O
Foot O
and O
Mouth O
Disease O
(HFMD). O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

CONCLUSION: O
The O
findings O
of O
this O
study O
showed O
that O
BZSF O
as O
an O
adjunctive O
therapy O
to O
ceftriaxone O
may O
be O
not O
superior O
to O
the O
ceftriaxone O
alone O
for O
Chinese O
female O
patients O
with O
uncomplicated O
gonorrhea O
after O
10 O
days O
treatment. O
[]

The O
difference O
in O
morphine B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
was O
not O
statistically O
significant O
for O
the O
PCM O
+ O
IBU O
group O
vs O
HS-PCM O
+ O
IBU O
(8 O
mg O
[99.6% O
CI, O
-2 O
to O
16]; O
P O
= O
.005) O
or O
for O
the O
PCM-alone O
group O
vs O
IBU O
alone O
(10 O
mg O
[99.6% O
CI, O
-2 O
to O
16]; O
P O
= O
.004) O
after O
adjustment O
for O
multiple O
comparisons O
and O
2 O
co-primary O
outcomes. O
[['Resource-use']]

Title: O
School-based O
surveillance O
for O
detection O
of O
children O
with O
acute B-outcome ['Physiological-Clinical']
pharyngitis I-outcome ['Physiological-Clinical']
, O
rheumatic B-outcome ['Physiological-Clinical']
fever/rheumatic I-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
in O
Shimla O
district, O
Himachal O
Pradesh, O
India-A O
cluster O
randomized O
controlled O
trial. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Modified O
classical O
pilates O
exercises O
were O
performed O
by O
the O
experimental O
group O
three O
times O
a O
week O
over O
a O
12-week O
period. O
[]

Findings O
will O
contribute O
to O
a O
better O
understanding O
of O
the O
optimal O
distribution O
mechanisms O
of O
repellent, O
context O
specific O
effectiveness O
and O
inform O
policy O
makers O
and O
implementers O
of O
malaria O
elimination O
programs O
in O
the O
GMS. O
[]

Few O
studies O
have O
described O
belatacept O
pharmacokinetics, O
and O
the O
effect O
of O
therapeutic O
drug O
monitoring O
has O
not O
been O
investigated. O
[]

There O
was O
a O
decrease O
in O
albumin B-outcome ['Physiological-Clinical']
levels O
in O
both O
groups O
(p O
? O
[['Physiological-Clinical']]

Assessment O
of O
plaque B-outcome ['Physiological-Clinical']
index O
(PI)], O
gingival B-outcome ['Physiological-Clinical']
index O
(GI)], O
probing B-outcome ['Physiological-Clinical']
pocket I-outcome ['Physiological-Clinical']
depth I-outcome ['Physiological-Clinical']
, O
and O
clinical B-outcome ['Physiological-Clinical']
attachment I-outcome ['Physiological-Clinical']
levels I-outcome ['Physiological-Clinical']
(CAL) I-outcome ['Physiological-Clinical']
were O
done O
at O
the O
baseline O
and O
at O
the O
4th O
week. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

However, O
no O
differences O
between O
groups O
were O
observed O
in O
the O
group-by-time O
interaction O
of O
the O
hormonal B-outcome ['Physiological-Clinical']
parameters O
(p O
> O
0.05). O
[['Physiological-Clinical']]

Participants O
were O
selected O
based O
on O
specific O
inclusion O
and O
exclusion O
criteria, O
and O
randomly O
allocated O
into O
two O
groups: O
Group O
1 O
(G1) O
- O
iodoform O
paste O
(iodoform O
+ O
camphorated O
parachlorophenol O
+ O
ointment O
comprising O
prednisolone O
acetate O
5.0 O
mg O
and O
rifamycin O
1.5 O
mg); O
Group O
2 O
(G2) O
- O
Calen(R)/ZO O
paste. O
[]

Journal O
ID: O
0313225 O
[]

Title: O
Acute O
GVHD O
prophylaxis O
plus O
ATLG O
after O
myeloablative O
allogeneic O
haemopoietic O
peripheral O
blood O
stem-cell O
transplantation O
from O
HLA-identical O
siblings O
in O
patients O
with O
acute O
myeloid O
leukaemia O
in O
remission: O
final O
results O
of O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
and O
long-term O
outcome O
analysis O
of O
a O
phase O
3 O
randomised O
study. O
[['Life-Impact']]

Conclusions: O
This O
study O
was O
implemented O
in O
challenging O
circumstances. O
[]

Twenty O
seven O
patients O
with O
advanced O
colorectal O
cancer O
who O
had O
failed O
at O
least O
2 O
lines O
chemotherapy O
were O
treated O
with O
apatinib O
(500 O
mg/day). O
[]

In O
the O
modified O
localization O
group, O
all O
32 O
patients O
succeeded O
in O
the O
localization B-outcome ['Life-Impact']
, O
and O
the O
success B-outcome ['Life-Impact']
rate O
was O
100%. O
[['Life-Impact'], ['Life-Impact']]

Title: O
Prospective, O
randomized, O
double-blinded, O
placebo-controlled O
study O
on O
safety O
and O
tolerability B-outcome ['Life-Impact']
of O
the O
krill O
powder O
product O
in O
overweight O
subjects O
with O
moderately O
elevated O
blood O
pressure. O
[['Life-Impact']]

The O
tear B-outcome ['Physiological-Clinical']
breakup I-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
(TBUT) I-outcome ['Physiological-Clinical']
, O
Schirmer O
test O
with O
anesthesia, O
and O
fluorescein B-outcome ['Physiological-Clinical']
staining I-outcome ['Physiological-Clinical']
scores O
were O
measured O
preoperatively O
and O
postoperatively O
on O
days O
7, O
14, O
30 O
and O
90. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
date: O
2019/03/09 O
06:00 O
[medline] O
[]

Scapular B-outcome ['Physiological-Clinical']
upward I-outcome ['Physiological-Clinical']
rotation I-outcome ['Physiological-Clinical']
did O
not O
change O
after O
taping O
in O
any O
group O
(P O
> O
.05). O
[['Physiological-Clinical']]

Journal O
ID: O
2985248R O
[]

Short- O
and O
long-term O
wound B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
were O
not O
improved O
with O
NPWT. O
[['Physiological-Clinical']]

Journal O
ID: O
100968547 O
[]

There O
was O
a O
minor O
change O
(0.0 O
to O
0.3 O
mm) O
in O
peri-implant B-outcome ['Physiological-Clinical']
mucosal I-outcome ['Physiological-Clinical']
zenith I-outcome ['Physiological-Clinical']
positions I-outcome ['Physiological-Clinical']
over O
time O
and O
between O
groups. O
[['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Title: O
Comparison O
of O
the O
immunogenicity B-outcome ['Physiological-Clinical']
and O
safety O
of O
3 O
inactivated O
hepatitis O
A O
vaccines O
in O
Korean O
children O
aged O
12 O
to O
18 O
months: O
An O
open-label, O
randomized, O
prospective, O
multicenter O
study. O
[['Physiological-Clinical']]

Microbiome O
profiles O
were O
generated O
by O
16S O
rRNA O
gene O
sequence O
analysis, O
supplemented O
by O
targeted O
nanopore O
sequencing. O
[]

Journal O
ID: O
100967802 O
[]

Journal-Name:The O
New O
England O
journal O
of O
medicine O
[]

RESULTS: O
After O
treatment, O
NES O
showed O
greater O
effectiveness O
in O
reducing O
the O
severity O
of O
nausea B-outcome ['Physiological-Clinical']
(P O
= O
.02), O
and O
vomiting B-outcome ['Physiological-Clinical']
(P O
= O
.04), O
as O
well O
as O
the O
appetite B-outcome ['Physiological-Clinical']
improvement O
(P O
= O
.02), O
compared O
with O
the O
sham O
NES. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Electromyographic B-outcome ['Physiological-Clinical']
amplitude I-outcome ['Physiological-Clinical']
did O
not O
differ O
between O
limbs O
or O
groups O
at O
the O
end O
of O
the O
intervention. O
[['Physiological-Clinical']]

BACKGROUND: O
Based O
on O
our O
pre-clinical O
data, O
we O
hypothesized O
that O
sequencing O
chemotherapy O
with O
erlotinib O
would O
increase O
the O
tumor O
response B-outcome ['Physiological-Clinical']
rate O
in O
patients O
with O
metastatic O
colorectal O
cancer. O
[['Physiological-Clinical']]

METHODS: O
From O
October O
2015 O
to O
December O
2017, O
a O
total O
of O
79 O
patients, O
who O
received O
preoperative O
localization O
of O
small O
pulmonary O
nodules O
and O
surgical O
treatment O
in O
the O
Department O
of O
Thoracic O
Surgery O
of O
Hohhot O
First O
Hospital, O
were O
enrolled O
into O
this O
study. O
[]

Objective: O
To O
evaluate O
the O
intervention O
effects O
of O
peer O
support O
education O
mode O
for O
type B-outcome ['Physiological-Clinical']
2 I-outcome ['Physiological-Clinical']
diabetes I-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
in O
rural O
residents. O
[['Physiological-Clinical']]

Publication O
Type: O
Journal O
Article, O
Randomized O
Controlled O
Trial, O
Research O
Support, O
Non-U.S. O
Gov't, O
[]

Work-related B-outcome ['Life-Impact', 'Life-Impact']
fear I-outcome ['Life-Impact', 'Life-Impact']
of I-outcome ['Life-Impact', 'Life-Impact']
pain I-outcome ['Life-Impact', 'Life-Impact']
was O
reduced O
in O
both O
the O
Combined- O
(p O
= O
0.003) O
and O
Exercise-arm O
(p O
= O
0.002). O
[['Life-Impact', 'Life-Impact']]

Our O
findings O
confirm O
that O
lactobacilli O
decrease O
cry B-outcome ['Life-Impact', 'Life-Impact']
and Seperator ['Life-Impact', 'Life-Impact']
fuss B-outcome ['Life-Impact', 'Life-Impact']
time E1-outcome ['Life-Impact', 'Life-Impact']
and O
provide O
a O
dietary B-outcome ['Physiological-Clinical']
support I-outcome ['Physiological-Clinical']
in O
exclusively O
breastfed O
infants O
with O
colic. O
[['Life-Impact', 'Life-Impact'], ['Physiological-Clinical']]

Secondary O
endpoints: O
longitudinal O
HIV B-outcome ['Physiological-Clinical']
viral I-outcome ['Physiological-Clinical']
load I-outcome ['Physiological-Clinical']
, O
T B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
, O
body B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
(BMI) I-outcome ['Physiological-Clinical']
, O
middle-upper-arm B-outcome ['Physiological-Clinical']
circumference I-outcome ['Physiological-Clinical']
(MUAC) I-outcome ['Physiological-Clinical']
, O
and O
25(OH)D(3) B-outcome ['Physiological-Clinical']
levels O
in O
plasma. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

We O
measured O
and O
compare O
the O
knowledge B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
and Seperator ['Life-Impact']
incidences X ['Life-Impact']
of X ['Life-Impact']
hand B-outcome ['Life-Impact']
food I-outcome ['Life-Impact']
mouth I-outcome ['Life-Impact']
disease E4-outcome ['Life-Impact']
between O
2 O
groups. O
[['Life-Impact']]

DISCUSSION: O
This O
project O
will O
contribute O
much O
needed O
evidence O
on O
the O
efficacy O
of O
an O
electronic O
wellbeing O
intervention O
for O
Indigenous O
people O
with O
ESKD O
- O
a O
group O
in O
which O
distress O
is O
likely O
to O
be O
unacceptably O
high, O
yet O
relatively O
untreated. O
[]

In O
the O
MRI-guided O
group, O
the O
treatment O
goal O
was O
absence B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
MRI I-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
marrow I-outcome ['Physiological-Clinical']
edema I-outcome ['Physiological-Clinical']
combined I-outcome ['Physiological-Clinical']
with O
clinical O
remission O
, O
defined O
as O
DAS28-CRP O
of O
3.2 O
or O
less O
and O
no O
swollen O
joints. O
[['Physiological-Clinical']]

The O
visual O
analog O
score O
was O
used O
to O
measure O
the O
pain B-outcome ['Physiological-Clinical']
. O
The O
mean O
operative B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
patient-controlled O
intravenous O
analgesia B-outcome ['Life-Impact']
pressing I-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
time B-outcome ['Life-Impact']
for O
first O
out-of-bed O
activity O
, O
first B-outcome ['Physiological-Clinical']
anus I-outcome ['Physiological-Clinical']
exhaust I-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
, O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
duration I-outcome ['Resource-use']
, O
and O
complications B-outcome ['Adverse-effects']
were O
recorded. O
[['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Physiological-Clinical'], ['Resource-use'], ['Adverse-effects']]

1.6% O
reported O
sexual O
abuse, O
8.0% O
recent O
eve O
teasing O
and O
6.3% O
having O
no O
parental O
emotional O
support. O
[]

Full-mouth O
scaling O
and O
root O
planing O
(SRP) O
was O
performed O
followed O
by O
the O
application O
of O
curcumin O
gel O
on O
a O
single O
side. O
[]

The O
trial O
was O
stopped O
early O
for O
benefit O
on O
its O
primary O
outcome O
(a O
composite O
of O
cardiovascular B-outcome ['Physiological-Clinical']
events) O
and O
all-cause B-outcome ['Mortality']
mortality I-outcome ['Mortality']
on O
August O
20, O
2015. O
[['Physiological-Clinical'], ['Mortality']]

Lastly, O
EMLA O
lowered O
overall B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
score O
at O
the O
time O
of O
first O
analgesic O
request O
in O
ward O
compared O
to O
control O
group O
(P O
= O
.02). O
[['Physiological-Clinical']]

In O
terms O
of O
adverse B-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
, O
the O
incidence O
of O
bone B-outcome ['Physiological-Clinical']
marrow I-outcome ['Physiological-Clinical']
suppression I-outcome ['Physiological-Clinical']
, O
gastrointestinal B-outcome ['Physiological-Clinical']
reaction I-outcome ['Physiological-Clinical']
and O
low-protein B-outcome ['Physiological-Clinical']
reaction I-outcome ['Physiological-Clinical']
was O
significantly O
lower O
in O
group O
A O
than O
that O
in O
group O
BP<0.05. O
[['Adverse-effects'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

BACKGROUND: O
Hypomethylating O
agents, O
such O
as O
decitabine, O
are O
the O
standard O
of O
care O
for O
older O
patients O
with O
newly O
diagnosed O
acute O
myeloid O
leukaemia. O
[]

The O
G1 O
presented O
higher O
values O
of O
CRP B-outcome ['Physiological-Clinical']
in O
relation O
to O
the O
G2 O
significantly O
(p O
? O
[['Physiological-Clinical']]

There O
were O
no O
deaths B-outcome ['Mortality']
, O
discontinuations B-outcome ['Life-Impact', 'Adverse-effects']
due I-outcome ['Life-Impact', 'Adverse-effects']
to I-outcome ['Life-Impact', 'Adverse-effects']
adverse I-outcome ['Life-Impact', 'Adverse-effects']
events I-outcome ['Life-Impact', 'Adverse-effects']
, O
or O
treatment-related O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
. O
INTERPRETATION: O
Treatment O
with O
subcutaneously O
administered O
pegbelfermin O
for O
16 O
weeks O
was O
generally O
well O
tolerated O
and O
significantly O
reduced O
hepatic B-outcome ['Physiological-Clinical']
fat I-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
in O
patients O
with O
non-alcoholic O
steatohepatitis. O
[['Mortality'], ['Life-Impact', 'Adverse-effects'], ['Adverse-effects'], ['Physiological-Clinical']]

Journal O
ID: O
2985248R O
[]

Title: O
The O
acute O
effects O
of O
caffeine O
intake O
on O
time B-outcome ['Physiological-Clinical']
under O
tension O
and O
power B-outcome ['Physiological-Clinical']
generated O
during O
the O
bench O
press O
movement. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

The O
study O
participants O
were O
divided O
randomly O
into O
two O
groups: O
the O
supplemented O
group O
ingested O
caffeine O
before O
exercise O
(GCAF), O
while O
the O
control O
group O
was O
given O
a O
placebo O
(GCON). O
[]

Subjects O
were O
randomly O
allocated O
to O
take O
either O
50,000 O
IU O
vitamin O
D O
every O
2 O
weeks O
plus O
8 O
x O
10(9) O
CFU/day O
probiotic O
(n O
= O
30) O
or O
placebo O
(n O
= O
30) O
for O
12 O
weeks. O
[]

Journal-Name:The O
western O
journal O
of O
emergency O
medicine O
[]

The O
incidence O
of O
postoperative O
shivering B-outcome ['Physiological-Clinical']
was O
higher O
in O
the O
HR O
group O
than O
in O
the O
LR O
group O
[10 O
(22%) O
vs O
2 O
(4%), O
difference O
17%, O
95% O
CI O
2%-33%, O
P O
= O
.027]. O
CONCLUSION: O
A O
relatively O
large O
dose O
of O
intraoperative O
remifentanil O
increased O
the O
incidence O
of O
postoperative B-outcome ['Physiological-Clinical']
sore I-outcome ['Physiological-Clinical']
throat I-outcome ['Physiological-Clinical']
in O
patients O
for O
orthopedic O
surgery O
under O
general O
anesthesia. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

For O
dexmedetomidine O
vs O
propofol, O
only O
breakthrough O
analgesia O
was O
significantly O
different O
(median, O
328.8 O
vs O
397.5 O
microg; O
difference, O
-69 O
[95% O
CI, O
-155 O
to O
-4]; O
P O
= O
.04). O
[]

Anxiety B-outcome ['Physiological-Clinical', 'Life-Impact']
and O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
levels O
were O
measured O
at O
the O
beginning O
of O
the O
study. O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact']]

If O
patients O
were O
found O
to O
have O
reflux-related O
heartburn, O
we O
randomly O
assigned O
them O
to O
receive O
surgical O
treatment O
(laparoscopic O
Nissen O
fundoplication), O
active O
medical O
treatment O
(omeprazole O
plus O
baclofen, O
with O
desipramine O
added O
depending O
on O
symptoms), O
or O
control O
medical O
treatment O
(omeprazole O
plus O
placebo). O
[]

Funded O
by O
the O
National O
Institute O
for O
Health O
Research; O
OVIVA O
Current O
Controlled O
Trials O
number, O
ISRCTN91566927 O
.). O
[]

The O
current O
study O
protocol O
aims O
at O
scaling O
up O
these O
results O
at O
a O
provincial O
level O
using O
a O
randomized O
controlled O
trial O
design. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

There O
were O
no O
improvements O
in O
the O
control O
group. O
[]

However, O
no O
condition O
x O
time O
interactions O
were O
observed. O
[]

Publication O
date: O
2019/02/16 O
06:00 O
[medline] O
[]

A O
significance O
level O
of O
p O
< O
0.05 O
was O
established. O
[]

The O
median O
progression-free B-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
(PFS) I-outcome ['Physiological-Clinical', 'Mortality']
was O
significantly O
longer O
for O
apatinib O
group O
than O
for O
observation O
group O
(2.0 O
vs. O
1.1 O
months; O
HR O
= O
3.88; O
95% O
confidence O
interval O
[CI], O
1.91-7.88; O
P O
< O
.001). O
[['Physiological-Clinical', 'Mortality']]

The O
incidence O
of O
patient O
involuntary B-outcome ['Physiological-Clinical']
movement I-outcome ['Physiological-Clinical']
and O
spontaneous B-outcome ['Physiological-Clinical']
respiration I-outcome ['Physiological-Clinical']
, O
the O
mean O
MEP B-outcome ['Physiological-Clinical']
amplitude I-outcome ['Physiological-Clinical']
, O
coefficient O
of O
variation O
(CV), O
the O
incidence O
of O
MEP B-outcome ['Physiological-Clinical']
stimulus I-outcome ['Physiological-Clinical']
change I-outcome ['Physiological-Clinical']
and O
train-of-four B-outcome ['Physiological-Clinical']
(TOF) I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
were O
compared. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

METHODS: O
Cross-sectional O
survey O
of O
1191 O
low O
caste O
girls O
in O
two O
districts O
in O
north O
Karnataka, O
conducted O
as O
part O
of O
a O
cluster O
randomised-control O
trial. O
[]

METHODS: O
Forty-five O
adult, O
hypertensive O
patients O
taking O
ACEi O
or O
ARB O
and O
scheduled O
for O
elective, O
noncardiac O
surgery O
completed O
the O
study. O
[]

For O
SAT, O
39 O
samples O
(n O
= O
8, O
n O
= O
10, O
n O
= O
9, O
n O
= O
12, O
respectively) O
were O
available. O
[]

Title: O
The O
effectiveness O
of O
Mindfulness-Based O
Cognitive O
Therapy O
on O
the O
illness B-outcome ['Life-Impact']
perception I-outcome ['Life-Impact']
and O
Psychological B-outcome ['Life-Impact']
Symptoms I-outcome ['Life-Impact']
in O
patients O
with O
Rheumatoid O
Arthritis. O
[['Life-Impact'], ['Life-Impact']]

METHODS: O
We O
randomly O
assigned O
female O
healthcare O
workers O
with O
recurrent O
non-specific O
LBP O
to O
one O
of O
four O
study-arms: O
Combined O
neuromuscular O
exercise O
and O
back O
care O
counseling; O
Exercise; O
Counseling; O
and O
no O
intervention O
Control. O
[]

Journal-Name:The O
New O
England O
journal O
of O
medicine O
[]

METHODS: O
This O
is O
a O
3-arm, O
waitlist, O
single-blind O
randomised O
controlled O
trial O
testing O
the O
efficacy O
of O
the O
Stay O
Strong O
App O
in O
improving O
psychological B-outcome ['Life-Impact']
distress I-outcome ['Life-Impact']
, O
depressive B-outcome ['Physiological-Clinical', 'Life-Impact']
symptoms I-outcome ['Physiological-Clinical', 'Life-Impact']
, O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
and O
treatment B-outcome ['Life-Impact']
adherence I-outcome ['Life-Impact']
among O
Indigenous O
clients O
undergoing O
haemodialysis O
for O
ESKD O
in O
Alice O
Springs O
and O
Darwin O
with O
follow O
up O
over O
two O
periods O
of O
3 O
months O
(total O
of O
6 O
months O
observation). O
[['Life-Impact'], ['Physiological-Clinical', 'Life-Impact'], ['Life-Impact'], ['Life-Impact']]

Several O
small O
trials O
have O
suggested O
that O
supplementing O
the O
enteral O
diet O
of O
very O
preterm O
infants O
with O
lactoferrin, O
an O
antimicrobial O
protein O
processed O
from O
cow's O
milk, O
prevents O
infections O
and O
associated O
complications. O
[]

Interventions: O
Participants O
were O
randomized O
to O
receive O
paracetamol O
(acetaminophen) O
1000 O
mg O
plus O
ibuprofen O
400 O
mg O
(n O
= O
136; O
PCM O
+ O
IBU), O
paracetamol O
1000 O
mg O
plus O
matched O
placebo O
(n O
= O
142; O
PCM), O
ibuprofen O
400 O
mg O
plus O
matched O
placebo O
(n O
= O
141; O
IBU), O
or O
half-strength O
paracetamol O
500 O
mg O
plus O
ibuprofen O
200 O
mg O
(n O
= O
140; O
HS-PCM O
+ O
IBU) O
orally O
every O
6 O
hours O
for O
24 O
hours O
postoperatively, O
starting O
1 O
hour O
before O
surgery. O
[]

In O
the O
PRP O
group O
(n O
= O
40), O
in O
addition O
to O
HRT, O
0.5-1 O
cc O
of O
PRP O
was O
infused O
into O
the O
uterine O
cavity O
on O
the O
13th O
day O
of O
HRT O
cycle. O
[]

Title: O
[Effect O
of O
Kangfuxin O
liquid O
combined O
with O
Garlicin O
Capsules O
in O
treatment O
of O
children O
with O
recurrent O
oral O
ulcer O
and O
on O
immune B-outcome ['Physiological-Clinical']
regulation I-outcome ['Physiological-Clinical']
]. O
[['Physiological-Clinical']]

BACKGROUND: O
Postoperative O
complications B-outcome ['Adverse-effects']
, O
especially O
pulmonary B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
, O
affect O
more O
than O
half O
the O
patients O
who O
undergo O
open O
esophagectomy O
for O
esophageal O
cancer. O
[['Adverse-effects'], ['Physiological-Clinical']]

Publication O
date: O
2018/12/17 O
00:00 O
[accepted] O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Background: O
Foot O
and O
ankle O
characteristics O
and O
dynamic O
knee O
valgus O
differ O
in O
people O
with O
and O
without O
patellofemoral O
(PF) O
pain. O
[]

No O
change O
in O
Pgp3-specific B-outcome ['Physiological-Clinical']
antibody I-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
were O
observed O
after O
treatment O
in O
the O
control O
or O
treatment O
arms. O
[['Physiological-Clinical']]

Title: O
Seafood O
Consumption, O
Omega-3 O
Fatty O
Acids O
Intake, O
and O
Life-Time O
Prevalence O
of O
Depression B-outcome ['Physiological-Clinical', 'Life-Impact']
in O
the O
PREDIMED-Plus O
Trial. O
[['Physiological-Clinical', 'Life-Impact']]

METHODS: O
CD80 O
was O
used O
to O
trap O
belatacept O
onto O
streptavidin-coated O
wells. O
[]

Compared O
with O
the O
routine O
treatment O
group, O
the O
28-day O
neonatal B-outcome ['Life-Impact']
behavioral I-outcome ['Life-Impact']
neurological I-outcome ['Life-Impact']
assessment O
score O
of O
the O
SBH O
treatment O
group O
was O
increased O
by O
2.9 O
[95% O
confidence O
interval O
(95%CI) O
= O
1.0-4.8], O
Bayley O
scales O
of O
infant B-outcome ['Life-Impact', 'Life-Impact']
development I-outcome ['Life-Impact', 'Life-Impact']
(BSID) O
score O
at O
15 O
months O
of O
age O
was O
improved O
significantly, O
mental B-outcome ['Life-Impact']
development I-outcome ['Life-Impact']
index O
(MDI) O
score O
was O
increased O
by O
11.8 O
(95%CI O
= O
4.3-19.3), O
and O
psychomotor B-outcome ['Life-Impact']
development I-outcome ['Life-Impact']
index O
(PDI) O
score O
was O
increased O
by O
12.4 O
(95%CI O
= O
2.5-22.3), O
with O
significant O
differences O
between O
the O
two O
groups O
(all O
P O
< O
0.05). O
[['Life-Impact'], ['Life-Impact', 'Life-Impact'], ['Life-Impact'], ['Life-Impact']]

Results: O
After O
intervention, O
the O
observation O
group O
had O
significantly O
higher O
forced B-outcome ['Physiological-Clinical']
expiratory I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
in O
1 O
second O
(FEV(1) O
), O
forced B-outcome ['Physiological-Clinical']
vital I-outcome ['Physiological-Clinical']
capacity I-outcome ['Physiological-Clinical']
(FVC) I-outcome ['Physiological-Clinical']
, O
arterial B-outcome ['Physiological-Clinical']
partial I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
(PaO(2) I-outcome ['Physiological-Clinical']
) O
, O
and O
six-minute O
walk B-outcome ['Physiological-Clinical']
distance I-outcome ['Physiological-Clinical']
than O
the O
control O
group O
(P<0.05) O
, O
while O
there O
were O
no O
significant O
differences O
between O
the O
two O
groups O
in O
FEV(1)/FVC B-outcome ['Physiological-Clinical']
and O
partial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
carbon I-outcome ['Physiological-Clinical']
dioxide I-outcome ['Physiological-Clinical']
(P>0.05) O
. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

In O
both O
studies, O
end-of-day B-outcome ['Life-Impact', 'Life-Impact']
and Seperator ['Life-Impact', 'Life-Impact']
momentary B-outcome ['Life-Impact', 'Life-Impact']
positive I-outcome ['Life-Impact', 'Life-Impact']
affect E2-outcome ['Life-Impact', 'Life-Impact']
and O
negative B-outcome ['Life-Impact']
affect I-outcome ['Life-Impact']
were O
measured O
in O
daily O
life O
for O
3 O
days O
pre- O
and O
post-intervention O
using O
ambulatory O
assessments. O
[['Life-Impact', 'Life-Impact'], ['Life-Impact']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

The O
primary O
endpoint O
was O
cumulative O
incidence O
of O
chronic B-outcome ['Physiological-Clinical']
graft-versus-host I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
(cGVHD) I-outcome ['Physiological-Clinical']
at O
2 O
years. O
[['Physiological-Clinical']]

Introduction: O
Acute O
pancreatitis O
(AP) O
is O
an O
inflammatory O
disease O
of O
the O
pancreas O
that O
spans O
a O
wide O
range O
ranging O
from O
mild O
to O
critical O
forms. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Journal-Name:BMC O
public O
health O
[]

Journal O
ID: O
0374675 O
[]

Title: O
Controlled O
Trial O
of O
Two O
Incremental O
Milk-Feeding O
Rates O
in O
Preterm O
Infants. O
[]

DESIGN: O
Randomized O
and O
blinded O
clinical O
trial. O
[]

Lancet O
2019;393:2213-21.This O
project O
was O
funded O
by O
the O
NIHR O
Health O
Services O
and O
Delivery O
Research O
Programme O
(project O
number O
12/5005/10).To O
read O
the O
full O
NIHR O
Signal, O
go O
to O
https://discover.dc.nihr.ac.uk/content/signal-000789/national-quality-improvement O
-programmes-need-time-and-resources-to-have-impact. O
[]

BACKGROUND: O
Exacerbations O
of O
chronic O
obstructive O
pulmonary O
disease O
(COPD) O
are O
associated O
with O
loss O
of O
lung O
function O
and O
poor O
outcomes O
for O
patients. O
[]

The O
primary O
efficacy O
end O
point O
was O
0.6% O
in O
both O
the O
conventional O
60 O
mg O
loading O
dose O
(LD) O
and O
lower O
30 O
mg O
LD O
groups O
(p O
= O
not O
significant). O
[]

Results: O
Twenty-four O
children O
with O
HIV O
and/or O
PHE O
were O
randomized O
into O
one O
of O
the O
two O
intervention O
groups. O
[]

DESIGN: O
Double O
blind, O
parallel O
group, O
placebo O
controlled, O
multicentre O
trial. O
[]

Intraoperative O
measures O
included O
anesthetic B-outcome ['Life-Impact']
concentration, O
EEG B-outcome ['Physiological-Clinical']
suppression I-outcome ['Physiological-Clinical']
, O
and O
hypotension B-outcome ['Physiological-Clinical']
. O
Adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
included O
undesirable B-outcome ['Physiological-Clinical']
intraoperative I-outcome ['Physiological-Clinical']
movement I-outcome ['Physiological-Clinical']
, O
intraoperative B-outcome ['Physiological-Clinical', 'Life-Impact']
awareness I-outcome ['Physiological-Clinical', 'Life-Impact']
with O
recall O
, O
postoperative O
nausea B-outcome ['Physiological-Clinical']
and O
vomiting O
, O
medical O
complications B-outcome ['Adverse-effects']
, O
and O
death B-outcome ['Mortality']
. O
Results: O
Of O
the O
1232 O
randomized O
patients O
(median O
age, O
69 O
years O
[range, O
60 O
to O
95]; O
563 O
women O
[45.7%]), O
1213 O
(98.5%) O
were O
assessed O
for O
the O
primary O
outcome. O
[['Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Adverse-effects'], ['Physiological-Clinical'], ['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical'], ['Adverse-effects'], ['Mortality']]

The O
patients' O
preoperative O
and O
intraoperative O
anxiety B-outcome ['Physiological-Clinical', 'Life-Impact']
scores O
were O
assessed O
with O
the O
State O
Anxiety B-outcome ['Physiological-Clinical', 'Life-Impact']
Inventory O
(SAI) O
on O
the O
day O
before O
and O
on O
the O
first O
day O
after O
the O
surgery, O
respectively. O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact']]

Publication O
Type: O
Journal O
Article O
[]

METHODS: O
One O
hundred O
and O
three O
high O
school O
athletes O
completed O
the O
study O
(M O
age O
= O
15.3, O
SD O
= O
1.2; O
70.9% O
male; O
37.9% O
Afr. O
[]

Title: O
[Efficacy O
and O
safety O
of O
selective O
brain O
hypothermia O
therapy O
on O
neonatal O
hypoxic-ischemic O
encephalopathy]. O
[]

Journal-Name:BMC O
public O
health O
[]

Publication O
date: O
2019/01/25 O
06:00 O
[entrez] O
[]

The O
results O
of O
nine-gene O
based O
SPC O
assay O
were O
classified O
as O
prognostication O
(SPC-prognosis) O
and O
prediction O
of O
chemotherapy O
benefit O
(SPC-prediction). O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Journal-Name:Journal O
of O
the O
International O
Society O
of O
Sports O
Nutrition O
[]

beta-Eudesmol, O
an O
oxygenated O
sesquiterpene, O
is O
reported O
to O
accumulate O
in O
a O
particular O
hop O
cultivar. O
[]

CONCLUSION: O
Thus, O
the O
use O
of O
BiPAP O
in O
PAR O
can O
promote O
restoration O
of O
expiratory B-outcome ['Physiological-Clinical']
reserve I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
and O
contribute O
to O
the O
reduction O
of O
atelectasis. O
[['Physiological-Clinical']]

CONCLUSIONS: O
TPI O
and O
EMLA O
with O
occlusive O
dressing O
effectively O
reduced O
the O
shoulder B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
after O
total O
laparoscopic O
hysterectomy. O
[['Physiological-Clinical']]

Title: O
Effects O
of O
Vitamin O
D O
Supplementation O
on O
Haematological B-outcome ['Physiological-Clinical']
Values O
and O
Muscle B-outcome ['Physiological-Clinical']
Recovery I-outcome ['Physiological-Clinical']
in O
Elite O
Male O
Traditional O
Rowers. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

CONCLUSION: O
There O
was O
no O
clear O
benefit O
of O
the O
24-hour O
or O
48-hour O
infusions O
over O
the O
single-shot O
ACB O
for O
the O
primary O
endpoint O
of O
the O
study. O
[]

Of O
those O
in O
the O
intervention O
group O
who O
tested, O
64.5% O
chose O
the O
self-test B-outcome ['Life-Impact']
and O
35.5% O
chose O
the O
standard O
provider-administered O
blood-based O
HIV B-outcome ['Life-Impact']
test I-outcome ['Life-Impact']
. O
Although O
the O
intervention O
more O
than O
doubled O
HIV B-outcome ['Life-Impact']
testing I-outcome ['Life-Impact']
rates, O
because O
HIV B-outcome ['Life-Impact']
testing I-outcome ['Life-Impact']
rates O
were O
so O
low O
in O
this O
population O
(by O
design O
as O
we O
selected O
irregular O
testers), O
even O
in O
the O
intervention O
group O
more O
than O
96% O
of O
participants O
did O
not O
test B-outcome ['Life-Impact']
. O
CONCLUSIONS: O
Announcing O
the O
availability O
of O
HIV O
self-testing O
via O
text O
message O
increased O
HIV B-outcome ['Life-Impact']
testing I-outcome ['Life-Impact']
rates O
among O
truckers O
who O
were O
not O
regularly O
accessing O
HIV O
testing. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

Likewise, O
triglyceride B-outcome ['Physiological-Clinical']
net O
AUC O
was O
increased O
by O
80 O
+/- O
28 O
mumol/Lx270 O
min O
(p O
= O
0.012) O
after O
breakfast O
but O
reduced O
by O
320 O
+/- O
60 O
mumol/Lx180 O
min O
(p O
< O
0.001) O
after O
lunch O
on O
the O
CRHP O
compared O
with O
CD O
diet. O
[['Physiological-Clinical']]

A O
total O
of O
2961 O
eligible O
patients O
were O
identified O
from O
September O
2015 O
to O
January O
2017. O
[]

CONCLUSIONS: O
Among O
patients O
with O
normal O
G6PD O
enzyme O
activity, O
the O
decline O
in O
hemoglobin B-outcome ['Physiological-Clinical']
level O
with O
tafenoquine O
did O
not O
differ O
significantly O
from O
that O
with O
primaquine. O
[['Physiological-Clinical']]

Journal-Name:Aerospace O
medicine O
and O
human O
performance O
[]

The O
control O
group O
(n O
= O
43) O
was O
only O
received O
HRT. O
[]

Journal-Name:Medicine O
[]

RESULTS: O
Vitamin O
D O
and O
probiotic O
co-supplementation, O
compared O
with O
the O
placebo, O
significantly O
improved O
beck O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
inventory O
[beta O
(difference O
in O
the O
mean O
of O
outcomes O
measures O
between O
treatment O
groups) O
- O
0.58; O
95% O
CI, O
- O
1.15, O
- O
0.02; O
P O
= O
0.04], O
general B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
questionnaire O
scores O
(beta O
- O
0.93; O
95% O
CI, O
- O
1.78, O
- O
0.08; O
P O
= O
0.03) O
and O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
, O
anxiety B-outcome ['Physiological-Clinical', 'Life-Impact']
and O
stress B-outcome ['Life-Impact']
scale O
scores O
(beta O
- O
0.90; O
95% O
CI, O
- O
1.67, O
- O
0.13; O
P O
= O
0.02). O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact'], ['Life-Impact']]

Journal O
ID: O
100968562 O
[]

Primary O
outcome O
data O
for O
2182 O
infants O
(1093 O
[99.5%] O
of O
1098 O
in O
the O
lactoferrin O
group O
and O
1089 O
[99.0] O
of O
1101 O
in O
the O
control O
group) O
were O
available O
for O
inclusion O
in O
the O
modified O
intention-to-treat O
analyses. O
[]

Minor O
stroke O
were O
categorized O
into O
SAI O
and O
MAIs O
by O
infarction O
numbers O
in O
diffusion O
weighted O
imaging. O
[]

The O
objective O
of O
this O
controlled O
clinical O
study O
is O
to O
verify O
the O
effect O
of O
aPDT O
in O
the O
treatment O
of O
halitosis O
by O
evaluating O
the O
formation O
of O
volatile O
sulphur O
compounds O
with O
gas O
chromatography O
and O
microbiological O
analysis O
before O
and O
after O
treatment. O
[]

Infants O
aged O
4(-)12 O
weeks O
received O
L. O
rhamnosus O
19070-2 O
and O
L. O
reuteri O
12246 O
in O
a O
daily O
dose O
of O
250 O
x O
10(6) O
CFU, O
3.33 O
mg O
of O
fructooligosaccharide, O
and O
200 O
IU O
of O
vitamin O
D(3) O
(84 O
infants, O
probiotic O
group) O
or O
just O
vitamin O
D(3) O
(84 O
infants, O
control O
group) O
for O
28 O
days. O
[]

The O
preoperative O
sedation B-outcome ['Physiological-Clinical']
score, O
the O
status B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
separation I-outcome ['Life-Impact']
from I-outcome ['Life-Impact']
parents I-outcome ['Life-Impact']
, O
compliance B-outcome ['Life-Impact']
with O
the O
mask O
and O
hemodynamic B-outcome ['Physiological-Clinical']
parameters O
were O
recorded O
by O
an O
anesthesiologists O
until O
anesthesia O
induction. O
[['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact'], ['Physiological-Clinical']]

However, O
there O
was O
a O
statistically O
significant O
improvement O
in O
child O
and O
parent O
reported O
pain B-outcome ['Physiological-Clinical']
, O
coordination B-outcome ['Life-Impact']
and O
grip B-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
in O
both O
groups. O
[['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact']]

Title: O
Cost-effectiveness O
and O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
of O
a O
diet O
intervention O
postpartum: O
2-year O
results O
from O
a O
randomized O
controlled O
trial. O
[['Life-Impact']]

The O
current O
randomized, O
cross-over O
behavioral O
trial O
tried O
to O
bridge O
the O
latter O
gaps. O
[]

They O
were O
randomly O
assigned O
to O
an O
intervention O
group O
(410 O
participants) O
or O
comparison O
group O
(202 O
participants). O
[]

Single-step O
advancement O
was O
achieved O
in O
the O
MA O
group O
until O
an O
edge-to-edge O
incisor O
relationship O
or O
an O
overcorrected O
Class O
I O
molar O
relationship O
was O
obtained. O
[]

Journal O
ID: O
101234168 O
[]

PMID: O
31596411 O
[]

Journal O
ID: O
100968551 O
[]

Title: O
Effectiveness O
of O
incremental O
vs O
maximum O
bite O
advancement O
during O
Herbst O
appliance O
therapy O
in O
late O
adolescent O
and O
young O
adult O
patients. O
[]

Publication O
date: O
['2019/10/10 O
06:00' O
[]

The O
incidence O
of O
undetectable O
MEP B-outcome ['Physiological-Clinical']
did O
not O
differ O
as O
measured O
in O
both O
groups. O
[['Physiological-Clinical']]

METHOD: O
This O
Study O
is O
A O
Prospective, O
randomized, O
open-label, O
comparative O
study. O
[]

Journal-Name:The O
bone O
& O
joint O
journal O
[]

Additionally, O
30 O
healthy O
people O
were O
selected O
as O
control O
group O
(NC O
group). O
[]

Title: O
Efficacy O
of O
different O
interaction O
devices O
using O
non-immersive O
virtual O
tasks O
in O
individuals O
with O
Amyotrophic O
Lateral O
Sclerosis: O
a O
cross-sectional O
randomized O
trial. O
[]

Clinical O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
similar O
in O
both O
groups. O
[['Adverse-effects']]

Thus, O
branched-chain O
amino O
acids O
may, O
at O
least O
in O
part, O
mediate O
the O
effects O
of O
whey O
to O
reduce O
energy O
intake O
and/or O
blood O
glucose. O
[]

SETTING: O
Hospital O
outpatient O
clinics O
at O
six O
hospitals O
in O
Norway. O
[]

Title: O
The O
effect O
of O
Baduanjin O
qigong O
combined O
with O
CBT O
on O
physical B-outcome ['Physiological-Clinical']
fitness I-outcome ['Physiological-Clinical']
and O
psychological B-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
of O
elderly O
housebound. O
[['Physiological-Clinical'], ['Life-Impact']]

Methods: O
This O
was O
a O
prospective O
study O
conducted O
from O
November O
2017 O
to O
March O
2018. O
[]

The O
CMFCs O
were O
defined O
as O
having O
emergency B-outcome ['Resource-use']
C-section I-outcome ['Resource-use']
, O
perineal B-outcome ['Physiological-Clinical']
trauma I-outcome ['Physiological-Clinical']
, O
pregnancy-induced B-outcome ['Physiological-Clinical']
hypertension I-outcome ['Physiological-Clinical']
and O
preeclampsia O
, O
prematurity B-outcome ['Physiological-Clinical']
, O
large-for-gestational-age B-outcome ['Physiological-Clinical']
, O
and/or O
small-for-gestational-age B-outcome ['Physiological-Clinical']
. O
A O
total O
of O
874 O
women O
were O
stratified O
into O
three O
groups O
according O
to O
late O
first-trimester O
compliance O
with O
six O
food O
targets: O
>12 O
servings/week O
of O
vegetables, O
>12 O
servings/week O
of O
fruits, O
<2 O
servings/week O
of O
juice, O
>3 O
servings/week O
of O
nuts, O
>6 O
days/week O
consumption O
of O
extra O
virgin O
olive O
oil O
(EVOO), O
and O
>/=40 O
mL/day O
of O
EVOO. O
[['Resource-use'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Funded O
by O
Paratek O
Pharmaceuticals; O
OPTIC O
ClinicalTrials.gov O
number, O
NCT02531438 O
.). O
[]

Results: O
: O
Among O
207 O
cases O
followed O
till O
delivery, O
the O
prevalence O
of O
parasitaemia B-outcome ['Physiological-Clinical']
was O
lower O
in O
three-dose O
group O
than O
in O
two-dose O
group O
for O
both O
peripheral B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
(9.3% X ['Physiological-Clinical', 'Physiological-Clinical']
versus X ['Physiological-Clinical', 'Physiological-Clinical']
27.8%) X ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
placental B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
(10.6% X ['Physiological-Clinical', 'Physiological-Clinical']
versus X ['Physiological-Clinical', 'Physiological-Clinical']
25.6%) X ['Physiological-Clinical', 'Physiological-Clinical']
parasitaemia E1-outcome ['Physiological-Clinical', 'Physiological-Clinical']
. O
The O
adjusted O
odds O
ratios O
(aOR) O
were O
0.15 O
[95% O
confidence O
interval O
(CI), O
0.05 O
- O
0.45 O
and O
0.17 O
(95% O
CI, O
0.06-0.51), O
respectively. O
[['Physiological-Clinical'], ['Physiological-Clinical', 'Physiological-Clinical']]

CONTEXT: O
Deviations O
in O
scapular O
motions O
and O
subsequent O
alterations O
in O
associated O
soft O
tissues O
are O
thought O
to O
contribute O
to O
overuse O
shoulder O
injuries O
in O
overhead O
athletes. O
[]

Physical B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
participation I-outcome ['Life-Impact']
, O
the O
primary O
outcome O
variable, O
and O
psychological O
mediators O
from O
the O
trans-contextual O
model O
will O
be O
measured O
at O
pre-trial, O
post-trial, O
and O
at O
one-, O
three- O
and O
six-months O
post-trial. O
[['Life-Impact']]

Publication O
Type: O
Journal O
Article O
[]

Journal-Name:BMC O
ophthalmology O
[]

There O
were O
no O
statistical O
differences O
in O
the O
incidence O
of O
adverse B-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
between O
the O
two O
groups. O
[['Adverse-effects']]

Publication O
date: O
['2019/10/11 O
06:00' O
[]

CONCLUSION: O
We O
conclude O
that O
yoga O
has O
strong O
effects O
on O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
symptoms I-outcome ['Physiological-Clinical', 'Life-Impact']
and O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
therefore O
it O
can O
be O
used O
as O
a O
complementary O
or O
alternative O
remedy O
for O
PMS O
patients. O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical']]

Final O
irrigation O
was O
done O
with O
cold O
(4 O
degrees O
C, O
2.5 O
degrees O
C, O
and O
room O
temperature) O
17% O
EDTA O
and O
10 O
mL O
of O
cold O
saline O
solution. O
[]

Medical O
sciences O
[]

Journal-Name:Journal O
of O
cardiac O
surgery O
[]

Journal-Name:Medicine O
[]

The O
incidence O
of O
severe B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
perinatal I-outcome ['Adverse-effects']
outcomes I-outcome ['Adverse-effects']
was O
1.7% O
(n=118) O
for O
the O
intervention O
strategy O
and O
1.8% O
(n=106) O
for O
usual O
care. O
[['Adverse-effects']]

The O
secondary O
outcomes O
consisted O
of O
stool B-outcome ['Physiological-Clinical']
consistency I-outcome ['Physiological-Clinical']
, O
measured O
by O
the O
Bristol O
Stool O
Form O
Scale, O
abdominal B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
flatulence B-outcome ['Physiological-Clinical']
, O
as O
well O
as O
the O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
. O
All O
outcomes O
were O
measured O
at O
baseline O
and O
after O
6-weeks O
treatment. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Adverse-effects']]

Publication O
date: O
2019/01/08 O
06:00 O
[medline] O
[]

Publication O
date: O
2019/03/05 O
06:00 O
[medline] O
[]

Materials O
and O
Methods: O
In O
this O
prospective O
study, O
80 O
patients O
that O
underwent O
radical O
resection O
for O
colorectal O
cancer O
were O
randomly O
divided O
into O
four O
groups: O
(1) O
the O
parecoxib O
group, O
with O
preintravenous O
injection O
of O
parecoxib O
and O
postoperative O
PCIA O
after O
surgery; O
(2) O
the O
TAP O
group, O
with O
TAP O
block O
and O
postoperative O
PCIA; O
(3) O
the O
parecoxib O
+ O
TAP O
group, O
with O
parecoxib O
combined O
with O
TAP O
block O
and O
postoperative O
PCIA; O
and O
(4) O
the O
control O
group, O
with O
only O
postoperative O
PCIA O
and O
preinjection O
of O
normal O
saline. O
[]

BACKGROUND: O
The O
onset O
of O
puberty O
and O
menarche O
is O
a O
specifically O
vulnerable O
time O
for O
girls, O
during O
which O
they O
begin O
to O
show O
interest O
in O
the O
opposite O
sex, O
while O
becoming O
exposed O
to O
a O
myriad O
of O
external O
pressures, O
including O
sexual O
coercion O
or O
harassment O
from O
boys O
and O
men, O
expectations O
to O
marry O
from O
their O
families, O
and O
the O
need O
to O
perform O
well O
in O
primary O
school O
in O
order O
to O
qualify O
for O
secondary O
school. O
[]

Title: O
Comparison O
of O
sufentanil-midazolam O
and O
sevoflurane O
for O
anesthesia O
induction O
in O
children O
undergoing O
cardiac O
surgery O
by O
real-time O
hemodynamic B-outcome ['Physiological-Clinical']
and O
cardiac B-outcome ['Physiological-Clinical']
efficiency O
monitoring: O
A O
prospective O
randomized O
study. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Journal O
ID: O
2985248R O
[]

The O
statistical O
analysis O
showed O
that O
there O
were O
significant O
differences O
between O
groups O
regarding O
the O
total O
dose B-outcome ['Life-Impact']
of O
used O
gonadotropins O
(P O
< O
0.001), O
stimulation B-outcome ['Physiological-Clinical']
duration I-outcome ['Physiological-Clinical']
(P O
< O
0.001), O
number O
of O
retrieved B-outcome ['Physiological-Clinical']
oocytes I-outcome ['Physiological-Clinical']
(P O
= O
0.01) O
and O
top O
quality O
embryo B-outcome ['Physiological-Clinical']
(P O
< O
0.001) O
and O
also O
cancellation B-outcome ['Life-Impact']
(P O
= O
0.002) O
and O
fertilization B-outcome ['Physiological-Clinical']
rates O
(P O
= O
0.002). O
[['Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact'], ['Physiological-Clinical']]

Accumulating O
evidence O
suggests O
that O
some O
single O
strains O
of O
lactobacilli O
may O
play O
a O
positive O
dietary O
role O
in O
attenuation O
of O
colic O
in O
exclusively O
breastfed O
infants. O
[]

Publication O
date: O
2019/01/08 O
06:00 O
[medline] O
[]

METHODS: O
In O
a O
prospective O
randomized O
contralateral O
eye O
study O
of O
LASIK O
versus O
SMILE O
procedures, O
21 O
consecutive O
patients O
(42 O
eyes) O
were O
evaluated O
with O
corneal O
epithelial O
mapping O
by O
anterior O
segment O
optical O
coherence O
tomography O
for O
up O
to O
2 O
years. O
[]

Title: O
Randomized O
Trial O
of O
Medical O
versus O
Surgical O
Treatment O
for O
Refractory O
Heartburn. O
[]

Publication O
date: O
2019/03/08 O
06:00 O
[medline] O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Whether O
a O
briefer O
treatment O
interval O
would O
be O
efficacious O
has O
not O
been O
studied. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

RESULTS: O
Of O
131 O
subjects O
who O
underwent O
routine O
phacoemulsification, O
analyzable O
endothelial O
images O
at O
24 O
months O
were O
available O
for O
126 O
subjects O
(96.2%). O
[]

Publication O
date: O
2019/01/12 O
06:00 O
[medline] O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

In O
this O
study, O
we O
aimed O
to O
determine O
the O
safety O
and O
efficacy O
of O
ixazomib O
as O
maintenance O
therapy O
following O
ASCT. O
[]

Journal-Name:Nan O
fang O
yi O
ke O
da O
xue O
xue O
bao O
= O
Journal O
of O
Southern O
Medical O
University O
[]

In O
the O
present O
post O
hoc O
analysis, O
patients O
who O
continued O
to O
perform O
daily O
home O
spirometry O
and O
completed O
at O
least O
one O
measurement O
per O
week O
for O
a O
56-day O
period O
before O
and O
after O
the O
start O
of O
a O
moderate O
or O
severe O
exacerbation O
were O
included. O
[]

Publication O
Type: O
Comparative O
Study, O
Journal O
Article, O
Multicenter O
Study, O
Randomized O
Controlled O
Trial, O
Research O
Support, O
Non-U.S. O
Gov't, O
[]

We O
calculated O
cause-specific O
hazard O
ratio's O
(HR's) O
for O
effects O
of O
time-dependent O
macrolide B-outcome ['Life-Impact']
and O
fluoroquinolone B-outcome ['Life-Impact']
exposure O
as O
compared O
to O
beta-lactam O
monotherapy O
on O
cardiac B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
, O
defined O
as O
new O
or O
worsening O
heart B-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
failure, I-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
arrhythmia, B-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
or Seperator ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
myocardial B-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
ischemia I-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
during I-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
hospitalization E2-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
. O
RESULTS: O
Cardiac B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
occurred O
in O
146 O
(6.9%) O
of O
2107 O
patients, O
including O
heart B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
(n O
= O
101, O
4.8%), O
arrhythmia B-outcome ['Physiological-Clinical']
(n O
= O
53, O
2.5%), O
and O
myocardial B-outcome ['Physiological-Clinical']
ischemia I-outcome ['Physiological-Clinical']
(n O
= O
14, O
0.7%). O
[['Life-Impact'], ['Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Respiratory O
muscle O
training O
of O
the O
experiment O
group O
was O
performed O
using O
the O
respiratory O
endurance O
training O
device O
combined O
with O
traditional O
techniques. O
[]

However, O
we O
found O
that O
using O
the O
motion O
tracking O
device O
led O
to O
transfer B-outcome ['Life-Impact']
of O
performance O
to O
the O
touchscreen. O
[['Life-Impact']]

However, O
no O
significant O
differences O
in O
bacteriological B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
(P O
= O
.34), O
clinical B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
(P O
= O
.11), O
and O
safety O
were O
found O
between O
2 O
groups. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

The O
median O
follow-up O
time O
was O
6.0 O
months O
(2.0-16.0 O
months). O
[]

In O
this O
study O
(APEX, O
Part O
I), O
we O
evaluated O
the O
efficacy/safety O
outcomes O
of O
DMF O
in O
a O
predominantly O
East O
Asian O
population O
of O
patients O
with O
RRMS. O
[]

antibiotics O
in O
the O
treatment O
of O
CT-scan O
confirmed O
uncomplicated O
acute O
appendicitis. O
[]

We O
investigated O
the O
effects O
of O
intraduodenally O
administered O
L-valine O
on O
antropyloroduodenal B-outcome ['Physiological-Clinical']
pressures I-outcome ['Physiological-Clinical']
, O
plasma O
cholecystokinin B-outcome ['Physiological-Clinical']
, O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
and O
energy B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
. O
Twelve O
healthy O
lean O
men O
(age: O
29 O
+/- O
2 O
years, O
BMI: O
22.5 O
+/- O
0.7 O
kg/m(2)) O
were O
studied O
on O
3 O
separate O
occasions O
in O
randomised, O
double-blind O
order. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact']]

The O
objective O
of O
current O
article O
is O
to O
present O
the O
protocol O
for O
a O
PE O
teacher-delivered O
theory-based O
trial O
to O
promote O
secondary O
school O
students' O
participation B-outcome ['Life-Impact']
in O
physical O
activity O
out-of-school O
contexts. O
[['Life-Impact']]

Twelve O
deaths B-outcome ['Mortality']
(8 O
in O
the O
omadacycline O
group O
and O
4 O
in O
the O
moxifloxacin O
group) O
occurred O
during O
the O
trial. O
[['Mortality']]

Yi O
xue O
ban O
= O
Journal O
of O
Peking O
University. O
[]

Publication O
date: O
2019/02/28 O
06:00 O
[medline] O
[]

TRIAL O
REGISTRATION: O
This O
trial O
was O
retrospectively O
registered O
on O
20/12/2018 O
under O
the O
number O
( O
NCT03782051 O
). O
[]

For O
a O
better O
application O
of O
TXA O
function, O
we O
explored O
the O
effect O
of O
intravenous O
injection O
(IV) O
of O
TXA O
combined O
with O
intra-articular O
injection O
(IA) O
of O
TXA O
in O
patients O
after O
TKA. O
[]

Refractory B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
developed O
in O
no O
patients O
in O
the O
caplacizumab O
group O
and O
in O
three O
patients O
in O
the O
placebo O
group. O
[['Physiological-Clinical']]

Both O
groups O
participated O
in O
the O
follow-up O
of O
three O
months. O
[]

Patients O
were O
randomly O
assigned O
in O
a O
3:2 O
ratio O
to O
oral O
ixazomib O
or O
matching O
placebo O
on O
days O
1, O
8, O
and O
15 O
in O
28-day O
cycles O
for O
2 O
years O
following O
induction, O
high-dose O
therapy, O
and O
transplantation. O
[]

Pain B-outcome ['Physiological-Clinical']
visual O
analog O
scale O
(VAS), O
patient's O
global B-outcome ['Physiological-Clinical']
assessment I-outcome ['Physiological-Clinical']
(PGA), O
flexional B-outcome ['Physiological-Clinical']
angles I-outcome ['Physiological-Clinical']
, O
patient-controlled O
analgesia B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
, O
percentage O
of O
patients O
receiving O
pethidine B-outcome ['Resource-use']
, O
pethidine B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
, O
and O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
assessed. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Resource-use'], ['Resource-use'], ['Resource-use'], ['Adverse-effects']]

The O
future O
researches O
with O
longer O
pursuing O
period's O
efficacy O
continuation O
are O
suggested. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

The O
number O
of O
mature B-outcome ['Physiological-Clinical']
follicles I-outcome ['Physiological-Clinical']
and O
cervical B-outcome ['Physiological-Clinical']
mucus I-outcome ['Physiological-Clinical']
score], O
follicular B-outcome ['Physiological-Clinical']
development I-outcome ['Physiological-Clinical']
rate O
and O
single B-outcome ['Physiological-Clinical']
follicle I-outcome ['Physiological-Clinical']
ovulation I-outcome ['Physiological-Clinical']
rate, O
cycle B-outcome ['Physiological-Clinical']
pregnancy I-outcome ['Physiological-Clinical']
rate, O
early B-outcome ['Mortality']
miscarriage I-outcome ['Mortality']
rate, O
ovulation B-outcome ['Physiological-Clinical']
rate, O
endometrial B-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
, O
positive O
rate O
of O
three B-outcome ['Physiological-Clinical']
lines I-outcome ['Physiological-Clinical']
sign I-outcome ['Physiological-Clinical']
, O
follicle B-outcome ['Physiological-Clinical']
stimulating I-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
level O
and O
luteinizing B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
level O
were O
compared O
between O
the O
two O
groups. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Mortality'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

The O
upper O
boundary O
of O
the O
95% O
confidence O
interval, O
when O
comparing O
short O
and O
long O
protocols, O
was O
below O
the O
pre-specified O
margin O
of O
non-inferiority O
(p O
= O
0.027). O
[]

Twelve O
patients O
were O
treated O
with O
SuperPATH O
approach O
(SuperPATH O
group) O
and O
12 O
patients O
with O
posterolateral O
approach O
(control O
group). O
[]

The O
patients O
in O
the O
control O
and O
treatment O
groups O
all O
showed O
elevated O
serum O
levels O
of O
fibroblast B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
factor I-outcome ['Physiological-Clinical']
23 I-outcome ['Physiological-Clinical']
(FGF23) I-outcome ['Physiological-Clinical']
, O
fibroblast B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
factor I-outcome ['Physiological-Clinical']
receptor I-outcome ['Physiological-Clinical']
(FGFRs) I-outcome ['Physiological-Clinical']
and O
Klotho B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
compared O
with O
the O
normal O
subjects O
(P O
&lt; O
0.01); O
fibroblast B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
factor I-outcome ['Physiological-Clinical']
23 I-outcome ['Physiological-Clinical']
(FGF23) I-outcome ['Physiological-Clinical']
, O
fibroblast B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
factor I-outcome ['Physiological-Clinical']
receptor I-outcome ['Physiological-Clinical']
(FGFRs) I-outcome ['Physiological-Clinical']
and O
Klotho B-outcome ['Physiological-Clinical']
levels O
were O
significantly O
reduced O
in O
the O
treatment O
group O
(P O
&lt; O
0.05) O
but O
remained O
unchanged O
in O
the O
control O
group O
(P&gt;0.05), O
showing O
significant O
differences O
between O
the O
two O
groups. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Parents, O
caregivers, O
and O
outcome O
assessors O
were O
unaware O
of O
group O
assignment. O
[]

Amla O
extract O
(500 O
mg) O
or O
a O
matching O
placebo O
capsule O
was O
administered O
twice O
daily O
for O
12 O
weeks O
to O
the O
respective O
group O
of O
patients. O
[]

Publication O
date: O
2019/02/01 O
06:01 O
[medline] O
[]

NCT01709253 O
; O
registered O
October O
18, O
2012; O
retrospectively O
registered). O
[]

OBJECTIVES: O
We O
describe O
a O
research O
protocol O
and O
lessons O
learned O
from O
a O
partnership O
between O
Johns O
Hopkins O
Health O
System O
and O
11 O
CBOs. O
[]

CONCLUSION: O
Both O
the O
regimens O
achieved O
therapeutic O
goals, O
however O
DR O
was O
found O
to O
be O
superior O
as O
it O
achieved O
greater O
reduction O
in O
total O
cholesterol B-outcome ['Physiological-Clinical']
(TC) O
and O
low B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
lipoprotein-cholesterol I-outcome ['Physiological-Clinical']
(LDL-C) I-outcome ['Physiological-Clinical']
. O
Further, O
these O
findings O
are O
substantiated O
by O
correlation O
of O
lipid B-outcome ['Physiological-Clinical']
indices O
with O
serum O
hydroxymethylglutaryl-CoA B-outcome ['Physiological-Clinical']
reductase I-outcome ['Physiological-Clinical']
enzyme I-outcome ['Physiological-Clinical']
(HMGCR) I-outcome ['Physiological-Clinical']
levels. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
date: O
2019/02/16 O
06:00 O
[medline] O
[]

We O
evaluated O
the O
prognostic O
value O
of O
histopathological O
measures O
with O
a O
Cox O
proportional-hazards O
model. O
[]

The O
intervention O
group O
was O
on O
250 O
mg/day O
of O
elemental O
Mg O
for O
three O
months O
while O
the O
control O
group O
did O
not O
receive O
any O
type O
of O
supplements O
throughout O
the O
intervention O
period. O
[]

METHODS: O
The O
study O
generated O
five O
data O
sets. O
[]

Journal-Name:Indian O
heart O
journal O
[]

87.3 O
+/- O
7.7 O
kg) O
with O
at O
least O
2 O
years O
of O
experience O
in O
resistance O
training. O
[]

Primary O
outcome O
was O
incidence O
of O
active O
bleeding B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
and O
secondary O
outcomes O
were O
incidence O
of O
six O
weeks O
rebleeding B-outcome ['Physiological-Clinical']
, O
complications B-outcome ['Adverse-effects']
, O
and O
mortality B-outcome ['Mortality']
among O
the O
studied O
patients. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Adverse-effects'], ['Mortality']]

2019;18(1):32-38. O
[]

In O
FZD O
group, O
92 O
patients O
were O
treated O
with O
FZD O
plus O
esomeprazole, O
bismuth O
potassium O
citrate, O
and O
amoxicillin O
for O
14 O
days. O
[]

Success O
rate O
of O
spinal B-outcome ['Physiological-Clinical']
deformity I-outcome ['Physiological-Clinical']
correction I-outcome ['Physiological-Clinical']
following O
surgical O
procedure O
regardless O
of O
type O
of O
administered O
rod O
was O
86.76 O
+/- O
11.30 O
percent O
(62.5-100%). O
[['Physiological-Clinical']]

We O
discuss O
possible O
explanations O
for O
this O
null O
effect, O
including O
the O
impact O
of O
participants' O
low O
perceived O
susceptibility O
to O
the O
risks O
shown O
on O
these O
pictorial O
health O
warning O
labels. O
[]
